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Abstract 
 
For decades, dietary restriction (DR) has been documented to extend health and lifespan across 
numerous model organisms. Two compounds, rapamycin (an immuno-suppressant) and 
metformin (a drug used to treat type II diabetes) have been proposed to mimic these health and 
lifespan benefits. Interestingly, DR, rapamycin and metformin result in the inhibition of the 
mammalian target of rapamycin (mTOR), a major nutrient sensing and signalling hub in the 
cell. The unexpected side-effect of this inhibition is the proposed extension in both health and 
lifespan in cell cultures and organisms. Despite the impact of inhibiting mTOR being well 
established at the biochemical level, the impact of mTOR inhibition on genome function (gene 
expression) and organization (organization of the genome in three-dimensional space) is poorly 
understood. Normal human fibroblasts were grown in culture and treated with either rapamycin 
or metformin for 120 h. It was established that with both treatments applied individually, 
population doubling times increased with no evidence of cell death; however, cellular 
morphology was divergent, with rapamycin-treated fibroblasts reminiscent of quiescence, 
whilst metformin-treated fibroblasts still exhibited the morphology of proliferating cells. 
Analysis of chromosome territory positioning revealed similar re-location of chromosomes 18 
and 10 whilst RNA sequencing analyses demonstrated divergent transcript profiles. In 
particular, transcripts changing significantly in response to rapamycin treatment were enriched 
for the cytokine-cytokine receptor interaction pathway, whilst genes changing significantly in 
response to metformin were enriched in the AP-1 transcription factor pathway. Chromatin 
immuno-precipitation analyses revealed STAT5A/B as a potential mediator of rapamycin-
mediated changes in gene expression. Together, these data demonstrated that although 
rapamycin and metformin are potential mimetics of DR, they elicit differential changes in gene 
expression and function through divergent mechanisms. Finally, these findings indicate that 
there are multiple targets for treatments which could result in increased health and lifespan in 
humans.  
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1.0 Review of the Literature 
1.1 Introduction 
Physical organisation of the genome is essential for the proper maintenance of cellular 
function. Genome disruption has been implicated in a number of diseases, including 
Hutchinson-Gilford Progeria Syndrome (HGPS), a premature ageing disease in which patients 
usually die from age-related complications (Cao et al. 2011). Within the last decade, the 
importance of genome function (transcription) and organisation (folding in three-dimensional 
space) as an area of active research has become apparent, and although focus is now shifting 
towards this field, many questions remain on how genome function links with genome 
organization.   
Dietary restriction (DR) can be defined as the reduction of nutrient intake without 
inducing malnutrition. In both primate and non-primate model organisms, DR has been 
demonstrated to extend lifespan, delaying the onset of age-related diseases such as cancer, 
diabetes and cardiovascular disease (McCay et al. 1935; Bordone and Guarente 2005; Colman 
et al. 2009; Cruzen and Colman 2009). One major impact of DR is the inhibition of the 
mammalian target of rapamycin (mTOR) pathway, a major nutrient-sensing pathway within the 
cell responding to cellular nutrients such as glucose and amino acids. This inhibition induces 
downstream effects such as up-regulating autophagy (self-eating) and inhibiting protein 
synthesis (Stanfel et al. 2009). The commonly-used compounds, rapamycin and metformin (an 
immunosuppressant and treatment for type II diabetes, respectively), both disrupt mTOR 
signalling with the unexpected side effect of extending longevity in several species including 
model organisms (Harrison et al. 2009; Onken and Driscoll 2010; Anisimov et al. 2011; Martin-
Montalvo et al. 2013; Miller et al. 2014), non-human primates (Colman et al. 2009; Cruzen and 
Colman 2009; Mattison et al. 2012; Colman et al. 2014) and human cells growing in tissue 
culture (Dowling et al. 2007; Chen et al. 2009; Dowling et al. 2011). Although the mTOR 
cascade has been extensively studied, it is unclear what impact decreased mTOR function, 
either through decreased nutrient levels or disrupted nutrient sensing, has on genome function 
and organisation in normal human cells. Understanding changes in genome function and 
organisation will be essential in understanding how rapamycin and metformin act to promote 
extended health and lifespan. 
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1.2 Genome Organization 
1.2.1 Basic Genome Organization: From Helix to Chromatin 
A genome contains all of the information necessary for an organism to grow, develop, 
and exhibit certain behavioural characteristics. The basic building blocks of life that make up 
the genome are nucleotides (adenine (A), guanine (G), cytosine (C), thymine (T)) that will base-
pair with complementary partners (A with T; C with G) in a sequence that combine with a 
deoxyribose-phosphate backbone to form the DNA double helix.  Two copies of the human 
genome exist in the majority of cells (with the exception of, for example, red blood cells and 
the germline), comprising ~3.2 billion base pairs (bp). Such a large volume of genetic 
information presents a packaging problem for the cell. From end-to-end the human genome 
measures ~2 metres in length and must be condensed into a nuclear volume measuring ~10 µm 
in diameter (Schneider and Grosschedl 2007). Furthermore, this DNA is negatively charged 
and must remain readily and quickly accessible for processes such as transcription, DNA repair 
and replication.  In order to address these requirements, several levels of genome organization 
exist [reviewed in (Schneider and Grosschedl 2007)].  
1.2.2 Topology of Chromatin Folding 
One method by which the problem of genome packaging within the nucleus is addressed 
is via the wrapping of DNA into nucleosomes. This wrapping is the first of many levels of 
organization within human cells. Oudet et al., provided the first evidence of these structures 
within the eukaryotic genome (Oudet et al. 1975). Nucleosomes consist of ~147 base pairs of 
DNA wrapped ~1.65 times around a histone octamer (Kornberg 1974; Noll 1974; Oudet et al. 
1975; Finch et al. 1977; Luger et al. 1997). Histones are groups of basic proteins found in 
chromatin that, in the case of DNA packaging, favour binding to negatively charged DNA 
polymers, neutralizing charges and allowing for the folding of DNA. An octamer consists of 
two copies of the histones (H) H2A, H2B, H3 and H4; known as the canonical histones. The 
genes encoding for the histone proteins are normally only expressed during DNA synthesis (S-
Phase) (Kornberg 1974; Kamakaka and Biggins 2005).  Core histones all contain a conserved 
C-terminal histone fold domain and an N-terminal tail. The N-terminal tail, when modified, 
gains various different biophysical properties and can act as binding sites for other proteins, 
allowing for additional interactions between proteins and nucleosomes. Each 11 nm 
nucleosome is linked to the next in a “beads-on-a-string” type structure, with stretches of linker 
DNA, bound by linker histone 1 (H1) (Olins and Olins 1974; Oudet et al. 1975; Holde 1995). 
The resultant protein-DNA complex arising from the wrapping of DNA around histones is 
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known as chromatin and may have higher-order folding structures, the first of which is a 
proposed 30 nm fibre partially mediated by nucleosome-nucleosome interactions (Kornberg 
1974). There are several models that exist for the wrapping of the genome into higher order 
structures, the first of which is the One Start model. In this model, nucleosomes are organized 
along the same helical path, with sequential interactions between the histone cores. The second 
model, the Two Start model proposes that two opposite nucleosomes are connected by linker 
DNA creating a structure of alternate histone cores which interact. The resulting linked structure 
is further folded onto itself, with other structures in between, forming a 300 nm structure with 
sub-chromosomal domains (Figure 1-1) (reviewed in (Cremer and Cremer 2001; Belmont 
2014)). Controversy exists over whether or not the 30 nm chromatin structure is present in vivo. 
Multiple studies claim that original observations were artefacts and that the basic structure of a 
chromosome is a compact aggregation of 11 nm nucleosome fibres (Dubochet et al. 1988; 
Maeshima and Eltsov 2008; Maeshima et al. 2014). Yet some argue that methods used to form 
this conclusion involved a technique called “defocusing” which may in fact hide the presence 
of the structures. Further study by Conway and Steven attempted to elucidate the existence of 
a 30 nm fibre, and again, the fibre was not detected; however, controversy still exists (Conway 
and Steven 1999). For a more in-depth review of the existence of the 30 nm chromatin fibre, 
see publications by (Fussner et al. 2011; Maeshima et al. 2014). 
The primary purpose of canonical histones is to form the core of nucleosomes; however, 
other classes of histones exist with specialised functions, known as histone variants. Histone 
variants differ from canonical histones in that the gene coding for the protein is normally 
expressed throughout the cell cycle, not just during S-Phase. Some variants have unique 
biophysical characteristics which act to facilitate various cellular processes by modulating 
chromatin via altering nucleosome properties, whilst others localise to specific regions of the 
genome to achieve similar affects (reviewed in (Kamakaka and Biggins 2005; Weber and 
Henikoff 2014)). A unique H2A histone variant, macroH2A, has a 30 kDa non-histone domain 
at its C-terminal, making it three times larger than its canonical counterpart (Pehrson and Fried 
1992). MacroH2A is generally associated with heterochromatin and has been linked to X 
chromosome inactivation in eutherian female mammals, with further evidence suggesting that 
macroH2A is involved in regulation of gene expression programs during cellular differentiation 
with some studies proposing the variant as an epigenetic regulator of cancer (Buschbeck et al. 
2009; Buschbeck and Di Croce 2010).  
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EviIn 1928, Emil Heitz characterised two forms of chromatin; euchromatin and 
heterochromatin [Reviewed in (Straub 2003)]. These two forms can be observed in distinct 
structures; highly-compact heterochromatin and less-compact euchromatin. Evidence suggests 
that these regions are important for gene expression, with data linking regions of 
heterochromatin to silencing gene expression and euchromatic regions to activating gene 
expression. This argues that occupancy in three-dimensional space is important for gene 
regulation  (Cavalli and Misteli 2013).    
Figure 1-1: The Proposed Levels of Genome Organization Within the Mammalian 
Genome. Double stranded DNA (2 nm) wraps around nucleosomes (11 nm) which then 
undergo further folding to form the controversial 30 nm chromatin fibre. Further folding to 
form mitotic chromosomes (1,400 nm) occurs in a somewhat undefined manner. Reproduced 
with permission and adapted from (Felsenfeld and Groudine 2003). 
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1.2.3 Epigenetics and Chromatin  
Multicellular organisms, including humans, have large genomes that have evolved to 
produce cell-type specific phenotypes. Although nearly all cells share the same genome, various 
phenotypes are observed, allowing cells to carry out diverse functions. This specificity is 
normally determined during development, whereby DNA is packaged with both histone and 
non-histone proteins, giving rise to distinct gene expression patterns, although it is important to 
note that other features, such as transcription factors (discussed later) are also very important 
in determining the gene expression of a cell. The packaging of chromatin is regulated by 
multiple mechanisms, including DNA modifications (e.g. methylation), and post-translational 
modifications of histones (phosphorylation, acetylation, etc.)  [reviewed in (Chen and 
Maklakov 2014)]. Changes in these DNA modifications, or post-translational modifications, 
have been linked to diseases such as cancer (Rodriguez-Paredes and Esteller 2011). These 
covalent modifications to DNA and its associated histones are often referred to as epigenetics 
[reviewed in (Siggens and Ekwall 2014)]. The majority of epigenetic modifications are 
reversible, meaning it is possible to change the behaviour of genomes. The reversible nature of 
these epigenetic modifications could provide a potential route for developing disease 
treatments.  
Combinatorial patterns of DNA and histone modifications, alongside histone variants, 
mark areas of distinct genome function. These areas of function are reflected in their influence 
on chromatin-associated processes (transcription, DNA replication, DNA repair, etc.) and can 
define which regions of the genome are active or inactive [reviewed in (Siggens and Ekwall 
2014)]. Epigenetically, heritable domains of heterochromatin exist, and these control the 
structure and expression of large chromosome domains. Heterochromatin is assembled by many 
enzymes and proteins that work in unison in a stepwise manner that involves rounds of histone 
modification (Eissenberg and Elgin 2014). 
Post-translational modification of histones and DNA can occur throughout a lifetime. 
These post-translational modifications directly alter genome function, with work in twins 
demonstrating that the ageing process is influenced predominantly by epigenetic modification 
of histones and chromatin as a result of lifestyle (Fraga et al. 2005). It has previously been 
described that the difference in epigenetic patterns between identical twins is likely the result 
of internal factors (such as ageing and defects in the transmission of epigenetic information 
through cell divisions) and external factors (such as smoking, physical activity and diet) (Fraga 
et al. 2005). Specifically, evidence suggests DNA methylation and histone modifications linked 
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to chromatin structure are involved in a global response to DR, regulating the expression of key 
genes (reviewed in (Li et al. 2011)). 
1.2.4 Genome Organization on the Linear Chromosome  
All human cells, with the exception of the gametes, contain 46 chromosomes. 
Chromosomes are the result of DNA packaging, with the entire genome tightly-coiled around 
histones to carry genetic material. Organization of genes along the linear chromosome is 
important for genome function, with disruption of this organization often resulting in disease. 
One level of this organization is via the formation of gene clusters, regions of genes along the 
chromosome that interact with one another as a result of genome folding. These clusters can 
range from a few to hundreds of genes (Hurst et al. 2004). These gene clusters are non-random 
and are essential in understanding both evolution (with gene clusters conserved across 
eukaryotic species (Lee and Sonnhammer 2003)) and disease (Joos et al. 1992; Zhou et al. 
2003; Hurst et al. 2004; Kleinjan and van Heyningen 2005). Examples of gene clusters include 
the Hox and globin gene cluster, initially thought to have occurred by chance but now 
recognized as having a function, and mammalian imprinted genes (Reik and Walter 2001). 
Additional examples include the immunoglobulin heavy-chain variable-region (Ig VH) gene 
cluster, reported in both mice and humans (Hughes and Yeager 1997). Interestingly, genes 
physically clustering on the chromosome often share functionality, indicating that the genome 
is organized to facilitate the expression of like-regulated genes, with functionally-linked genes 
able to span over 1000 kb in more complex organisms (Cho et al. 1998; Cohen et al. 2000; 
Spellman and Rubin 2002; Lercher et al. 2003). In addition to these findings, it has been 
proposed that gene clusters are cell-type specific.  
1.2.5 Spatial Genome Organization 
Gene clusters exist along the linear chromosome. Interactions between these genes have 
created further levels of genome organization, which when folded, are defined as linear units 
of chromatin that fold in discrete three-dimensional structures favouring internal interactions 
(Ciabrelli and Cavalli 2015). These structures are referred to as topologically associated 
domains (TADs).  TADs have only been detected in animal cell types, spanning on average 
every 1 mega base (Mb) in humans (Caron et al. 2001). TADs usually have distinct boundaries 
and are proposed to be involved in genome regulation and function, contain housekeeping genes 
(genes required for basic cellular function and are constitutively active) and insulator sites (a 
boundary that prevents interaction between enhancers and promoters) (Figure 1-2) (Phillips-
 7 
 
Cremins and Corces 2013). This results in highly interacting genes within TADs, but less 
frequent interactions between the genes in the TADs and genes of other TADs.  
 
 
Figure 1-2: The Structure of Topologically Associated Domains and Nuclear 
Organization. Visualization of the structuring of a topologically associating domain (TADs). 
TADs can span variable regions of the genome and at their edges contain high concentrations 
of insulators, preventing interaction between genes with the TAD and others in other TADs. 
Reproduced with permission and adapted from (Matharu and Ahanger 2015). 
1.2.6 Chromosome Territories 
Chromosomes are organized within the nuclear volume and are known to occupy 
specific regions, referred to as chromosome territories (Figure 1-3) (Cremer et al. 2006; 
Meaburn et al. 2009). The existence of chromosome territories was first proposed in 1885 by 
Carl Rabl in Salamandra maculate; however, direct visual evidence remained unavailable until 
the development of fluorescence in-situ hybridization (FISH) with chromosome paints 
[reviewed in (Cavalli and Misteli 2013)]. In order to further understand chromosome territories 
and their positioning, experiments were conducted identifying chromosome 19 (a gene-rich 
chromosome) as existing predominantly in the nuclear interior whilst the gene-poor 
chromosome 18 exists primarily at the periphery. This work highlighted a correlation between 
gene density and chromosome positioning, and proposed that similar findings would be found 
for all human chromosomes (Boyle et al. 2001; Cremer and Cremer 2001). Since this work 
HiC, a derivative of chromatin conformation capture (3C), as providing concordant data 
demonstrating other gene rich chromosomes (1, 16, 17, 19 and 22) as localised at the nuclear 
interior (reviewed in (Bickmore 2013)). A further level of organization has been proposed 
within the chromosome territory, with gene-poor regions of the chromosome preferentially 
orientated towards the nuclear periphery (Boyle et al. 2001; Kupper et al. 2007). Additionally, 
it has been documented that parts of the genome preferentially associated with components of 
the nuclear periphery, with >1000 domains documented as coming into contact with the nuclear 
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periphery. These domains were called lamin-associated domains (LADS) and are gene-poor 
(Guelen et al. 2008). Furthermore, tethering of loci to the nuclear periphery induced the down-
regulation of a number of relocated genes (Finlan et al. 2008). Other research, such as that by 
Bolzer et al., has demonstrated that small chromosomes move towards the nuclear interior, 
whilst larger chromosomes preferentially locate towards the periphery (Bolzer et al. 2005). 
Although this may be a partial factor in chromosome territory positioning, it has previously 
been demonstrated that chromosome 18, a relatively small chromosome, exists preferentially at 
the periphery; therefore, other factors should also be considered [161]. Although it is often 
argued that chromosome territories are based on the presence of greater regions of 
heterochromatin at the nuclear periphery and greater regions of euchromatin at the nuclear 
interior, it is far more likely that chromosome territory positioning is more complex.  
Chromosome territories do not remain stationary within the nucleus. In primary human 
fibroblasts, chromosome territory positioning is altered during quiescence and senescence 
(Bridger et al. 2000; Meaburn et al. 2007; Mehta et al. 2010; Mehta et al. 2011). When exiting 
the cell cycle, gene-poor human chromosome 18 relocates to the nuclear interior before 
returning to the periphery upon re-entering the cell cycle. Further to this, chromosome territory 
repositioning has been observed in serum-starved fibroblasts; perhaps not surprising as this 
induces quiescence. This change in nuclear location occurred within 15 minutes of serum 
starvation. This process requires energy, with evidence suggesting the involvement of nuclear 
actins and myosins (Mehta et al. 2010). Actin (which forms filaments) and myosin (a molecular 
motor) may potentially be involved in chromosome territory re-location (Bridger et al. 2000; 
Mehta et al. 2010). Interestingly, pathogens have also been implicated in altering host genome 
organisation in order to induce favourable conditions for the pathogen; however, this has only 
been observed once in Biomphalaria glabrata (snails) (Arican-Goktas et al. 2014). Viruses 
have also been documented to reorganize the nucleus to meet their transcriptional demands 
(Lieberman 2008).  These studies have provided further evidence of the plasticity of the human 
genome in somatic cells, demonstrating that the removal of growth factors impacts chromosome 
territory positioning.   
Genome organization and chromosome territory positioning has been associated with 
human health and disease. Mutations of genes encoding proteins known as lamins at the nuclear 
periphery cause diseases known as laminopathies, with alteration in radial chromosome 
organization reported in patients suffering laminopathies (Meaburn et al. 2007). In the 
premature ageing disease Hutchinson-Gilford Progeria Syndrome (HGPS), mutation in lamin 
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A results in the accumulation of the mutation protein progerin (Cao et al. 2007; Dechat et al. 
2007) with altered genome interactions reported when comparing lamin A and progerin, 
specifically that lamin A-associated genes are often transcriptionally-silent and that loss of this 
silencing results in relocation of chromosomes from the periphery (Kubben et al. 2012). 
Furthermore, in HGPS cells, loss of heterochromatin has been documented. Cao et al. reported 
restoration of heterochromatin domains in response to rapamycin treatment, improving DNA 
repair kinetics and inducing autophagy mediated degradation of progerin (Cao et al. 2011). 
Contributing to the statement of the plasticity of the human genome, when treated with 
farnesyltransferase inhibitors (Mehta et al. 2011)  chromosome territories returned to a position 
similar to those in normal human fibroblasts, indicating the importance of genome organization 
in health and disease.  
There is some debate over whether or not chromosome territories are truly discrete. 
Genes have been reported to loop distances out of the chromosome territory in regions of 
constitutively high gene expression or when gene expression is induced (reviewed by (Fraser 
and Bickmore 2007)). Some models have suggested that active genes are found in direct contact 
with an inter-chromatin domain (ICD) which separates chromosome territories (Kosak and 
Groudine 2004; Scheuermann et al. 2004). However, this does not allow for the existence of 
significant chromosome territory intermingling proposed by simulations (Holley et al. 2002). 
Intermingling of chromosome territories has been detected for all chromosome pairs analysed 
by Branco & Pombo across multiple cell types, with data indicating chromosome intermingling 
is influenced by transcription dependent interactions (Branco and Pombo 2006). Using the 
Hoxb gene cluster, which is activated as it relocates away from the chromosome territory, it has 
been suggested that looping allows the locus to interact with a greater number of chromosomes. 
This raises a number of questions, including, where are the genes going and why and how are 
the genes leaving the territory (Chambeyron et al. 2005; Branco and Pombo 2006)?    
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Figure 1-3: Chromosomes Organized in Chromosome Territories. (A) A deconvoluted 
mid-plane section of the nuclear volume with chromosome territories labelled by spectral 
karyotype (SKY) FISH. Every individual colour represents a chromosome territory. (B) RGB 
colors of the 23 differentially labelled chromosome territories within the nucleus. (C) 
Deconvoluted mid-plane section of a prometaphase rosette from a male fibroblast. 
Chromosome territories labelled by 24-colour SKY FISH. (D) RGB colours of labelled 
chromosome territories. Reproduced with permission and adapted from (Bolzer et al. 2005). 
1.2.7 Organization of Transcription within the Nuclear Volume – The Transcription 
Factory Model 
Contrary to the traditionally taught model of transcription, evidence now indicates that 
transcription machinery exists at discrete sites throughout the nucleus. Transcription factories 
are protein-rich nuclear sub-compartments containing high concentrations of hyper-
phosphorylated RNA Polymerase II (RNAPII) (Iborra et al. 1996; Eskiw et al. 2008). The low 
numbers of transcription factories to active genes and transcription suggests that factories are 
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shared among active genes, further supported by evidence of co-localization at RNAPII foci 
between genes involved in the same processes (e.g. globin synthesis), indicating the existence 
of large scale transcription networks (Osborne et al. 2004; Schoenfelder et al. 2010).  Genes 
transcribed by RNAPII (the majority of protein coding genes), engage in long-range, 
transcription-dependent associations (Osborne et al. 2004; Mitchell and Fraser 2008). The 
existence of specialised transcription factories, or transcription networks, could act to influence 
genome organisation. These specialised transcription factories may arise either via the 
deterministic model in which key players in transcription become concentrated at a subset of 
factories, where genes requiring the factory will move towards it, or via the self-organisation 
model in which genes and their bound regulatory factors engage factories in their local 
environments (reviewed in (Cope et al. 2010)).   
1.2.8 Transcription and Genome Folding 
A long range chromatin interaction is an interface that exists between two or more 
regions of the chromosome. Long-range chromatin interactions can occur either between 
regions of the same chromosome (cis) or between regions of different chromosomes (trans) 
(Figure 1-4). These long-range interactions between genes and enhancers (regulatory DNA 
sequences that enhance transcription of associated genes when bound by transcription factors) 
have been directly associated with gene regulation. The disruption of looping as a result of these 
interactions causes changes in expression (Drissen et al. 2004; Vakoc et al. 2005). For example, 
the cis interaction between the erythroid-specific β-globin gene and its distal enhancer locus 
control region (LCR) acts to regulate β-globin gene transcription during erythroid development 
through the exclusion of a 50 kB loop of DNA (Carter et al. 2002; Tolhuis et al. 2002). Deletion 
of transcription factor binding sites and cofactors required for the aforementioned interaction 
leads to decreased levels of β-globin gene transcription, highlighting necessity for the LCR-β-
globin interaction and the importance of the 50 kB loop (reviewed in (Cope et al. 2010)). 
Similarly, trans interactions, such as that between T-helper cell 2 LCR on chromosome 11 and 
interferon γ promoter on chromosome 10 in naïve murine T-cells have also been identified 
(Spilianakis et al. 2005).  Combined, these studies further implicate that cis- and trans- 
interactions frequently occur throughout a genome organised in three dimensional networks of 
genes and regulatory elements and support the concept of genome structure affecting genome 
function.   
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Figure 1-4: Genome Organization: Cis/Trans interactions. Active genes exist on chromatin 
loops that extend outside of chromosome territories. Both cis (blue) and trans (red) interactions 
are shown here. Interactions can occur at sites with local concentrations of polymerase II, called 
transcription factories (blue). 
1.3 Nutrient Sensing and Caloric Restriction  
1.3.1 How do cells sense nutrients? 
Although we know that the body utilizes nutrients from our diets to perform daily 
functions and maintenance, such as breaking food down into basic building blocks required for 
use by cells, how do cells actually sense the availability of these building blocks?  One major 
route is through the mammalian target of rapamycin (mTOR) pathway, a major nutrient-sensing 
pathway within cells that detects input from insulin signalling, amino acid availability, and 
cellular energy status (i.e. ATP:AMP ratio).  The downstream effects of this pathway can result 
in promotion of cellular growth, repair and autophagy.  
1.3.1.1 Mammalian Target of Rapamycin Pathway  
The target of rapamycin (TOR) pathway is highly-conserved across species and is a 
major signalling hub within cells. The TOR, or mammalian (m)TOR signalling cascade, detects 
and responds to levels of nutrients within the cellular environment and responds accordingly, 
either directing growth and proliferation or promoting maintenance, repair and autophagy 
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[reviewed in (Laplante and Sabatini 2012; Laplante and Sabatini 2013)]. Central to the mTOR 
pathway is the 289 kDa mTOR serine/threonine protein kinase belonging to the 
phosphoinositide 3-kinase (PI3K) related kinase family which acts as a key catalytic kinase 
subunit within both the well-characterized mTOR complex 1 (mTORC1) and the less-
characterized mTORC2, each with distinct downstream targets. An essential pathway, mTOR 
deregulation has been associated with numerous human diseases including cancer, 
cardiovascular disease, type II diabetes and neurodegeneration (Sarbassov et al. 2005; Zoncu 
et al. 2011). Furthermore, inhibition of the mTOR pathway has been linked to beneficial 
impacts in human health in addition to potentially extending lifespan (Bjedov and Partridge 
2011; Evans et al. 2011; Wilkinson et al. 2012; Johnson et al. 2013).  
1.3.1.2 The Mammalian Target of Rapamycin Complexes 1 and 2 
mTOR exists as two structurally-distinct complexes, mTORC1 and mTORC2. 
mTORC1 is composed of 6 proteins in addition to mTOR: DEP domain containing mTOR-
interacting protein (DEPTOR) (Peterson et al. 2009), regulatory-associated protein of mTOR 
(Raptor), mammalian lethal with sec-13 (mLST8), tti1/tel2, and proline-rich AKT substrate 
40kDa (PRAS40) (Takahara et al. 2006; Wang et al. 2007). Within the mTORC1 complex, 
DEPTOR is an mTOR inhibitor (Peterson et al. 2009), whilst Raptor regulates the assembly, 
localization and substrate binding of mTORC1, tti1/tel2 is responsible for assembling and the 
stability of mTORC1 (Kaizuka et al. 2010). PRAS40 binds and inhibits mTOR under serum or 
nutrient deprivation (Vander Haar et al. 2007; Laplante and Sabatini 2012). The function of 
mLST8 remains unknown (Kim et al. 2003; Jacinto et al. 2004).  
mTORC2 is poorly characterized in comparison to mTORC1; however, it is proposed 
to be involved in cytoskeletal organization, with recent work documenting that mTORC2 is 
insensitive to nutrients in the local environment; however, responds to growth factor signalling. 
As with mTORC1, mTORC2 also contains DEPTOR, mLST8 and tti1/tel2, which exhibit the 
same functions in both complexes. Further to these protein components, mTORC2 also consists 
of: rapamycin-insensitive companion of mTOR (RICTOR), protein observed with rictor 1 and 
2 (Protor 1/2) and mammalian stress-activated kinase-interacting protein 1 (mSin1). RICTOR 
functions to regulate assembly and substrate binding of mTORC2 (Jacinto et al. 2004; 
Sarbassov et al. 2004), whilst protor 1/2 increases activation of SGK1 mediated by mTORC2. 
mSin1 complements protor 1/2, regulating mTORC2 assembly and interaction with SGK1 
(Jacinto et al. 2004; Frias et al. 2006). 
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1.3.1.3 Activation and Inactivation of the Mammalian Target of Rapamycin 
Pathway 
mTORC1 is activated by a number of upstream signals such as growth factors (insulin), 
nutrients (amino acids) (Blommaart et al. 1995; Hara et al. 1998) and cellular energy status 
(ATP:AMP ratio) (Inoki et al. 2003). mTORC1 responds to these inputs in order to control and 
direct downstream processes (Figure 1-5). Although all these signals are sensed via the major 
mTORC1 complex, the upstream pathways to mTORC1 activation are slightly varied.  
Growth factors (such as insulin-like growth factor 1 (IGF1)) activate mTORC1 through 
the PI3K-phosphoinositide-dependent kinase 1 (PDK1)-AKT pathway (reviewed by (Laplante 
and Sabatini 2013)). Activated AKT phosphorylates the tuberous sclerosis complex 2 (TSC2) 
causing inhibition of TSC1 (Inoki et al. 2002; Manning et al. 2002; Roux et al. 2004; Ma et al. 
2005).  The resulting complex has GTPase activating protein (GAP) activity for the Rheb 
GTPase. GTP-loaded RHEB binds to the mtor catalytic domain, activating mTORC1, although 
the precise mechanisms behind this binding are unclear. Alternatively, nutrient signalling 
(amino acids) activates mTORC2 via RAS-realated GTP-binding protein (RAG) family of 
small GTPases, with a RAG heterodimer mediating translocation of mTORC1 to the surface of 
a lysosome from the cytoplasm (Bar-Peled and Sabatini 2014). On the lysosome membrane, 
mTORC1 is activated by RHEB (Saucedo et al. 2003). Alternatively, in response to a high 
ATP:AMP ratio, mTORC1 is activated by AMPK inhibition. Conversely, mTORC2 regulation 
(activation and inhibition) is poorly understood. Growth factors are proposed to stimulate 
mTORC2 through PI3K-dependent association of mTORC2 with the ribosome; however, more 
research is needed to form a complete picture of mTORC2 regulation and function.  
A number of non-nutrient based inputs also exist for the mTOR pathway. These 
pathways are essential during development and include; Notch (involved in controlling cell 
proliferation (Bray 2006)), Hippo (which determines organ size via controlling cell number 
(Zhao et al. 2011)) and WNT (which promotes expression of genes involved in cell 
proliferation, differentiation, polarity and migration (Niehrs 2012)) signalling pathways. When 
hyper-activated, Notch signalling increases expression of RAPTOR, promoting mTOR-
RAPTOR interactions and therefore promoting mTORC1 signalling (Pajvani et al. 2013). The 
major downstream effector of the Hippo signalling pathway is the yes-associated protein 
(YAP), which is phosphorylated and inhibited by the Hippo pathway kinase large tumor 
suppressor homologue (LATS). The hypo-phosphorylated YAP translocates into the nucleus, 
inducing and inhibiting transcription of genes encoding proteins that promote proliferation and 
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apoptosis. Therefore, inhibition of YAP by Hippo inhibits proliferation and activates apoptosis. 
YAP further promotes transcription of the micro-RNA mir-29 which inhibits translation of 
phosphatase and tensin homologue (PTEN), activating PI3K signalling and therefore both 
mTORC1 and mTORC2 (Tumaneng et al. 2012; Shimobayashi and Hall 2014).  
WNT signalling activates mTORC1 via inhibition of the TSC1/2 complex. WNT is 
activated via binding of the WNT ligand to the cell surface receptor Frizzled and the co-
receptors low-density lipoprotein receptor-related protein 5 (LRP5) or LRP6 (MacDonald and 
He 2012). Activation of the receptor results in release of GSK3b, inhibiting phosphorylation of 
-catenin which translocates to the nucleus and enhances expression of genes involved in cell 
proliferation, differentiation, polarity and migration (Niehrs 2012). In the absence of WNT 
signalling, AMPK dependent phosphorylation of TSC2 by glycogen synthase kinase 3 beta 
(GSK3B) activates the TSC1/2 complex and inhibits mTORC1 (Valvezan et al. 2013).  
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Figure 1-5: Upstream Inputs and Downstream Effects of the Mammalian Target of 
Rapamycin (mTOR) Pathway. A summary of the upstream and downstream pathways of 
mammalian target of rapamycin (mTOR) signalling. Upstream inputs and their respective 
signalling cascades are shown for (A) insulin pathway, (B) amino acids, (C) high AMP/ATP 
ratio, (D) Hippo pathway and (E) the WNT pathway, highlighted by blue boxes. Downstream 
effects of these pathways have been documented to include protein and lipid synthesis, 
autophagy, energy metabolism and cell survival (via mTORC1) and cytoskeletal organization 
(via mTORC2). The points in this pathway affected by rapamycin and metformin are labelled 
in red. Reproduced with permission and adapted from (Shimobayashi and Hall 2014).  
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1.3.1.4 Downstream of the Mammalian Target of Rapamycin Pathway  
The mTOR pathway (specifically via mTORC1) has a number of downstream effects 
to complement its numerous inputs. These downstream processes include protein synthesis, 
regulating the synthesis of lipids required for cells to generate membranes, positively regulating 
cellular metabolism and ATP production and negatively regulating autophagy and the 
biogenesis of lysosomes.   
Protein synthesis is perhaps one of the best characterized downstream processes 
mediated by the mTOR pathway, via the induction of ribosome biogenesis and mRNA 
translation (Hands et al. 2009). Under conditions favourable for growth, protein synthesis is 
promoted by mTORC1 via phosphorylation of eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and S6K1. As a result of this phosphorylation, binding of 
4E-BP1 to eIF4E is prevented, enabling eIF4E to promote cap-dependent translation (Richter 
and Sonenberg 2005; Ruvinsky and Meyuhas 2006). S6K also phosphorylates ribosome protein 
S6 (S6). In the presence of nutrients, protein synthesis machinery is upregulated by mTORC1. 
This is achieved via activation of the regulatory element tripartite motif-containing protein-24 
(TIF1A) and via phosphorylation and inhibition of the Pol II repression Maf1, therefore 
inducing 5S rRNA (Mayer and Grummt 2006)and tRNA transcription (Kantidakis et al. 2010; 
Shor et al. 2010). In this way, mTORC1 acts via mRNA translation initiation and progression 
to influence the rate of protein synthesis within cells (Ma and Blenis 2009; Johnson et al. 2013). 
In Saccharomyces cervisiae, Caenorhabditis elegans, Drosophila melanogaster and Mus 
musculus, regulation of mRNA translation has been associated with increased longevity 
(Kaeberlein and Kennedy 2011), with global reduction of mRNA translation attenuating ageing, 
inducing a shift towards maintenance of protein homeostasis in response to protein aggregation 
and oxidative damage (Kaeberlein and Kennedy 2007). It could be argued that the observed 
changes in longevity result from the attenuation of age-associated pathologies in response to a 
decline in mRNA translation; however, evidence in Saccharomyces cerevisiae,  Caenorhabditis 
elegans and Drosophila melanogaster indicates that the differential translation of specific 
mRNAs may be of greater influence on lifespan, with enhanced translation efficiency of 
metabolic and stress genes (Johnson et al. 2013).   
A second highly-regulated process downstream of mTORC1 is autophagy; a multi-step 
catabolic process in which proteins and cellular components are degraded and recycled 
(Codogno et al. 2012). Inhibition of mTORC1 under conditions of low nutrients results in an 
increase in autophagy. mTORC1 mediates autophagy through unc-51-like kinase 1 (ULK1), 
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autophagy-related gene 13 (ATG13) and focal adhesion kinase family interacting protein of 
200 kDa (FIP200) (Ganley et al. 2009; Hosokawa et al. 2009; Jung et al. 2009). As a result of 
mTORC1 inhibition, autophagosomes form and engulf cytoplasmic proteins and organelles, 
fusing with lysosomes to degrade cellular components and recycle building blocks. In the 
presence of nutrients, mTORC1 phosphorylates ULK1, preventing interaction with AMPK, 
inhibiting autophagy. mTORC1 impacts autophagy mechanisms such as the regulation of 
death-associated protein 1 (DAP1, a suppressor of autophagy) (Koren et al. 2010) or through a 
mammalian orthologue of Atg18 in yeast (Hsu et al. 2011). Autophagy is becoming a key player 
in contributing towards improved health and lifespan. Autophagy declines with age; this 
declination could result in the accumulation of cellular damage (Cuervo 2008; Johnson et al. 
2013). Inhibition of TORC1, therefore activating autophagy, has been reported to maintain 
cellular function during ageing by degrading aged cellular components (Hansen et al. 2007; 
Alvers et al. 2009), with age-associated diseases such as cancer and diabetes being linked to 
dysregulation of autophagy (Mizushima et al. 2008; Johnson et al. 2013).  
1.3.2 The Impact of Dietary Restriction on the Mammalian Target of Rapamycin, 
Genome Function, Organization and Longevity  
1.3.2.1 Dietary Restriction 
Dietary restriction (DR), the reduction of nutrient intake without inducing malnutrition, 
has been demonstrated to increase health and lifespan in numerous model organisms. In 1935, 
the first published DR studies were conducted and demonstrated increased lifespan of Rattus 
norvegicus (brown rat) (McCay et al. 1935), with similar results observed in yeast, worms 
(Walker et al. 2005), flies (Metaxakis and Partridge 2013), fish (Inness and Metcalfe 2008), 
dogs (Kealy et al. 2002), non-human primates (Bodkin et al. 2003; Mattison et al. 2012; 
Colman et al. 2014) and humans (McCay et al. 1935; Bordone and Guarente 2005). Not only 
was lifespan extended in these model organisms, but evidence indicated that DR delayed the 
onset of age-related disease and improved patient outcomes when used alongside cancer 
therapies (Champ et al. 2013). Furthermore, DR is nearly as effective when initiated in adult 
rodents as in those treated early in life (Weindruch and Walford 1982). However, in Mus 
musculus (mice) with varied genetic backgrounds, it was demonstrated that lifespan extension 
by DR may not be universal, with the majority of mice exhibiting a shortened lifespan (Liao et 
al. 2010). Advanced maternal age has often been associated with deleterious effects on 
offspring. In the microscopic metazoan Brachionus manjavaos, maternal DR partially rescued 
these deleterious effects in female but not male progeny (Gribble et al. 2014). Combined, these 
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data provided justification for studies in both non-primate and non-human primate model 
organisms.  
Findings in Macaca mulatta (rhesus macaques), a model organism that exhibits ageing 
phenotypes and pathologies similar to that of humans (Ramsey et al. 2000; Raman et al. 2005; 
Fischer and Austad 2011), were contradictory. Bodkin, et al., (Bodkin et al. 2003) demonstrated 
an increase in the average age of death in DR macaques; however, the sample size was small. 
This delayed death in the macaques was associated with prevention of age-related diseases and 
hyperinsulinemia (Bodkin et al. 2003). A further study in which 76 rhesus monkeys underwent 
DR also demonstrated increased longevity and later onset of disease when compared to non-
DR animals  (Colman et al. 2009; Colman et al. 2014). Contradicting these results, a parallel 
study demonstrated no significant difference in lifespan between DR and non-DR animals 
(Mattison et al. 2012). Re-analysis of these data  by Colman et al. (Colman et al. 2014), 
concluded that animals in both DR and non-DR groups of the parallel study were underweight 
at the start of the trial, perhaps already having undergone a form of DR (Mattison et al. 2012; 
Colman et al. 2014). Further study attempted to elucidate the above findings and indicated that 
at any time point, the non-DR macaques had 2.9 times the rate of death from age related 
pathologies (such as cardiovascular disease) compared to animals under DR (Colman et al. 
2014). Long term studies in rhesus monkeys have demonstrated that DR decreases the 
metabolic cost of movement and does not lead to a decrease in physical activity during ageing, 
contrary to short term DR (Yamada et al. 2013). DR in both non-human primates and humans 
has been demonstrated to have a positive effect on the risk factors of cardiovascular disease – 
a disease often associated with ageing (Cruzen and Colman 2009). For all studies it is important 
to consider where the rhesus macaques originated, their genetic background and how they were 
raised. These factors may influence the outcome of the animal trials, especially given that DR 
has been documented to have beneficial effects even if started late in life, or in early life 
influencing later life (Weindruch and Walford 1982).  The studies provide data to support DR 
as a method of lifespan extension across multiple species, delaying the onset of age-related 
pathologies, with some evidence linking the beneficial effects of DR to changes in DNA 
damage accumulation and chromatin structure. The positive impact of DR in non-human 
primates further supports the proposal of an increase in health and lifespan as a result of 
depleted nutrient availability in tissue culture.    
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1.3.2.2 Dietary Restriction and Mechanisms of Promoting Longevity 
A number of potential hypotheses exist as to how humans age, and therefore specifically 
how DR can promote longevity. One hypothesis states that reduced levels of reactive oxygen 
species (ROS) and increased DNA repair are responsible for promoting increased lifespan (Ray 
et al. 2012). Reactive oxygen species (ROS) can cause DNA damage, with reduction in ROS 
reducing DNA damage, and therefore decreasing the chance of mutations that could lead to 
cancer, often considered an age-associated disease. Evidence of DR reducing ROS has been 
reported in rat tissues (Cabelof et al. 2002; Um et al. 2003), although this is controversial with 
some data indicating that ROS are not reduced enough to have a significant impact on DNA 
damage (Kabil et al. 2007). Other hypotheses suggest that human ageing is impacted by 
circulating glucose and insulin, with DR decreasing levels of both. Decreased levels of both 
glucose and insulin have concomitantly been observed with an increased in lifespan in 
numerous model organisms (Kannan and Fridell 2013; Murphy and Hu 2013; Zhang and Liu 
2014). The third hypothesis links ageing with circulating growth hormone and IGF1 levels 
(Fontana et al. 2008; Fontana et al. 2015), whilst the fourth suggests that cells move from 
proliferation and growth to maintenance and repair (Calabrese et al. 2011). Again, DR has been 
documented to potentially work via these hypotheses. These hypotheses are based on the mTOR 
pathway, specifically the upstream sensing of nutrients that dictates the outputs of this pathway.  
Inhibition of the mTOR pathway has similarly been associated with promoting health 
and lifespan. DR is one manner in which mTOR may become inhibited, most likely through 
decreased levels of amino acids, growth factors and glucose/insulin. Specifically, as a result of 
DR, AMPK phosphorylates TSC1/2 as previously described, inhibiting TORC1 and the 
downstream signalling cascade (Laplante and Sabatini 2009). The sirtuin deacetylase family 
member SIRT1 is also stimulated in response to decreased energy levels, increasing cellular 
levels of nicotinamide adenine dinucleotide (NAD) (Lau et al. 2014). SIRT1 is a deacetylase 
and targets LKB1. Deacetylation of this protein further drives activation of AMPK and inhibits 
mTOR (Lan et al. 2008). AMPK and SIRT1 share common targets, such as p53, suggesting 
these proteins could be essential in controlling DR mediated changes in gene expression that 
promote health and lifespan. A number of potential mimetics of DR have been identified, 
including the compounds rapamycin and metformin, which have also been identified to promote 
health and lifespan in model organisms, potentially via modulation of the mTOR pathway. 
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1.4 Rapamycin 
1.4.1 Overview 
Rapamycin, a macrocyclic lactone-based compound, was first isolated from the 
bacterium Streptomyces hygroscopicus found in the soil of Easter Island (Sehgal et al. 1975). 
Structural similarities identified between rapamycin and the antibiotic FK506 prompted follow-
up studies demonstrating the functionality of rapamycin as an antibacterial and antifungal agent 
and immunosuppressant (Abraham and Widerrecht 1996). As a result, rapamycin is now  
commonly-used in human patients following organ transplantation (Camardo 2003). 
Rapamycin is a well-known inhibitor of the mTOR pathway (Dumont and Su 1996), resulting 
in the downstream decrease in cap-mediated protein translation (Richter and Sonenberg 2005) 
and an increase in autophagy (Jung et al. 2010); both associated with promoting health and 
lifespan. Furthermore, rapamycin has been reported to ameliorate age-associated phenotypes, 
decrease cellular proliferation and increase autophagy in numerous cell-based models, 
including: cancer (Shapira et al. 2006; Fang et al. 2011; Suzuki et al. 2011), cardiovascular 
disease (Das et al. 2014), the premature ageing disease HGPS (Cao et al. 2011) and 
neurodegenerative diseases (Santos et al. 2011). Rapamycin has also been documented to 
extend the health and lifespan of a variety of model organisms, including S. cerevisiae (Powers 
et al. 2006), D. melanogaster (Bjedov et al. 2010) and M. musculus (Miller et al. 2014).  
1.4.2 Mechanism 
Rapamycin, and many derivatives known as ‘rapalogs’, have been extensively 
demonstrated to inhibit the mTORC1 complex, thus preventing protein  and lipid synthesis and 
energy metabolism, whilst up-regulating autophagy (Dumont and Su 1996). Chronic rapamycin 
treatment has similarly been documented to inhibit mTORC2 (Jacinto et al. 2004; Sarbassov et 
al. 2004; Sarbassov et al. 2006), although the downstream impact of this inhibition is poorly 
understood and an open area of research. Rapamycin, and its rapalogs, achieve inhibition of 
mTOR by forming a complex with FK506 binding protein -12 (FKBP12), a 12 kDa cytosolic 
protein found in all eukaryotes (Dumont and Su 1996; Shimobayashi and Hall 2014). The 
rapamycin-FKBP12 complex then directly binds mTORC1, inhibiting its kinase activity 
(Figure 1-6). This mechanism is poorly characterized; however, crystallography of an mTOR-
mLST8 complex revealed that the catalytic cleft of the mTOR kinase domain is highly restricted 
(reviewed in (Shimobayashi and Hall 2014)). In vitro, binding of rapamycin by FKBP12 
inhibits mTOR. Auto-phosphorylation and phosphorylation of 4EBP1, are also indicative of 
changes in the FKBP-rapamycin-binding (FRB) domain supporting this theory on the influence 
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on the catalytic domain (Marz et al. 2013). Rapamycin has also been demonstrated as binding 
with a lower affinity to the FRB domain in the absence of FKBP12 [76].  
 
 
 
 
Figure 1-6: Rapamycin Chemical Structure. The chemical structure of the rapamycin with 
the FKBP12 binding site shown (blue). Components of the TOR protein (bottom) are also 
shown, with the site at which rapamycin binds (FRB, red) to inhibit mTOR activity highlighted. 
Reproduced with permission and adapted from (Bauer and Bronstrup 2014) .  
 
1.4.3 Rapamycin, Genome Function and Longevity  
Rapamycin functions as an immunosuppressant; however, an unusual side effect of this 
compound is the extensively-documented increase in both health and lifespan of model 
organisms treated with the drug. This extension is likely the result of downstream changes in 
genome function as a result of mTOR inhibition; however, these downstream changes in gene 
expression are poorly understood.  
The accumulation of cells in senescence (no longer able to divide and grow) has been 
extensively linked to disease, ageing and the ageing phenotype (Kong et al. 2011). The 
clearance of senescent cells has been documented to improve symptoms of age-associated 
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diseases, such as decline in skeletal muscle and formation of cataracts, in mice (Baker et al. 
2011). Mesangial cells (MC) entered senescence as a response to high glucose, increasing 
mTOR expression (likely as a result of excess nutrient availability) and decreased SIRT1 
expression (Zhang et al. 2012). rapamycin treatment of MC interfered with senescence, 
concomitant with an increase in SIRT1 expression (Zhang et al. 2012). The senescence 
associated secretory phenotype (SASP) is a process in which pro-inflammatory cytokines are 
secreted from senescent cells into the local tissues, inducing further deleterious effects in the 
surrounding environment and is extensively linked to the ageing phenotype (Coppe et al. 2010). 
In macrophages, inhibiting SIRT1 results in the overexpression of inflammation associated 
genes (tumour necrosis factor (TNF)-, interleukin (IL)-6) through nuclear factor (NF)-B 
signalling, with rapamycin-treatment ameliorating SIRT1 inhibition and reducing NF-B 
mediated inflammation (Takeda-Watanabe et al. 2012). rapamycin has further been linked to 
cytokine expression and regulation in numerous cell-types, although reports are conflicting. In 
orbital fibroblasts, rapamycin suppressed programmed cell death 4 (PDCD4) degradation, 
therefore increasing TNF induced IL-6 and IL-8 secretion (Lee et al. 2013). Experiments 
conducted in human macrophages were in agreement with these findings, with rapamycin 
increasing TNF, IL-6 secretion and decreasing IL-10 levels (Su et al. 2015). However, in human 
oral keratinocytes, suppression of toll-like receptor 3 (TLR3) and resultant nuclear factor-kB 
(NF-B) signalling by rapamycin inhibits the production of interleukin-1 beta (IL-1), 
TNFand IFN, but increased IL-12p70 production (Zhao et al. 2010). Similarly, in senescent 
fibroblasts treated with rapamycin a decrease in cytokine production was observed (Laberge et 
al. 2015). With SIRT1 noted as inhibiting NF-kB activity, it is likely that it is essential in 
regulating ageing during the ageing process, reducing inflammation-linked signalling and 
promoting health and longevity in response to rapamycin. Furthermore, although it is clear that 
inflammation and SASP are core to the ageing process, there is conflicting evidence in response 
across various cell lines. Therefore, it is likely that this response is influenced by species, cell 
type and cell cycle state in addition to dose and length of rapamycin treatment. In the 
epididymal white adipose tissue of mice treated with rapamycin for 6 months, just 6 down-
regulated genes were identified (Fok et al. 2014). This finding further solidifies that argument 
that response to rapamycin is tissue/dose/time-dependent. It is possible that cells acclimatise to 
long-term exposure of rapamycin. This is further supported through studies that document 
chronic rapamycin exposure as inducing inhibition of TORC2 under the same concentrations 
that only activate TORC1 under short-term exposure (Sarbassov et al. 2006).  
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1.5 Metformin 
1.5.1 Overview 
Metformin, (N,N- dimethylimidodicarbonimidic diamide), derived from the French 
Lilac (Galega officinalis), is a common guanidine-based hypoglycaemic agent used in the 
treatment of patients with type II diabetes (TIID) (Figure 1-7) (Witters 2001). Metformin 
functions to inhibit hepatic gluconeogenesis and increases muscle sensitivity to insulin (Hundal 
et al. 2000; Zhou et al. 2001). Although the mechanism by which metformin functions is poorly 
understood, it is proposed that the compound mimics DR, acting indirectly through AMPK to 
inhibit mTOR (Zhou et al. 2001). Previously, inhibition of mTOR has been associated with 
health and lifespan extension across numerous model organisms; treatment with metformin has 
demonstrated similar effects, decreasing cancer incidence in TIID patients treated (Evans et al. 
2005) and extending health and lifespan in some model organisms (Onken and Driscoll 2010; 
Anisimov et al. 2011; Martin-Montalvo et al. 2013), although in others no significant impact is 
observed (Smith et al. 2010; Slack et al. 2012). Though these findings are somewhat well-
documented, the impact of metformin on genome function (changes in gene expression) and 
genome organization are poorly understood. 
 
 
 
 
 
 
 
Figure 1-7: The Chemical Structure of Metformin (N,N- dimethylimidodicarbonimidic 
diamide). The chemical structure of metformin. In the commonly used biguanide, metformin 
is associated with hydrochloride.   
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1.5.2 Mechanism 
Metformin has been widely used in T2D treatment for over 50 years (Rena et al. 2013). 
Despite this, the mechanisms behind metformin function at the cellular/molecular level are 
poorly documented, remaining a great question for diabetes research. In recent years, canonical 
and non-canonical pathways for the action of metformin have been proposed.  
Metformin is thought to activate the major cellular energy sensor and regulator of 
homeostasis, AMPK (Zhou et al. 2001; Hardie et al. 2012). AMPK is highly-conserved and in 
most species, including humans, exists as a heterotrimer, containing an alpha () catalytic 
subunit and two regulatory sub units, beta () and gamma () (reviewed in (Hardie 2011)). It is 
important to note that each subunit has multiple isoforms encoding it;  (1 and 2), (1 and 
2) and  (1, 2 and 3) (Hardie 2007). AMPK is activated in response to energy stresses that 
increase either cellular ADP:ATP or AMP:ATP ratios (Hardie et al. 2012). Ratios are altered 
by decreasing catabolic production of ATP (e.g. by nutrient deprivation) or by promoting ATP 
usage (e.g. exercise). Specifically, as a result of lowered ATP levels, AMP or ADP directly 
binds to the  subunit of AMPK, causing conformational changes that normally protect against 
phosphorylation and activation of AMPK (Oakhill et al. 2011; Xiao et al. 2011). Metformin 
has been documented to cause mild inhibition of the mitochondrial respiratory-chain complex 
I. Therefore, it is possible that upstream of AMPK, metformin alters production of ATP in 
mitochondria, thus inducing changes in ADP:ATP/AMP:ATP ratios (El-Mir et al. 2000; Owen 
et al. 2000; Zhou et al. 2001). In addition to the conformation changes of AMPK, it has been 
documented that phosphorylation by the serine/threonine kinase liver kinase B1 (LKB1) may 
be directly involved in mediating and activating AMPK at Thr172 (Hawley et al. 2003; Woods 
et al. 2003; Shaw et al. 2004). Activation of AMPK results in the inhibition of mTOR signalling 
and results in similar downstream influences, including promotion of autophagy (either directly 
through ULK1 or indirectly) and inhibition of protein synthesis, cell growth and proliferation. 
Although well reported as involved in cellular response to metformin, it is unlikely that the 
compound directly binds to AMPK, or the activator LKB1, as metformin did not affect 
phosphorylation of AMPK by LKB1 in cell-free assays (Hardie 2006). 
Metformin has also been associated with a number of pathways acting independently of 
AMPK (Ben Sahra et al. 2011). In a mouse study in which AMPK was knocked down, it was 
documented that AMPK was not required for the anti-hyperglycaemic effects of metformin 
(Foretz et al. 2010), with similar results documented in prostate cancer cells (Ben Sahra et al. 
2008). One group suggests that the inhibitory effects of metformin on the mitochondria may 
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result in direct change in gluconeogenesis, bypassing AMPK activation (Owen et al. 2000). 
Other mechanisms, such as the up-regulation of DNA damage inducible transcript 4 (DDIT4) 
expression in a p53 dependent manner have been identified (Ben Sahra et al. 2008). DDIT4 is 
up-regulated in response to DNA damage, nutrient depletion, glucocorticoid and insulin and is 
a target gene of hypoxia-inducible factor 1 (HIF1) (Ellisen et al. 2002; Shoshani et al. 2002). 
DDIT4 has further been documented to regulate mTOR (Brugarolas et al. 2004), linking 
AMPK-independent signalling back to mTOR regulation of the cell.  
1.5.3 The Impact of Metformin on Genome Function and Longevity  
An unexpected, yet beneficial, side effect of metformin is its association with extending 
both health and lifespan in-vitro and in-vivo. Numerous studies report increased apoptosis and 
decreased proliferation of various cancer cell lines (e.g. lung  (Kato et al. 2012), retinoblastoma 
(Leclerc et al. 2013) and oesophageal squamous cell carcinoma (Li et al. 2014)) in response to 
metformin treatment. Patients with TIID treated with metformin have been reported to have a 
lower incidence of cancer than control TIID patients (Evans et al. 2005). Furthermore, model 
organisms (C. elegans (Cabreiro et al. 2013), M. musculus (Martin-Montalvo et al. 2013)) 
treated with metformin have documented health and lifespan extension, although these benefits 
are not without controversy, with no health or lifespan extension reported in D. melanogaster 
(Slack et al. 2012; Na et al. 2015) and R. norvegicus (Smith et al. 2010). Furthermore, 
metformin has proven useful in treating patients with metabolic syndrome; a condition which 
often exhibits age-associated conditions, such as cardiovascular disease, cancer and 
inflammatory disorders (Orchard et al. 2005; Ashinuma et al. 2012; Song et al. 2012; Alimova 
et al. 2014; Brodowska et al. 2014; Feng et al. 2014; Xu et al. 2015). Under conditions of 
excess nutrients, AMPK and SIRT1 (a deacetylase), are functionally down-regulated. 
Metformin induces the activation of both of these proteins (Nelson et al. 2012; Arunachalam et 
al. 2014). A target of SIRT1, and involved in the AMPK pathway, is the LKB1 kinase that 
when deacetylated, further phosphorylates AMPK, driving its activation. Both AMPK and 
SIRT1 share common targets, such as the p53 tumor suppressor gene.   
In human hepatic carcinoma (HepG2) cells, activation of AMPK and SIRT1 results in 
deacetylation of p53 and reduction of oxidative stress (potentially decreasing DNA damage), 
impeding p53 activation (Nelson et al. 2012). Mouse microvascular endothelial cells (MMEC) 
exposed to high glucose concentrations and treated with metformin were prevented from 
entering premature senescence as a result of up-regulated SIRT1 expression, modulating 
downstream FOXO1 and p53 (Arunachalam et al. 2014). In blood mononuclear cells (MNC) 
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of patients with carotid artery atherosclerosis, metformin ameliorated the pro-inflammatory 
response, decreasing Il-6, TNF-, and attenuating NF-B binding activity (Xu et al. 2015), with 
reported lower levels of acetylation likely the result of SIRT1 function. Amelioration of 
inflammatory genes has also been reported in the muscle and liver of metformin-treated mice, 
documenting down-regulation of inflammatory-associated Saa1 and Saa2 genes and a decrease 
in inflammatory markers NF-B and c-Jun N-terminal kinase (JNK) (Martin-Montalvo et al. 
2013). Concordantly, cytokine-inducible SH2-containing protein (CISH), a negative regulator 
of cytokine signaling, was up-regulated (Martin-Montalvo et al. 2013). Martin-Montalvo’s 
group also reported induction of stress-response and antioxidant-linked proteins in mouse livers 
treated with metformin, including SOD2, TrxR1, NQ01 and NQ02 (Martin-Montalvo et al. 
2013). Furthermore, in macrophages treatment with metformin decreased production of IL-1, 
and increased induction of anti-inflammatory IL-10 (Algire et al. 2012; Kelly et al. 2015). In 
contradiction, with other DR and DR mimetics, metformin resulted in increased levels of ROS 
which up-regulated expression of the uncoupling protein 2 (UCP2) transcripts (the protein of 
which functions to exchange anions and protons between the inner and outer mitochondrial 
membrane) in epididymal white adipose tissue of mice and in 3T3-L1 adipocytes (Anedda et 
al. 2008). However, inhibition of ROS was observed in macrophages in response to metformin 
treatment (Algire et al. 2012; Kelly et al. 2015). Combined, the increase in anti-oxidant genes 
and inhibition of ROS in some tissue contradicting the increased levels of ROS in others 
indicates that perhaps the induction/inhibition of ROS in response to metformin may be cell-
type specific, and may further be linked to the number of mitochondria in the tissue type. This 
could also be explained by the treatment concentration of metformin, with higher doses 
inducing greater stress upon the cell/tissue. Furthermore, together, these data indicate that 
metformin may inhibit multiple pro-inflammatory pathways via activation of SIRT1 and the 
repression of NF-B in addition to the up-regulation of CISH, as part of the mechanism 
influencing health and longevity in response to metformin.  
At the genome-wide level, transcript profiles from LoVo colon cancer cells were 
assessed by microarray (He et al. 2015). These analyses revealed that at 8 h, 10 mM metformin 
induced 134 differentially expressed genes, whilst at 24 h 3061 genes altered expression. It is 
likely that a cascade-effect occurs as a result of metformin treatment, with core genes changing 
expression and further impacting downstream transcription. Concentration of metformin has 
also been documented to have alternative impacts on health and lifespan, with 0.1% (w/w) 
metformin in the diets of C57BL/6 mice increasing lifespan whilst 1% (w/w) shortened lifespan 
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(Martin-Montalvo et al. 2013). It has previously been suggested that metformin may 
accumulate in skeletal muscle and other tissues over longer periods of times, resulting in 
potentially different effects (Musi et al. 2002). Furthermore, the concentration of metformin 
required to activate AMPK in either cultured muscle cells (Turban et al. 2012; Rena et al. 2013) 
or isolated rodent muscle tissue ex vivo (Zhou et al. 2001) was between 1-2 mM/L for 3-16 h, 
greater than the 4.5 M/L in plasma following administration of therapeutic doses (Bailey and 
Turner 1996; Hardie 2007). Rena, et al., (Rena et al. 2013) suggest that this evidence indicates 
no therapeutic effects are observed in muscle cells; however, work by Martin-Montalvo, et al., 
(Martin-Montalvo et al. 2013) have established an extension in lifespan of mice, with 
significant changes in gene expression following metformin administration. Interestingly, 
higher concentrations of metformin are noted in the liver when compared to other organs/tissues 
as a result of oral administration (Wilcock and Bailey 1993) (reviewed in (Rena et al. 2013)). 
This further provides evidence for the tissue-specific action of metformin. Furthermore, 
B6C3F1 mice also demonstrated lifespan extension; however, results were less significant than 
their C57BL/6 counterparts (Martin-Montalvo et al. 2013). Although CISH was consistently 
one of the most up-regulated genes between the mouse and liver tissues following metformin 
treatment of C57BL/6 mice, other genes were up-regulated in one but not the other (e.g. SOCS2 
in the liver, DDIT4 in the muscle) (Martin-Montalvo et al. 2013).  Therefore, the effects of 
metformin on genome function may not only be time and dose-dependent, but also strain/tissue- 
specific.  
The interplay between genome function and genome organization is complex, and 
although an active area of research, many questions remain, including the extent to which 
disrupted nutrient sensing can impact gene expression (genome function) and how this is linked 
to genome organization. Furthermore, it is unclear whether or not rapamycin and metformin are 
mimetics of one another and of dietary restriction, although it is clear that there are key proteins 
modulating response to these conditions (AMPK/SIRT1). This thesis will attempt to address 
some of these questions, determining in the same normal human cell line whether or not 
metformin and rapamycin induce the same effects on genome function and organization and 
further potentially proposing mechanisms for these effects.   
1.6 Summary 
Dietary restriction has been linked to increased health and lifespan in numerous model 
organisms. It is proposed that the inhibition of the mammalian target of rapamycin (mTOR) 
pathway as a result of decreased nutrient intake is the reason for these beneficial impacts. The 
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mTOR pathway is well established; however, the impact of this inhibition at the level of genome 
function (gene expression) and genome organization (folding in three dimensional space) is 
poorly understood. Both genome function and organization are essential in maintaining healthy 
cells and are often disrupted in disease. There are several compounds, including rapamycin and 
metformin, which have been proposed to mimic the beneficial effects of DR. Both compounds 
have recently been at the forefront of research, with human trials initiated into the impact of 
metformin on ageing and extensive work on both of these compounds in treating cancer. This 
thesis will examine the impact of inhibiting nutrient sensing, via rapamycin and metformin 
treatment, in normal human foreskin fibroblasts (designated 2DD) in order to determine the 
impact on genome function and organization. This work not only has applications in 
understanding fundamental biology, but in further understanding how to promote living 
healthier for longer.  
1.7 Hypothesis  
Human genome organization (folding in three-dimensional space) and function (gene 
expression) will be altered in response to rapamycin and metformin-mediated disruption of 
nutrient sensing.  
1.8 Objectives  
The objective of my project is to determine how genome function and organization 
respond to altered nutrient sensing as a function of treatment with either rapamycin or 
metformin. In order to address the main objective of this thesis, the following questions will be 
answered:  
1) Does disruption of nutrient sensing (via treatment with either rapamycin or metformin) in 
normal human foreskin fibroblasts induce changes in genome organization? 
a. Does disrupted nutrient sensing as a function of either rapamycin or metformin 
treatment impact cell growth and proliferation? 
b. Do significant areas of the genome (chromosomes) re-organize in response to 
disrupted nutrient sensing (via either rapamycin or metformin), therefore 
indicating changes in gene expression?  
2) Are transcript profiles changing in response to rapamycin or metformin mediated disruption 
of nutrient sensing?  
a. Which genes change expression significantly in response to disrupted nutrient 
sensing? 
b. Which biological pathways are responding to disrupted nutrient sensing? 
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2.0 Materials and Methods 
2.1 Cell Culture, Cell Counts, Cell Viability and Treatments 
Healthy human foreskin fibroblasts, designated 2DD (previously described in (Bridger 
et al. 1993), were grown in 1 X Dulbecco’s Modified Eagle Medium (pH 7.7; Corning, USA, 
Cat #: ca45000-304), containing high glucose (4.5 mg/mL), sodium pyruvate and glutamine. 
Media was supplemented with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, 
USA, Cat #: 12483-020) and 1.0% penicillin streptomycin (GE Healthcare Life Sciences, USA, 
cat #: SV30010). All cells were maintained in a humidified incubator at 37oC, 5.0% carbon 
dioxide (CO2) (Fischer Scientific, USA, Model #: 3532). In order to prevent contact inhibition, 
cultures proceeded no further than 70% confluency (covering an area no greater than 70% of 
the culture flask). Upon reaching 70% confluency cells were passaged; briefly, cells were 
incubated in 3 mL TrypLE Express (Life Technologies, USA, Cat #: 12604013) before 
undergoing centrifugation (174 g, 3 min), aspirating supernatant and re-suspending in 10 mL 
of culture media. Cell counts were conducted using 20 L of cell suspension on a 0.0025 mm2 
neubauer improved haemocytometer. Cells were seeded at a density of 3000 cells/cm2. For cell 
viability counts, cell suspensions were mixed 1:1 with 0.4% (v:v) trypan blue dye (VWR 
international, USA, Cat #: CA97063-702), and using a haemocytometer, total stained and 
unstained cells counted. Fibroblasts were left 24 hours (h) after passaging to re-adhere before 
commencing treatments. All experiments were conducted in fibroblasts less than passage 20.  
Quiescence was induced via decreased levels of FBS to 0.5% for 120 h. Media used for 
rapamycin and metformin treatments was identical to that used for proliferative cultures but 
included either 500 nM rapamycin (LC Laboratories, USA, Cat #: R-500) dissolved in dimethyl 
sulfoxide (DMSO), or 0.5 mM/1 mM metformin dissolved in distilled (d)H2O (Santa Cruz 
Biotechnology, USA, Cat #: sc-202000a) and filtered through a (polyvinylidene fluoride) 
PVDF 0.22 M pore-size syringe filter (Santa Cruz Biotechnologies, USA). Final DMSO 
concentrations in media were 0.046%, with parallel proliferative cultures treated with DMSO. 
Media was changed every 2-3 days to ensure drug presence over time. Cell counts following 
treatments were conducted in the same manner as described above. NB1 hTERT (immortalized 
NB1 fibroblasts) were grown under the same conditions and treatments carried out consistently.  
2.2 Immuno-labelling  
Proliferative, quiescent, rapamycin and metformin-treated cells were grown on 
sterilized 22 mm2 glass coverslips under the previously described conditions (2.1). Three 
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biological replicates were conducted. Cells were fixed with 4.0% formaldehyde (FA) in 1 X 
phosphate buffered saline (PBS, pH 7.0; Sigma Aldrich, USA, Cat #: P5493-1L) for 8 min at 
room temperature (RT). Cells were washed a further 3 times for 3 min in 1 X PBS and 
permeabilized with 0.5% Triton X-100/1 X PBS for 15 min before blocking in 1.0% bovine 
serum albumin (BSA)/1 X PBS for 30 min. Following this, cells grown on coverslips were 
labelled with 25 L primary antibody in 1.0% BSA for 1 h in a humidity chamber. Primary 
antibodies were; rabbit anti-LC3 (Abcam, UK, Cat #: ab48394) (1:2000 dilution) (for detection 
of autophagosomes associated with autophagy), rabbit anti-STAT5A/B (Abcam, UK, Cat #: 
ab7969) (1:200) and rabbit anti-STAT5 phospho-tyrosine 694 (Thermo Fisher Scientific, USA, 
Cat #: J.536.2) (1:100) (for the localization of the STAT5A/B protein). Coverslips were then 
washed for 2 min in 0.05% TritonX-100/1XPBS at RT. Each coverslip was incubated in 25 L 
of secondary antibody, goat anti-rabbit A488 (1:200) (Stratech/Jackson Scientific, UK, cat #: 
111-545-003-JIR) in a humidity chamber. All antibodies were diluted in in 1.0% BSA/1 X PBS. 
Nuclei were counterstained using either 20 L Hoechst 33342 dye (H33342; Invitrogen, USA, 
Cat #: h3570) (1:10,000 dilution in mounting media) or 20 L DAPI (Vector, USA, Cat #: H-
1200), mounted onto glass slides and sealed with nail varnish.  
For detection of the proliferative marker Ki67, cells were grown and treated as described 
above (2.1). Three biological replicates were conducted. Cells were fixed with 4.0% FA in 1 X 
PBS for 10 min at RT. Cells were dehydrated using an ethanol series (70%, 90%, 100%) at 5 
min per concentration. Cells on coverslips underwent further extraction with methanol:acetone 
(1:1 v:v, 5 min RT). Cells were rehydrated in ethanol series (100%, 90%, 70%) at 5 min per 
concentration before permeabilization with 0.5% Triton X-100/1 X PBS for 15 min and blocked 
in 1.0% BSA/1 X PBS for 30 min. Incubation with primary antibody rabbit anti-Ki67 
(Novacastra, USA, Cat #: NCL-Ki67p_CE) (1:5,000 dilution in 1.0% BSA/PBS) and secondary 
antibody incubation with goat anti-rabbit A488 (Stratech/Jackson Scientific, UK, Cat #: 111-
545-003-JIR) (1:200 dilution in 1.0% BSA/PBS) was conducted for 1 h each in a humidity 
chamber, washing for 3 min in 0.05% TritonX-100/1 X PBS between antibody incubations. 
Nuclei were counterstained using either Hoechst 33342 (H33342) dye (1:10,000 dilution in 
mounting media) or DAPI (Vector, Cat #: H-1200). Images were taken at 40 X magnification 
with constant exposure times. Grey-scale images were imported into ImageJ 
(https://imagej.nih.gov/ij/), an image processing software, and an arbitrary threshold selected 
for all images. Any images containing above threshold were considered positive.  
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2.3 5-ethynyl-2-deoxyuridine Incorporation 
Proliferative, quiescent, rapamycin and metformin-treated 2DD fibroblasts or NB1 
hTERTs were grown on glass coverslips under the previously described conditions (2.1). Three 
biological replicates were conducted. Live cells were incubated for 2 h with 5 M of 5-ethynyl-
2-deoxyuridine (EdU), fixed and permeabilized using the methods previously described for 
immuno-fluorescence (2.2). Following permeabilization, cells were blocked in 1.0% BSA for 
20 min before labelling using the Click-iT reaction cocktail (430 L 1 X Click-iT reaction 
buffer, 20 L copper sulphate (CuSO4), 1.2 L AlexaFluor555 azide and 50 L reaction buffer 
additive) (Life Technologies, USA, Cat #: C10338) and incubated in a humidity chamber for 1 
h. Nuclei were counterstained using either H33342 dye (1:10,000 dilution in mounting media) 
or DAPI. 
2.4 Cell Cycle Analysis by Flow Cytometry  
For flow cytometry, proliferative, quiescence-induced, rapamycin-treated and 
metformin-treated cells were grown for 120 h before fixing in a 70% ethanol:1 X PBS solution 
for 30 min, 4oC. Fixed cells were pelleted at 100 g, 10 min, RT, and washed 2 times in 1 X PBS 
for 3 min. Fibroblasts were then re-suspended in 1ml dH2O and 20 µL of propidium iodide 
solution (VWR International, USA, Cat #: CA421301-BL). 100 µg of RNase was added and 
samples were incubated at 37oC for 20 min. Analysis was performed using the BD Accuri C6 
flow cytometer, flow rate was set to slow and 10,000 events recorded. Events were plotted using 
forward scatter (FSC, X-axis) and side scatter (SSC, Y-axis) parameters in order to identify 
single cells, and gates were used to remove cellular debris and doublets from the analysis. A 
histogram with linear axes plotting fluorescence intensity units (X-axis) against events counted 
(Y-axis), and gates were set to determine the percentage of cells in G1/G0, S and G2 phase 
based on DNA content.  
2.5 Western Blotting 
Western blot analyses were conducted on protein extracts generated from proliferative, 
quiescent, 500 nM rapamycin-treated, and 0.5 mM/1 mM metformin-treated 2DD fibroblasts 
at 120 h. Following dissociation of cells from 150 cm culture dishes using 5 mL TrypLE 
EXpress for 3 min (Life Technologies, USA, Cat #: 12604013) cells were pelleted at 174 g, 
RT, supernatant removed and disrupted in 300 L RIPA buffer (25 nM Tris-HCl pH 7.6, 150 
mM NaCl, 1.0% NP-40, 1.0% sodium deoxycholate, 0.1% SDS). Protein extracts were 
quantified using Bradford assay (Biorad, cat #: 500-0006) and loaded with protein equivalents 
(amount loaded indicated in each figure). Briefly, Bradford solution was diluted 1:5 with dH2O 
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and 1 mL added to cuvettes containing a BSA concentration range of 0 g to 1000 g in 20 L 
volume.  Absorbance was measured using the Protein Bradford setting (595 nm absorbance; 
NanoDrop 2000, Theremo Scientific, USA) and a standard curve plotted. Protein extracts were 
diluted 1:4, 1:10 and 1:20 in dH2O and 20 mL combined with 1 mL 1:5 Bradford assay. Extracts 
were then measured against the standard curve to determine protein concentration and extracts 
were loaded equally in each western blot assay (volume loaded indicated in respective figures).  
Protein extracts were loaded in 1 X lamelli buffer (2 X: 1.25 mL 1 M Tris-HCl (pH 6.8), 4.0 
mL 10% (w/v) SDS, 2.0 mL glycerol, 0.5 mL 0.5M EDTA, 4 mg EDTA, 0.2 mL -
mercaptoethanol (14.3 M), to 10 mL with dH2O) and run on a polyacrylamide gel with a 5.0% 
polyacrylamide top-gel in 1 X running buffer (25 mM Tris, 190 mM glycine, 0.1% SDS (pH 
8.3) at 100 V for 1h 30 min. Protein was transferred to nitrocellulose membrane in transfer 
buffer (25 mM Tris, 190 mM glycine, 20% methanol (pH 8.3)) using semi-dry transfer 
equipment at 30 V for 1 h. The membrane was then blocked in 5.0% skim milk powder in Tris-
buffered saline containing 0.5% Triton X-100 (SMP/TBST) for 1 h. The membrane was then 
incubated overnight in primary antibody diluted in 2.5% SMP/TBST at 4oC. Primary antibodies 
used were rabbit anti-LIF (1:500 dilution, Abcam, UK, Cat #: ab113262), rabbit anti-p70-S6 
kinase-phospho421/424 (1:500 dilution, Cell Signaling, USA, Cat #: 9204S), rabbit anti-Actin 
B (1:2000 dilution, Abcam, UK, Cat #: ab8227), rabbit anti-ActC1 (1:500 dilution, Abcam, UK 
Cat #: ab151787), rabbit anti-STAT5A/B (Abcam, UK, Cat #: ab7969) (1:2000), rabbit anti-
phosphor-mTOR (ser2448) (1:500 dilution, Cell Signaling, USA, Cat #: 5536), rabbit anti-
LC3b (1:7500, Abcam, UK, Cat #: ab48394), rabbit anti-AMPK1 (1:500, Millipore EDM, cat 
#: 15-115), rabbit anti-AMPK2 (1:500 Millipore EDM, Germany, cat #: 15-115), rabbit anti-
AMPK(Thr172) (1:500, Millipore EDM, Germany, cat #: 15-115)). The membrane was 
washed 3 X in SMP/TBST for 5 min each before incubating in secondary diluted in 2.5% 
SMP/TBST for 1 h. Following secondary, the membrane was washed 3 X in SMP/TBST for 5 
min each, 1 X in 0.5% TBST and then developed using enhanced chemiluminescence (Fisher 
Scientific, USA, cat #: 45100100).  Secondary antibodies used were goat anti-rabbit horse 
radish peroxidase (HRP) (1:5000 dilution) or donkey anti-mouse HRP (1:5000 dilution, 
Jackson Scientific/Cedarlane, UK, Cat #: 715-035-150).  
2.6 2D FISH/Chromosome Painting and Erosion Analysis 
2DD fibroblasts were grown under proliferative, quiescence-induced, 500 nM 
rapamycin-treated and 0.5 mM/1 mM metformin treated conditions for 120 h. Probe generation 
and cell preparation were conducted following the protocol detailed by Mehta and colleagues 
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(Mehta et al. 2010). Briefly, cells were dissociated from the culture flasks using 5 ml Tryple 
Xpress incubated for 3 min and pelleted at 174 g, RT, before incubating in 75 mM potassium 
chloride (KCl) for 15 min. Fibroblasts underwent drop-wise fixation with cold 3:1 (v:v) 
methanol:acetic acid and were washed three times in the same solution. Coverslips were 
prepared by “huffing” to create moisture to assist the cells in adhering and then cells were added 
dropwise ~1 foot to the coverslip and incubated at RT for 2 days. Coverslips were warmed and 
cells denatured for 2 min at 70oC in 70% formamide, 2 X saline sodium citrate (SSC) followed 
by immediate dehydration in ice cold 70% ethanol. Coverslips then underwent a further 
dehydration series (90%, 100% EtOH) and left to dry at RT. Probe (15 L of chromosome X, 
10 or 18) was added and the coverslip sealed to a glass slide using rubber cement and incubated 
overnight in a humidity chamber at 37oC.  Probes were generated by Degenerative Oligo 
Primers (DOP)-PCR of chromosomes containing biotinylated uridine residues (biotin-16-UTP, 
Roche). The rubber cement was removed, coverslips lifted and washed in wash buffer A (45oC; 
50% formamide, 2 x SSC) for 15 min and then wash buffer B (60oC; 0.5 X SCC) for 15 min. 
Coverslips were transferred to 1 X PBS and underwent immuno-labelling for goat anti-
streptavidin-Cy3 (1:200; Vector laboratories, USA, cat #: Ba-0500) for 1 h, goat anti-
streptavidin conjugated to biotin (1:200; Cedarlane, UK, cat #: 111-065-003) 1 h and then a 
second streptavidin-Cy3 for 1 h. A 2 min 0.05% TritonX-100/1 X PBS wash was conducted 
between each antibody incubation. Samples were mounted in either DAPI of H33342. 
Photometrics cooled charged-coupled device (CCD; Photometrics) was used to capture digital 
grey-scale images of random nuclei. Images were false-coloured in Adobe Photoshop (CS6). 
Smart Capture VP V1.4, a Leica fluorescence microscope (Leitz DMRB) with Plan Fluor 100 
× oil-immersion lens was used to collect images. Newly-developed software (using Python 
coding language)  called the Cell Nucleus Analyzer for nuclear segmentation and analysis was 
used and was based on the analysis software used previously (Croft et al. 1999). This software 
divides the H33342 image into five concentric shells of equal area, the first being the most 
peripheral and innermost denoting the interior of the nucleus. The script measures pixel 
intensity of H33342 and the chromosome probe in these five shells. Normalization of the probe 
signal was conducted by dividing the percentage of the probe by the percentage of H33342 
signal in each shell. For each treatment condition (proliferating, quiescence-inducted, 
rapamycin or metformin-treated) ≥ 35 nuclei were measured for each chromosome. Ratios from 
each shell were averaged and the standard error of the mean calculated. Data were plotted as 
bar graphs with the X-axis representing the shell and the Y-axis the % signal chromosome/% 
signal H33342. Overlapping cells in the images were segmented using a semi-automatic method 
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based on the watershed algorithm (Vincent and Soille 1991) and user-specified markers. Both 
2-tailed Student’s T-tests for unequal variance and correlation calculations were performed in 
Microsoft Excel to demonstrate significant alterations in positioning.  
2.7 RNA Extraction 
RNA was extracted from proliferative, quiescent and rapamycin treated cells using 
either Trizol (Invitrogen) or the FastRNA Pro Green Kit with FastPrep-24 instrument (MP 
Biomedicals) according to the manufacturer’s instructions. Briefly, cell samples were added to 
RNAproTM solution and Lysing Matrix D. Samples were processed in the FastPrep-24 
instrument for 40 seconds at setting 6.0 before centrifugation at 12,000 g for 5 min at 4oC. The 
resulting upper phase was incubated at RTP for 5 min before addition of 300 l of chloroform 
and vortexing. Samples were incubated again for 5 min at RTP and centrifuged (12,000 g, 5 
min, 4oC). Samples were precipitated using 500 L of cold 100% EtOH, 20oC, for 30 min. 
Samples were again centrifuged under the same conditions and resulting pellet washed with 
cold 75% EtOH, pellet dried and RNA re-suspended in nuclease-free dH2O.  For proliferative, 
0.5 mM and 1 mM metformin-treated cells, RNA was extracted using RiboZol (Amresco, cat 
#: N580-100ML). Specifically, samples were disassociated from the surface of culture dishes 
using Tryple Xpress and pelleted. Cells were re-suspended in 1 mL RiboZol and incubated at 
RTP for 5 min. 200 L of chloroform was added and samples vigorously mixed and incubated 
at room temperature for 3 min. Samples underwent centrifugation (12,000 g, 5 min, 4oC) and 
the clear upper-phase separated from the sample. RNA was precipitated via addition of 2.5 X 
volume 100% EtOH and 1/10th sample volume 1.5 M sodium acetate overnight at -80oC. 
Samples were pelleted (12,000 g, 15 min, 4oC) and washed in 75% cold EtOH. The pellet was 
air-dried at RTP and re-suspended in nuclease-free dH2O.   RNA extraction for proliferative, 
quiescent and rapamycin treated fibroblasts were conducted at the same time for each replicate, 
as were RNA extractions for proliferative, 0.5 mM and 1 mM metformin treated samples. Three 
biological replicates were conducted. RNA concentration was determined using the 
NanoDrop2000 (Theremo Scientific) and aliquots stored at -80oC to avoid RNA degradation 
from freeze-thaw cycles. Cultures for treatment were expanded from a single flask of fibroblasts 
to prevent any variation in passage or chronological age of the culture. The integrity of all RNA 
was determined using a Bioanalyzer (Agilent Technologies) with RNA only with an RNA 
integrity number (RIN) above 8.40 used for further analysis.  
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2.8 cDNA Synthesis 
For the sample set comprising proliferative, quiescence-induced and rapamycin-treated 
fibroblasts, 5 g RNA was used in each reaction with 50 ng of random hexamer used as primers 
in SuperScriptIII reactions. Specifically, 5 g total RNA, 1 L of 50 ng/L random hexamers, 
1 L 10 mM dNTP mix made up to 10 L with nuclease free dH2O were incubated for 5 min 
at 65oC. A master mix of 2 L 10 X RT buffer, 4 L of 25 mM MgCl2, 2 L 0.1 M DTT, 1 L 
RNaseinTM (40 U/L) (Ambion, Cat #: AM2694) and 1 L of SuperScriptTM III RT (200 
U/L) (Thermo Fisher; Cat #: 18080051) was added to a total reaction volume of 20 L. 
Samples were incubated at 25oC for 10 min, 50oC for 50 min and 85oC for 5 min.  Synthesized 
cDNA was diluted to a total volume of 100 L dH2O.  For all other samples, 2 g RNA was 
used in an initial reaction with 1 L of 10 M random primers and 1 L of 10 mM dNTP mix. 
Reactions were made to 14.5 L with nuclease free dH2O and incubated at 65oC for 5 min 
before a further 1 min incubation on ice (ABM, cat #: G177). For the final reaction volume, 5.5 
L of master mix containing 4L 5X RT buffer, 0.5 L RNaseOFF Ribonuclease Inhibitor (40 
U/L) and 1 L EasyScript PlusTM RTase (200 U/L) was added to the reaction, incubated at 
25oC for 10 min, 50oC for 50 min and 85oC for 5 min.  Synthesised cDNA was diluted to 200 
L with nuclease free dH2O.  
2.9 Reverse Transcriptase-qPCR 
Following cDNA synthesis and dilution, cDNA for proliferative, quiescent and 
rapamycin-treated samples was further diluted 1:10. For proliferative, 0.5 mM and 1 mM 
metformin-treated samples, cDNA was further diluted 1:16. 1L of sample was used in each 
10 L reverse transcriptase (RT)-qPCR reaction with 300 nM forward and reverse primer, 1.5 
L nuclease free H2O and 5 L of qPCR mastermix (either BioRad, cat #: 1725272 or Life 
Technologies, cat #: 4472908). Each reaction was run in triplicate with no-template controls to 
ensure there was no contamination. Melt curve analyses were conducted to confirm the presence 
of single products in each reaction. RT-qPCR results were quantified using five normalizing 
genes (PRDX5, EFEMP2, FAU, SPARC and FKBP10) identified from RNA sequencing data. 
The fold change for each gene of interest was compared to each of the normalizers and the 
average fold change between the five genes calculated. S.E.M. were calculated for all genes of 
interest. A complete list of primers used for validation is given (Table 2-1).  
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Table 2-1: qPCR Primer Sequences 
Primer sequences used in the validation of both rapamycin and metformin RNAseq datasets. F 
represents forward primer; R represents reverse primer sequences. All primers are given in the 
5’-3’ direction.  
Gene/Direction Sequence (5’-3’) Gene/Direction Sequence (5’-3’) 
SPARC F TACATCGGGCCTTGCAAATAC LIF F AGATGTCTCCGGGCCCTTAT 
SPARC R GGTGACCAGGACGTTCTTGAG LIF R ACGATGGGGAGGAGAGACAA 
THY1 R CAGGGATGAGCAAGAGGAATG PTGS2 F GCCTACTGGAAGCCAAGCAC 
THY1 F CCTGTCTTGGCTGGTAAGTGG PTGS2 R TAAAGGGACAGCCCTTCACG 
PRDX5 R GCATAGTGAAGGCCCTGAATG NR4A1 F CCCTGACCCCTGAGTTCATC 
PRDX5 F GGGGTGGAGGAAGTAATCTGG NR4A1 R TGTAGCCGTCCATGAAGGTG 
EFEMP2 R GCCCAAACCTGTGTCAACTTC FAM180A F ACCCTGGCCTACACAGCCTA 
EFEMP2 F CGGTTCTCAGAGACCTGGATG FAM180A R AGGGCCTGGAAGAGGCTAAC 
FAU F CGCATGCTTGGAGGTAAAGTC EREG F CAAGCTAACCCTGGGGAGTCT 
FAU R TTCTCCTGTTTGGCCACCTTA EREG R GCATAGGGAACTGTCCACTGC 
FKBP10 F GCCGTGCTAATCTTCAACGTC GEM F TGCTACCCCTGAGGACCACT 
FKBP10 R GGTGGTCTCATTGCAGGTCTC GEM R GCTCCCCTATGAGCACCACT 
ADH1B F TCTCCCAGTACACGGTGGTG EDNRB F CGATGGAGAGATGCCAGTGA 
ADH1B R TGCAGACCCATAACCAGTCG EDNRB R GTGCTACCTGCCCCTTTGTC 
TNXB F CCCGGAGTGCTATGGATGAT SOX 4 F GAAGAGGCCTGTTTCGCTGT 
TNXB R GAGTTCTGGGTCACGGTGGT SOX 4 R GGAGCTGGTAATGGCAGGAG 
CYP21A2 F CTGATCGGTGGCACTGAGAC CXCL1 F ATTTCTGAGGAGCCTGCAACA 
CYP21A2 R CTGCAGTCGCTGCTGAATCT CXCL1 R CCCTGCCTTCACAATGATCTC 
APOD F GCATCCAGGCCAACTACTCAC TGFA F CACATGGGTCACCAGTTGCT 
APOD R GAGGTTAACTGGGGTGGCTTC TGFA R ACTAGAGGGCAGGGGTCTCC 
WISP2 F ACAGCTGCCGGAACATAAAGA CXCL2 F GCTTATTGGTGGCTGTTCCTG 
WISP2 R TTCGGTGTGCCTCTCATGTC CXCL2 R AACACATTAGGCGCAATCCAG 
PTGDS F CGTTGTCCATGTGCAAGTCTG HOTAIRM1 F TGGGGGTTTCTGTAGGCACT 
PTGDS R TTCGGGTCTCACACTGGTTTT HOTAIRM1 R TGCACAGGTTCAAGCCATAGA 
SFRP4 F AAAAGCTGTGCAGAGGAGTGG LAMA F CATCCCTGTCCCTGTCACTG 
SFRP4  R AGGGATGGGTGATGAGGACTT LAMA R GGCTTGGGTTACTGGTCAGG 
CTSK F GGGACATGACCAGTGAAGAGG FOXO3 F TCCTCTGGGGGTGATATTGG 
CTSK R GGGCTCTACCTTCCCATTCTG FOXO3 R AGGCAGGAGACGTGTGACAA 
PPL  F AAAGGCAAATACAGCCCCACT SATB1 F GACGAAGAGGCCATCCAGAC 
PPL  R TGTCCACGATGTTCTTCTCCA SATB1 R TGCCGTGGTGCTTGAGATAG 
APOE  F ACGAGGTGAAGGAGCAGGTG HIVEP1 F TGGATCCCAAGCCTGAACTT 
APOE R GCTCGAACCAGCTCTTGAGG HIVEP1 R TGGGACATGTTGGCTGAAAG 
FABP3  F ACTTGTGCGGGAGCTAATTGA PSG8 F GCCCGTGTGTTTGCAGATAA 
FABP3  R GTCAGCAACAGTGCAGTCAGG PSG8 R CGAGAGCCATCCACAGAATG 
LTBP4   F GGCTGGTCCTGGTTACCACT LACC1 F TCACATGGGCTCGAAAGATG 
LTBP4   R GTACGAGGCTGGCTGAGTGAC LACC1 R CAGTTTCATGCCCTGGTTCA 
COL14A1  F ACGACGTGACTGAGAACAGCA Neat1 F TCAGAGGGTTGTTTTGTTTGG 
COL14A1 R GGCCCTCTGTTAGAGGAGCAT Neat1 R ATCTGCTGCGTATGCAAGTCT 
C3   F GTCAACCACAAGCTGCTACCC SCN5A F CTCTTTGGGGCAAGATCCAG 
C3  R GCCAAGCTGGTTCTGAGAAGA SCN5A R AAGAGGTCCTGGGGGTGATT 
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RARRES2  F GCCCCATAGAGACCCAAGTTC JAK2 F TGATGCTAGCCAGCAAAGATG 
RARRES2  R GTAGAAGCTGTGGGGGTCCTC JAK2 R CTGGTGGCCTCATGAAGAAAA 
IL34 F CTGAGACTTCAAGGGGTGGTG Cables1 F AGCCAAAATTGGAAGTGACCT 
IL34  R ACAGAATCCCCCTCAAAGGAA Cables1 R CACTAACACCGGGAATTCAAA 
EGR2  F TAAGTGTGGAGGGCAAAAGGA MTMR8 F GGAGAATGGCACCCTATCCA 
EGR2  R CACAACCTGGAGACCCAACTC MTMR8 R TAAGGCTGCCCACAATCTCA 
IDI1  F CTGTTGACATTTGGGCTGGAT LAMB4 F GGGCTCTGTTGAACCTGTGA 
IDI1 R CTGTGGGTGTCACATGAGAGG LAMB4 R CATTTCAACCTCCAGCCACA 
IGF2  F AAGTCGATGCTGGTGCTTCTC RARB F AGGCTGGTCTACCACCTGGA 
IGF2  R ACAGACGAACTGGAGGGTGTC RARB R AATTAGCCCCTTGGCATCAA 
C1R F AGCTCGTCTTCCAGCAGTTTG GNG4 F CATCATTCCAGTGCCTGCAT 
C1R  R CCCCAGGCTTTTCTTATCAGC GNG4 R GGAGGCGTTTTCATCACACA 
CFH F TATAGACGTTGCCTGCCATCC Hbb R2 F AAGCTCGCTTTCTTGCTGTC 
CFH   R GGGAGTAGGAGACCAGCCATT Hbb R2 R GATGCTCAAGGCCCTTCATA 
C1S F TCTGTGCTGGAGGAGAGAAGG RIT2 F TGCCTGTAGGTAAAAGCAAGC 
C1S R CCAGCTGCGTAGAATTTGGTC RIT2 R TCCAGCTGATTGACAAAATCC 
FOSB F CCTTCCAGACCAGCCAAGAC PTPRB F CCCGATGGACCTGCTATGAT 
FOSB R AAGTTCAAGTCCTCGGCGAC PTPRB R TCCTGGCCTTCTTGACCACT 
FOS F CCCTCACCCTTTCGGAGTC LBX2 F CGGAAGTCCTGTGCAGCTTA 
FOS R GGCCTCCTGTCATGGTCTTC LBX2 R GCGGCTTTGTCTTCAATCGT 
NR4A2 F AGCACAGGCTACGACGTCAA RGS4 F AGCAGGAAGACGCTCAGAGG 
NR4A2 R AGGTGGCTGTGTTGCTGGTA RGS4 R GGAATTCGCAAGCAGGAAAG 
CRIM1 F TTCGGGATTTACGGAACCTG AGT F CCCAGTCTGAGATGGCTCCT 
CRIM1 R CGCTTCGTACTCGGTGAGG AGT R TGTGGATGACGAGGTGGAAG 
ATF3 F TGTATTGTCCGGGCTCAGAA NEFM F GGTGGAGCGCAAAGACTACC 
ATF3 R CCCCATACCACGACTGCTTAG NEFM R AGCGGCATTTGAACCACTCT 
HIST1H3A F TCCGCCGTTATCAGAAGTCC ANKRD1 F CCGATGGATCTGGTGCTACA 
HIST1H3A R GAGCTCTGGAAACGCAGGTC ANKRD1 R TGCCTTCAAAATGCCAGTGA 
PTPRN F CTATCTGGCCCAGGAGTTGC CTSK F GCACTTTGGAAGGGAGTTGG 
PTPRN R CAGGCTTCTCTCCACGATCC CTSK R GGTCATGGGTGGAGAGAAGC 
CNKSR1 F AACCCCAGCTTCTGACGTGT MAPKAPK5 F AACCAAGTGGCCTTGGAAGA 
CNKSR1 R CTCGGGGTGAGACCATGACT MAPKAPK5 R TGCTTGGCACAAAAATCACC 
MMP13 F AGAGGCTCCGAGAAATGCAG HES6 F CAGAGGTGGCAGAAATGGTG 
MMP13 R CCGCATCTTGGCTTTTTCAT HES6 R CAGTGCACCTGCCTCTCATC 
KRT16 F CCAACTGCTCACTCGCTCAC LCE1F F TCCCAAGTGCACTCCCAAG 
KRT16 R TTCATGGAGCTGGAGGAGGT LCE1F R TGCAGCAGGAAGAGACAGGA 
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2.10 RNA Sequencing and Mapping 
Extracted RNA from proliferative, quiescence-induced and rapamycin-treated 2DD 
fibroblasts were submitted to the Centre for the Analysis of Genome Evolution and Function, 
University of Toronto (Toronto, Canada) and poly-adenylated RNAs purified. cDNA libraries 
were constructed from 1 g of RNA using random hexamers to prime the reaction with average 
fragment lengths of ~300bp. These libraries underwent paired-end sequencing using the 
Illumina GIIx to generate 75 bp reads from two biological replicates of each sample. Reads 
were mapped back to a human reference genome (GRCh37/hg19 assembly from Ensembl) 
using the TUXEDO software package including TopHat2 with the following parameters: --
bowtie1 -p 8 -r 20 --solexa-quals --coverage-search--microexon-search--library-type fr-
unstranded. No clipping of reads was conducted. For proliferative, 0.5 mM and 1 mM 
metformin treated fibroblasts, cDNA libraries were constructed as previously described and 
underwent 150 bp paired-end sequencing using the Illumina HiSeq 2000 machine. Sequencing 
was conducted on two biological replicates of each sample. Reads were trimmed using Trim 
Galore: --phred33 --fastqc_args "--outdir=./fastqc_analysis/" --paired --illumina --clip_R1 12 -
-clip_R2 12 --length 80 --stringency 2 and mapped back to a human reference genome 
(GRCh38/hg19 assembly from Ensembl) using the TUXEDO software package, including 
TopHat2 with the following parameters: --library-type fr-unstranded --coverage-search --
microexon-search -p 8 -o.  For both rapamycin and metformin sample sets, BAM files were 
imported into the quantification and visualization tool SeqMonk 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk). Using the feature probe 
generator function, 149, 135 probes were produced for the rapamycin sample set and 169, 714 
probes for the metformin sample set. Probes were produced and reads quantified within these 
probes using the reads per kilobase of gene per million reads (RPKM) normalization method as 
previously defined (Mitchell et al. 2012). A read value of 0.05 was added to each probe to avoid 
infinite values during quantification. Examination of several transcripts demonstrated that 
genes from treated samples had sufficient read depth that the ≥5-fold change (quiescence-
induced and rapamycin-treated samples) and ≥2-fold change (metformin-treated samples) in 
these genes is not an artefact of low data volume. Probes were converted to genes in SeqMonk 
and genes that had significant fold changes in the treated fibroblasts calculated against 
proliferative reads as a baseline. Genes were analysed at multiple fold-change cut-offs, 
including either increased or decreased ≥2-fold, ≥3-fold and ≥5-fold.  
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2.11 Enzyme-Linked Immunosorbent Assays 
Cells were cultured as described in 2.1; however, cells were grown and maintained in 3 
mL of media for proliferative and rapamycin-treated fibroblasts for the duration of the 
experiment. Cells were grown for five days, media removed and stored at -80oC. Sandwich 
Enzyme-Linked Immunosorbent (ELISA) assays for IL-6 and IL-8 were conducted according 
to manufacturer’s instructions (R&D Systems) and quantified. Briefly, an antibody specific to 
the protein of interest (i.e. Il-6 or Il-8) was adsorbed to the bottom of a plate. The wells were 
then incubated with aliquots (500 L) of media from each treatment, allowing the proteins of 
interest to bind the primary antibody. Any protein of interest present attached to this antibody 
and excess sample was removed by washing. A secondary antibody specific to the protein of 
interest and conjugated to horse radish peroxidase (HRP) was added. If binding was successful, 
light was given off and measured. Results were compared against a standard curve. The amount 
of signal obtained was directly related to the amount of target protein in the sample. 
Significance was calculated using one tailed Student’s t-tests. 
2.12 Network Analyses 
Cytoscape (Shannon et al. 2003) and ReactomeFI (Wu et al. 2010) were utilized to 
identify enrichment of network annotation terms (Kyoto Encyclopaedia of Genes and Genomes 
(KEGG)) to categorize specific pathways either up-regulated or down-regulated in response to 
500 nM rapamycin, quiescence-induction, or 0.5 mM/1 mM metformin treatment. Lists of 
Ensembl gene IDs were input to the Gene Set/Mutation Analysis function (2014 network, gene 
set file format) and built-in functions of ReactomeFI Analyze Network Functions used to 
identify KEGG and Gene Ontology (GO) term enrichment within the constructed networks 
(including Pathway Enrichment).  Each module included a minimum of two genes to be 
included in KEGG analyses and GO term enrichment. GeneCodis was used to identify GO 
terms associated with biological processes for lists of genes that were up-regulated and down-
regulated in response to the various treatment conditions. For visualization of the networks, the 
most significantly enriched KEGG annotation terms were uploaded to Cytoscape using 
CytoKEGG. The nodes were coloured based on fold change with up-regulated represented in 
green and down-regulated in red, with more intensely coloured nodes representing those that 
had the greatest fold change.  
2.13 Promoter analysis 
Cis-Element Overrepresentation (CLOVER) (Frith et al. 2004), with the TRANSFAC 
database, was used to identify over-represented transcription factor binding sites in the 
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promoters of genes that exhibited a ≥5-fold change in transcript abundance during quiescence 
induction or rapamycin treatment. The complete set of human promoter sequences was used as 
a background baseline. Transcription factor binding sites were ranked based on raw score and 
only contained those with p-values <0.05. 
2.14 Chromatin Immuno-Precipitation 
2DD cells were grown to 70% confluence in 150 mm diameter dishes and treated as 
previously described (2:1).  The cells were fixed with 1% FA in 10 mL media for 10 min at 
37oC and washed 2 X with 10 mL PBS containing 1X protease and phosphatase inhibitors 
(Sigma).  Cell pellets were lysed for 10 min on ice in 600 l SDS Lysis buffer (1% SDS, 10 
mM EDTA, 50 mM Tris pH 8.0) with added inhibitors. The cells were sonicated on ice, for 
three cycles of 60 seconds at 30% duty cycle, into chromatin fragments ~500 bp in length. For 
the primary antibody, 5 g of anti-STAT5A/B (Abcam, Cat #: ab7969) was added to 107 cells 
and incubated overnight at 4oC, followed by binding of complexes of protein A Dynabeads 
(Invitrogen) overnight at 4oC.  For NFATC2 (Abcam, Cat #: ab2722) or RNAPII-S5 (Abcam, 
Cat #: ab5131) ChIP assays, 5 g of antibody was bound to protein G (EDM Millipore Cat #: 
16-201) or protein A agarose beads (EDM Millipore Cat #: 16-157), respectively, for 2h at 4oC. 
For non-specific binding controls, goat anti rabbit antibodies were bound to both protein A 
agarose and Dynabeads. The samples were washed with Low Salt buffer (0.1% SDS, 1% Triton 
X, 2 mM EDTA, 20 mM Tris pH 8.0, 150 mM NaCl), High Salt buffer (0.1% SDS, 1% Triton 
X, 2 mM EDTA, 20 mM Tris pH 8.0, 500 mM NaCl) and TE buffer, and eluted with 500 L 
Elution buffer (1% SDS, 0.1 M NaHCO3).  Crosslinks were reversed with 20 L 5M NaCl 
incubated at 65oC for 5 h, followed by phenol chloroform extraction and DNA 
precipitation.  DNA was re-suspended in 30 L ddH2O and 0.67 l used in 10 uL RT-qPCR 
reactions carried out with gene-specific (300 nM) primers. ChIP-qPCR data was normalized by 
the percent input method and enrichment calculated. Standard error was calculated as a function 
of the standard deviations between triplicates.  ChIP primers used are presented in (Table 2-2). 
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Table 2-2: ChIP Primers 
Primers designed for use in Chromatin Immuno-Precipitation (ChIP) assays. F represents 
forward primers whilst R represents reverse primers. All primers are given in the 5’-3’ direction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene/Direction Sequence 5’-3’ 
CXCL1 F GGCTGAGGCAGAGAGGATAATA 
CXCL1 R GAAGAGCGTTGTGTCTCGGAT 
CXCL8 F GCCCCCTAAGAGCAGTAACA 
CXCL8 R TGGTGAAGATAAGCCAGCCA 
IDI1 F CTTTCGGATTGGGAGGGCTT 
IDI1 R GCCAATCACGCTTTCGATCC 
IFNA1 F ACCAAAGTCTTCAGAGACCCA 
IFNA1 R TGAGCTGGTTCAGATGGATGAC 
IL1B F TGACTCGGGAAATATTCTGGGAA 
IL1B R GGAGCAGAGGCTTTGACACTA 
AMIGO2 F TGCCCCAAAGCAAAGCTCTA 
AMIGO2 R CACCCTTGGAGACCCACTTC 
CXCL2F ACTGCACTGGGTTCACGAAG 
CXCL2 R TCTCTTTCTGCCCCGAATCC 
CATSPERG F GGAAGCACAAGTAGGGACCG 
CATSPERG R AGAGGGTGCTGGAGACTACG 
ATR F AAAGAGGGACAAGAGCGGTG 
ATR R CCAGCGAGTAAAGGCCAAGA 
BAZ1A F TGGGAAAGTTGCTTTAGGGGAA 
BAZ1A R GGACCCCAGCATTCTTGAAAC 
BEND7 F CTCTTTCCACAATCCGCCCA 
BEND7 R ACTTACCCATTTGCGCTCTCT 
MDM2F TCCGCATTTGTCGCAGTTTC 
MDM2 R TAGCCGTTGCGCTATGTTTG 
BMP2 F GATTTCGCCTCCAGAGTCCC 
BMP2 R CTCCACTCCCTGCTCTCAAA 
IVL F CCCTGTGCCTAGGTCAGAAAA 
IVL R AAACCCTTTAGGGCCCCATT 
JAK2 F CATTGCCACGAAACAGCGT 
JAK2 R TTCTCCGCTTTCGGCTTTTC 
LIF F CCCAAACCCAGGTGAGTCAG 
LIF R GTTTTCCTGCCTGGCTTGTC 
IL6ST F CTCCAGTTCATGACCCCGTT 
IL6ST R TCGCCTCTCCCAGACTAGAT 
JARID F TCGCTCGGGTGTCTGGTTG 
JARID R ACAAGTTAGGGCTCCTCGGATA 
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3.0 Results: The Impact of Rapamycin on Genome Function and Organization  
3.1 Rapamycin Reduces Cell Proliferative Rates in the NB1 hTERT Cell Line 
Rapamycin treatment of immortalized or cancer-based cell lines has been extensively 
conducted, inducing apoptosis and autophagy whilst decreasing cell proliferation (Vignot et al. 
2005; Petroulakis et al. 2006; Jimenez et al. 2009; Suzuki et al. 2011). In order to determine if 
this was the case and to establish experimental conditions in fibroblasts, we tested a new 
immortalized cell line, NB1 hTERT, under normal growth conditions (proliferative) and in the 
presence of 500 nM rapamycin for 48 h, 120 h, 168 h and 220 h, whilst recording cell counts 
in order to calculate doubling times and total population doublings within culture (Figure 3-1A 
& 3-1B). Population doubling times of rapamycin treated NB1 hTERTs at 220 h of treatment 
was 54.6 h compared to 21.3 h in proliferative samples. Some fluctuations in population 
doubling times of rapamycin-treated fibroblasts were noted, with a decrease at 168 h to lower 
than proliferative fibroblasts (Figure 3-1A). In concordance with the overall increasing 
doubling times, total population doublings decreased from 12.4 in the control to 7.5 in the 500 
nM rapamycin-treated NB1 hTERT. To further establish that rapamycin was impacting NB1 
hTERT as expected, immunofluorescence detection of the proliferative marker Ki67, a marker 
that is no longer present 48 h after cells stop proliferating (Kill 1996), was conducted at 48h, 
120h and 217h (Figure 3-1C). Percent Ki67 reported was lower in rapamycin-treated than 
untreated 2DD fibroblasts at 48 h (71.7% treated vs 93.5% control), 120 h (57.7% vs. 90.1%) 
and 217 h (65.67% vs. 76.8%). Therefore, it was confirmed that 500 nM rapamycin treatment 
decreased cell population doubling times and cell proliferation in NB1 hTERT.  
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Figure 3-1: Rapamycin Decreased the Rate of NB1 hTERT Proliferation. (A) NB1 hTERT 
cells were grown under normal culture conditions or in the presence of 500 nM rapamycin for 
48 h, 120 h, 168 h, 220 h (X-axis) (red bars represent proliferative NB1 hTERT and black bars 
represent 500 nM rapamycin-treated NB1 hTERT for all panels). (B) The total number of 
population doublings were plotted for proliferative and 500 nM rapamycin-treated cultures at 
220 h. (C) Ki67 immuno-labelling of both proliferative and rapamycin-treated NB1 hTERT is 
shown for 48 h, 120 h, and 220 h (X-axis) with percent positive Ki67 shown on the Y-axis).  
Data are representative and two additional biological replicates were conducted. 
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3.2 Rapamycin Reduced Cell Proliferative Rates Without Inducing Cell Death in Normal 
Human Fibroblasts 
The impact of rapamycin treatment on normal proliferating human foreskin fibroblasts 
(designated 2DD) was previously unknown. Given that 500 nM rapamycin treatment was 
demonstrated to impact proliferation of the immortalized fibroblasts cell line NB1 hTERT, the 
normal fibroblast cell line, 2DD, were grown in the presence of 500 nM rapamycin to determine 
the impact of rapamycin on genome function and organization in normal human fibroblasts.  
Primary 2DD were grown with 500 nM rapamycin for 72 h, 120 h, 168 h and 216 h to determine 
impact at various time points. Following each time point, cell counts were conducted and 
doubling times and total population doublings calculated (Figure 3-2A & 3-2B). Increases in 
doubling times (from 31 h under proliferative conditions to 224 h following rapamycin 
treatment) were recorded concomitant with a decrease in the total number of population 
doublings; at 216 h total population doublings decreased from 7.0 under proliferative conditions 
to 2.1 total population doublings following rapamycin treatment. Furthermore, morphological 
changes of the fibroblasts treated with 500 nM rapamycin at 120 h were reminiscent of 
quiescence (Figure 3-2C).  Previously, it was demonstrated that decreased levels of serum in 
culture media (from 10% to 0.5%) induce quiescence, causing the population doubling times 
of 2DD fibroblasts to increase (Mehta et al. 2010). In addition to the noted changes in cellular 
morphology and population doubling times in response to rapamycin-treated and quiescence-
induction by decreasing serum, there was no evidence of cell death (Figure 3-2D). Neither 
rapamycin treatment nor quiescence induction resulted in deleterious effects on the fibroblasts, 
with cultures exhibiting 97.3% and 96.4% viability respectively via Trypan blue staining in 
comparison to 97.3% in proliferative cultures (Figure 3-2D).  
Given the impact of rapamycin on cell growth, proliferation and morphology, it is 
possible that a quiescent-like state was induced. Therefore, to establish the impact of rapamycin 
on cell proliferation, immunofluorescence using the proliferative marker Ki67 was performed. 
Following 168 h of rapamycin treatment, only 31% of fibroblasts exhibited Ki67 compared to 
70% in proliferating cultures (Figure 3-3A), indicating that fewer cells were actively in the cell 
cycle following rapamycin treatment. 500 nM rapamycin treatment increased population 
doubling times whilst decreasing percent positive Ki67 2DD fibroblasts. Decreased levels of 
serum in culture media (from 10% to 0.5%) induce quiescence, causing the population doubling 
times of 2DD fibroblasts to increase and the number of Ki67 positive cells to decrease (Mehta 
et al. 2010). 2DD fibroblasts were induced into quiescence by reducing serum in culture media 
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to 0.5% for 120 h, with 4.3% of quiescence-induced fibroblasts Ki67 positive and doubling 
times >500 h across three replicates. Therefore, both rapamycin treatment and quiescence 
induction result in fewer cells actively proliferating (Figure 3-3A). To determine the number of 
cells in S-phase, or actively replicating DNA, and further validate findings from 
immunofluorescence, fibroblasts were incubated with the thymidine analogue, 5’-ethynyl-
2’deoxyuridine (EdU) under each treatment condition. In agreement with Ki67, fewer 
fibroblasts incorporated EdU following rapamycin treatment and quiescence induction (Figure 
3-3B). Cell cycle analysis using propidium iodide staining of proliferating, quiescent and 
rapamycin-treated 2DD revealed 64.4%, 91% and 72.0% of cells in G1/0 respectively (Figure 
3-3C). Although it is evident that serum-induced quiescence induction has a greater impact in 
decreasing the number of actively proliferating 2DD fibroblasts (as measured by doubling 
times, Ki67 levels, EdU incorporation and flow cytometry), both decreased serum levels and 
rapamycin treatment exhibit similar patterns in decreasing proliferation and phenotypic 
changes. 
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Figure 3-2: Rapamycin Decreases Doubling Times and Total Population Doublings 
Without Decreasing Cell Viability in 2DD Fibroblasts. (A) 2DD fibroblasts were grown 
under proliferative (red) and 500 nM rapamycin-treated (black) conditions, population doubling 
times (Y-axis) calculated over 0 h, 72 h, 120 h, 168 h and 216 h (X-axis) are shown.  Red bars 
represent proliferative 2DD and black bars represent 500 nM rapamycin-treated 2DD, counts 
are representative and were replicated two additional times for A and B. (B) Total population 
doublings were plotted for proliferative and 500 nM rapamycin-treated cultures at 216 h. (C) 
Micrographs of proliferative, quiescent and 500 nM rapamycin-treated 2DD fibroblasts at 120 
h of treatment. (D) Trypan blue assays were conducted at 120 h to detect percent (%) viable 
cells (Y-axis) for proliferative (red), quiescent (blue) and 500 nM rapamycin-treated 2DD 
(black) (X-axis). Data are representative and two additional biological replicates were 
conducted. 
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Figure 3-3: Rapamycin Decreases 2DD Fibroblast Proliferation. (A) 2DD fibroblasts were 
grown under either proliferative or 500 nM rapamycin treated conditions from 0 h to 216 h. 
Percent positive Ki67 (Y-axis) immuno-labelled 2DD following treatment with 500 nM 
rapamycin for 0 h, 72 h, 120 h, 168 h, 216 h (X-axis) is shown. The upper left panel is an 
example of a Ki67 (green) positive (+ve) fibroblast with a nucleus counterstained with Hoechst 
dye (H33342, blue). The upper left panel is representative of a (Figure 3-3 Legend Continued) 
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Ki67 negative (-ve) fibroblast. (B) At 120 h, proliferative (Pro, red)), quiescence-induced (Qui, 
blue) and 500 nM rapamycin-treated (Rap, black) 2DD were incubated with the thymidine 
analogue EdU. and percentage positive for EdU reported (Y-axis). The left top panel is 
representative of an EdU negative (non-S-phase) fibroblast and the bottom left panel is an EdU 
(S-phase) positive fibroblast, with EdU in red and the nucleus counterstained with H33342 
(blue). Error bars for (A) and (B) are the S.E.M., scale bar = 10 µm. (C) Pro, Qui, and Rap-
treated fibroblasts were fixed and stained with propidium iodide and DNA content measured 
by flow cytometry at 120 h. Histograms demonstrate evens counted (Y-axis), fluorescence 
signal (Intensity Units, X-axis) measured and the percentage cells in G0/G1, S and G2 phase of 
the cell cycle for each treatment condition. 
 
3.3 Rapamycin Inhibits mTORC1 and Induces Autophagy in 2DD Fibroblasts  
In order to confirm that 500 nM rapamycin treatment was inducing the expected 
inhibition of the protein kinase mTOR, whole cell protein lysates were extracted and western 
blot analyses performed. These analyses revealed a decrease in activated phosphorylated 
mTOR alongside diminished levels of the downstream target of TORC1, phosphorylated p70-
S6 kinase (p70-S6K) (Figure 3-4A). Inhibition of TORC1 function is well documented to 
induce autophagy, increasing the number autophagosomes – marked by the presence of light 
change 3 (LC3) foci (Ladoire et al. 2012). Immuno-fluorescence for LC3 revealed an increase 
from 18% LC3 positive cells in proliferative to 72% in 500 nM rapamycin-treated culture at 
120 h (Figure 3-4B & 3-4C). Combined, these data confirm that rapamycin is inhibiting TOR 
function, decreasing levels of downstream phosphorylated p70-S6K and increasing autophagy 
in healthy human fibroblasts.  
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Figure 3-4: Rapamycin Inhibits mTOR Activity and Increases the Presence of Autophagy 
Markers in 2DD Fibroblasts. (A) Western blot analysis of protein extracts from proliferative 
(Pro) and rapamycin (Rap)-treated 2DD fibroblasts at 120 h. Levels of phosphorylated mTOR 
(serine 2448; 1st row), phosphorylated p70-S6K-S424 (serine 424, 2nd row) and ActB (loading 
control) (3rd row) were analyzed. Approximate molecular weights are listed to the right of the 
western blots. (B) Immuno-fluorescence was used to detect the precent positive of fibroblasts 
exhibiting LC3 foci (Y-axis) in proliferative (blue bar) and 500 nM rapamycin-treated (orange 
bar) 2DD fibroblasts at 120 h. (C) Representative micrographs of the LC3 protein in untreated 
(proliferative) and rapamycin-treated (500 nM rapamycin) fibroblasts are shown. Chromatin 
was counterstained with H33342 (blue). Scale bar = 10m. 
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3.4 Rapamycin Treatment and Serum Restriction Induce Genome Reorganization 
Previously, chromosome territories have been documented to reposition within the 
nuclear volume in response to decreased serum levels. Specifically, quiescence induction 
resulted in repositioning of chromosome 10 towards the periphery and 18 towards the interior 
of the nuclear volume in fibroblasts (Mehta et al. 2010), a finding we reproduced by conducting 
2D-DNA fluorescence in-situ hybridization (FISH) (Figure 3-5). FISH “paints” specific 
chromosome territories within the nuclear volume and position is determined through erosion 
analysis. This analysis breaks the nucleus into five concentric rings, with the outer most shell 
at the periphery considered 1 and the inner most shell considered 5. The percent of each 
chromosome that falls into each shell is measured and divided by the counter stain signal for 
chromatin, therefore normalizing for DNA content of each shell. rapamycin treatment of 2DD 
fibroblasts induced similar re-location of chromosome 18 as quiescence, towards a more 
interior nuclear location. Chromosome 10 was also reported to re-locate significantly to the 
nuclear periphery following rapamycin treatment and quiescence induction (Figure 3-5). These 
findings indicate a shift in genome organization following both treatment conditions. The X 
chromosome remained at the nuclear periphery for all treatment conditions (Mehta et al. 2010). 
Statistical analyses (t-test) revealed confirmed significant repositioning of chromosome 18 and 
10 under treatment conditions when compared to proliferative samples (p values ≤0.01). 
Furthermore, negative correlation trends were reported between chromosome 18 in proliferative 
vs. quiescent (R2 value = -0.83) and proliferative vs rapamycin-treated samples (R2 value = -
0.99). Correlation calculations also revealed similarities in chromosome 10 positioning between 
quiescent and rapamycin treated fibroblasts (R2 value = 0.87) than proliferative and quiescent 
(R2 value = 0.43); however, T-test’s did not demonstrate this as significance when comparing 
the ratios of signal intensity (Table 3-1).  
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Figure 3-5: Rapamycin Treatment and Quiescence Induction Result in Chromosome 
Territory Repositioning in 2DD Fibroblasts. (A) Chromosomes 18, (B) 10 and (C) the X 
chromosome were identified in proliferating (Pro, first column), quiescent (Qui, second 
column) and rapamycin-treated (Rap, third column) 2DD fibroblasts by chromosome painting. 
Cells were fixed following 120 h of treatment. Red signal represents the identified 
chromosomes; chromatin was counter stained with H33342 (blue). Scale bar = 5 m for all 
images. Following painting, erosion analysis was performed to designate the location of the 
chromosomes within the nuclear volume. Nuclei were broken into five concentric shells of area, 
shell 1 being most exterior and shell 5 being most interior. Graphs for each specific 
chromosome represents the measured ratio of % chromosome signal divided by the % H33342 
signal in each shell (Y axis) to normalize for DNA content in each shell (X axis).  Proliferative 
positioning is represented by blue bars, quiescent by red and rapamycin-treated in grey. Error 
bars = S.E.M.  Two-tailed Student’s test for unequal variance were used to demonstrate 
significant difference in chromosome positioning. ** indicates that both proliferative and 
quiescent measurements had p values ≤0.01. * indicates that (Figure 3-5 Legend Continued) 
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only rapamycin had significant changes in chromosome positioning. # indicates a significant 
difference (p values ≤0.01) between quiescent and rapamycin-treated samples. Correlation 
calculations were also performed to demonstrate if the trend in chromosome positioning was 
similar or divergent between the samples. Chromosome 18 Pro vs. Qui R2 = -0.83, Pro vs. Rap 
R2 = -0.99 and Qui vs. Rap R2 = 0.87. Chromosome 10 Pro vs. Qui R2 = 0.43, Pro vs. Rap R2 
= 0.64 and Qui vs. Rap R2 = 0.95. X chromosome: Pro vs. Qui R2 = 0.84, Pro vs. Rap R2 = 0.98 
and Qui vs. Rap R2 = 0.91.  
Table 3-1: Correlation Values (R2) for Chromosome Territory Re-Positioning in 2DD 
Fibroblasts in Response to 500 nM Rapamycin Treatment and Quiescence-Induction. 
Correlation values for chromosome territory re-positioning in 2DD fibroblasts threated for 120 
h with 500 nM rapamycin or induced into quiescence by 120 h of serum starvation. Correlations 
are given for chromosome 18, 10 and X between Proliferative (Pro) and Quiescence (Qui), Pro 
against Rap and Qui against Rap. 
R2 Values 
Chromosome 18 Chromosome 10 Chromosome X 
Qui Rap Qui Rap Qui Rap 
Pro -0.83 -0.99 0.43 0.64 0.84 0.98 
Qui  0.87  0.95  0.91 
 
3.5 Rapamycin Treatment and Serum Restriction Induced Divergent Transcript Profiles  
Rapamycin and quiescence induction both reduced proliferative rates, decreased the 
number of cells exhibiting Ki67/actively replicating DNA, and induced repositioning of 
chromosomes 18 and 10. Given these similarities, it may be that both treatments have 
overlapping impacts on cellular function. To determine if similarities exist between these 
conditions, mRNAs were isolated from proliferative, and 5-day quiescence-induced and 
rapamycin-treated fibroblasts and RNA sequencing (RNAseq) with subsequent comparative 
transcriptome analyses conducted. Raw sequence reads from Illumina-based sequencing were 
mapped to a reference genome (GRh37/hg19), normalized using the reads per kilobase of gene 
per million reads (RPKM) method, and analyzed using the tool SeqMonk 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/). RNAseq data were validated 
by reverse transcriptase-quantitative PCR (RT-qPCR) by selection of a sample of genes that 
changed/did not change expression for both quiescence-induced and rapamycin-treated 
fibroblasts (Fig. 3-6). Of the 22 genes determined to have increased ≥5-fold by RNAseq in 
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response to quiescence when compared to proliferative 2DD fibroblasts, 19 (86%) were also 
increased ≥5-fold by qRT-PCR. Similarly, of the 11 genes from RNAseq data up-regulated by 
rapamycin treatment, 7 (64%) were ≥5-fold up-regulated by qRT-PCR (Figure 3-6). 
Additionally, all genes tested (17) from the rapamycin RNAseq dataset that were below the ≥5-
fold cut-off, were also below the ≥5-fold cut off by RT-qPCR (Figure 3-6B).  
Figure 3-6: RNA-sequencing Validation of Gene Fold Changes by RT-qPCR in Response 
to Rapamycin Treatment and Quiescence Induction in 2DD Fibroblasts. RT-qPCR was 
conducted on a subset of genes identified to have changed transcript profiles by RNAseq. This 
was conducted for (A) 120 h quiescence-induced 2DD fibroblasts and (B) 120 h 500 nM 
rapamycin-treated 2DD fibroblasts. The relative fold change (using five individual normalizing 
genes) in these transcript profiles from proliferative cells is shown (blue bars) as well as the 
fold change predicted by RNAseq (red bars). The change in (Figure 3-6 Legend Continued) 
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scale of the vertical axis is denoted by a solid black line. Values on the left of the dashed line 
represent genes with RNAseq values ≥5-fold with RT-qPCR comparisons; to the right of the 
dashed line are selected genes that were ≤5-fold by RNAseq in rapamycin-treated fibroblasts 
with the corresponding RT-qPCR fold changes. Error bars were generated for the RT-qPCR 
fold change values and represent the S.E.M. 
Comparisons between RNAseq data sets were made using significant log-base (2) 
scatter plots. These comparisons included the log number of reads from quiescent fibroblasts 
or rapamycin fibroblasts against the log number of proliferative fibroblasts, with scatter plots 
presented for subsets of genes changing transcript profiles ≥2-fold (Figure 3-7A), ≥3-fold 
(Figure 3-7B) and ≥5-fold (Figure 3-7C). Further subsets of genes in these scatter plots have 
been highlighted. In log-transformed quiescent fibroblasts, 1176 genes changed ≥2-fold (704 
up-regulated; 472 down-regulated). At ≥3-fold, 933 genes changed expression (574 up-
regulated; 359 down-regulated) whilst at ≥5-fold 615 genes changed (386 up-regulated; 229 
down-regulated). In significant log-base (2) transformed rapamycin-treated compared to 
proliferative fibroblasts 1060 genes changed transcript profile ≥2-fold (862 up-regulated; 198 
down-regulated). At ≥3-fold, 832 genes changed expression, (683 up-regulated; 149 down-
regulated) and at ≥5-fold 494 genes changed transcript profile (407 up-regulated; 87 down-
regulated). Despite the majority of genes from both quiescence-induced and rapamycin-treated 
fibroblasts having similar read count values to those of proliferating cells (correlations of 0.933 
and 0.946, respectively), scatter plots based on log transformed data and Venn diagrams based 
on fold-change data revealed little overlap between the genes changing expression under each 
treatment condition (Figure 3-7D). For example, analysis of gene lists at ≥5-fold revealed that 
only 68 genes (61 up-regulated and 7 down-regulated; 6.5%) were common between quiescent 
and rapamycin-treated fibroblasts (Fig. 3-7D). Further analysis of quiescence-induced and 
rapamycin-treated fibroblasts based on a non-log transformed fold change were in agreement 
with these findings, although gene numbers varied slightly due to the nature of the 
bioinformatics analyses (Figure 3-8). Specifically, in rapamycin-treated fibroblasts, 4404 
transcripts were up-regulated ≥2-fold (3216 up-regulated; 1188 down-regulated). At ≥3-fold, 
1634 transcripts changed expression (1311 up-regulated; 323 down-regulated) and at ≥5-fold, 
483 genes changed transcript profile (421 up-regulated and 62 down-regulated). In response to 
quiescence-induction, 4840 transcripts changed expression ≥2-fold (2851 up-regulated; 1989 
down-regulated), 2044 transcripts changed expression ≥3-fold (1277 up-regulated; 767 down-
regulated) and just 728 transcripts changed expression ≥5-fold (469 up-regulated; 259 down-
regulated). In concordance with log-base (2) transformed data, just 88 (7.8%) of transcripts 
 56 
 
were identified as changing ≥5-fold in rapamycin-treated and quiescence-induced fibroblasts, 
(70 up-regulated; 18 down-regulated). Therefore, response to quiescence-induction and 
rapamycin-treatment in 2DD fibroblasts is predominantly divergent and unique for each 
condition.  
Figure 3-7: Scatter Plots and Venn Diagrams Demonstrate Divergent Transcript Profiles 
Between 500 nM Rapamycin-Treated and Quiescence-Induced 2DD Fibroblasts Based on 
Log Base (2) Transformed Data and Significance Analyses. (A) Scatter plots comparing 
changes in gene expression between proliferative fibroblasts and serum-induced quiescent 2DD 
(left panel) and between proliferative and 500 nM rapamycin- (Figure 3-7 Legend Continued) 
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treated fibroblasts (right panel) for transcript abundance changes of ≥2 fold. (B) Scatter plots 
comparing changes in gene expression between    proliferative 2DD fibroblasts and serum-
induced quiescent 2DD (left panel) and between proliferative 2DD fibroblasts and 500 nM 
rapamycin-treated 2DD (right panel) for transcript abundance changes of ≥3 fold. (C) Scatter 
(Figure 3-7 Legend Continued) plots comparing changes between proliferative 2DD 
fibroblasts and serum-induced quiescent 2DD (left panel) and between proliferative 2DD 
fibroblasts and 500 nM rapamycin-treated 2DD (right panel) for transcript abundance changes 
of ≥5 fold. For all plots, the number of counts for each transcript identified by RNAseq for 
proliferative (X-axes) and metformin treated (Y-axes) fibroblasts was log-base2 transformed. 
Each square represents an individual transcript. Transcripts exhibiting a significant fold change 
in response to quiescence-induction when compared to proliferative samples are coloured blue, 
in response to 500 nM rapamycin coloured red, and overlapping between the two treatment 
conditions coloured green. Grey squares represent transcripts that did not change abundance at 
the listed cut-off values.  (D) Venn diagrams demonstrating the number of genes up-regulated 
or down-regulated between quiescent (red) and 500 nM rapamycin (blue) treated fibroblasts in 
comparison to proliferative fibroblasts. Numbers in the overlapped areas indicate the number 
of genes changing expression in both treatment groups.  
 
Figure 3-8: Venn Diagrams for Transcripts Changing ≥2-Fold, ≥3-Fold and ≥5-Fold in 
Quiescence-Induced and Rapamycin-Treated Fibroblasts by Fold Change Analysis. Venn 
diagrams demonstrating the number of genes up-regulated or (Figure 3-8 Legend Continued) 
 58 
 
down-regulated between quiescent (red) and 500 nM rapamycin (blue) treated fibroblasts in 
comparison to proliferative fibroblasts. Numbers in the overlapped areas indicate the number 
of genes changing expression in both treatment groups. 
3.6 Network Analyses Reveal Enrichment in Cytokine-Related Pathways Following 
Rapamycin Treatment 
To determine if there was overlap or divergence in the biological pathways enriched for 
by either quiescence-induction or rapamycin treatment, network analyses using genes identified 
as significantly changing expression (≥5-fold) were conducted. Cytoscape (Shannon et al. 
2003) with ReactomeFI (Wu et al. 2010) was used to classify highly interacting groups of genes 
(modules) from the RNAseq datasets and to identify the associated pathway annotation terms 
(Kyoto Encylopedia of Genes and Genome; KEGG terms). Genes up-regulated ≥5-fold in 
response to quiescence-induction, and based on log-base (2) transformed and fold change 
analyses, 21 and 29 modules respectively were identified as over-expressed (p-vale <0.05, FDR 
<0.05) (Figure 3-9 & 3-10). KEGG terms associated with these modules in both analyses 
revealed significant enrichment in the complement and coagulation cascade, as well as for 
infection response, and for cadherin signalling and extracellular matrix organization (Table 3-
2 & 3-5). Examination of the module associated with this term showed several genes both 
increasing (Serping1, C2 and CFD) and decreasing (Serpine1, F2 and F12) transcript 
abundance. The enrichment of the KEGG-associated terms in up-regulated genes for the 
complement and coagulation pathways in response to reduced serum levels in normal human 
fibroblasts has only once been previously reported (Coller et al. 2006). Genes ≥5-fold up-
regulated in response to quiescence induction in both analyses also demonstrated enrichment 
for Gene Ontology (GO) for Biological Processes and Molecular Function terms. In both 
analyses, GO Biological Processes were enriched in collagen binding, calcium dependent cell-
cell adhesion and extracellular matrix organization (Figure 3-11 & Figure 3-12) (p-value <0.05, 
FDR <0.05). For GO Molecular Function, collagen binding and calcium ion binding were 
enriched (p-value <0.05, FDR <0.05) (Figure 3-11B & Figure 3-12B).  
In response to quiescence-induced genes ≥5-fold down-regulated, in log-transformed 
and fold change analyses, 12 and 9 modules respectively, were identified. Pathway analyses 
revealed that Mitotic Prometaphase, Aurora B signalling and Cell cycle were down-regulated. 
Furthermore, for both analyses, genes down-regulated by quiescence induction were enriched 
for GO Biological Processes such as mitosis, cell division and mitotic cell cycle. In GO 
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Molecular Function, Protein Binding and ATP-binding were enriched, indicating that gene 
expression patterns for cellular replication are inhibited in the absence of growth factors.  
Contrary to quiescence-induction, analysis of rapamycin-treated fibroblasts revealed the 
presence of networks of 16 distinct modules (14 up-regulated; 2 down-regulated) by log-base 
(2) analyses and 19 (18 up-regulated, 1 down-regulated) by fold-change analyses (Figure 3-9 
& Figure 3-10). In rapamycin up-regulated genes, KEGG pathway annotation terms associated 
with PIP3 activates AKT signalling (in log-transformed data) and NF-B signalling pathway 
and Signalling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) (in fold-change based 
analyses) were observed and linked these findings to known mTOR-associated pathways. The 
most significantly enriched pathway annotation terms identified for log-base (2) and fold-
change analyses were Pathways in Cancer and Cytokine-Cytokine Receptor Interactions 
respectively (Table 3-4 & 3-7). Further examination of the network associated with the 
cytokine-cytokine receptor interaction pathway demonstrated up-regulation of several 
cytokines and provides functional relationship between IL-6ST, IL-11, IL-1B, INHBA, CXCL-
1, CXCL-3, CXCL2, PF4V1, LIF, IFNA1, BMP2, IL-6, IL-8, TGFBR1 genes. Four of these 
identified genes (LIF, IL-8, IL-11 and INHBA) were ranked within the top 20 of all genes up-
regulated ≥5-fold in expression. Furthermore, many of these genes belong to the IL-6 signalling 
pathway.  GO Biological Processes term enrichment for genes up-regulated in rapamycin-
treated fibroblasts further supports negative regulation of cell proliferation (p-value <0.05; FDR 
<0.05), whist GO molecular function demonstrates enrichment of terms for cytokine and 
growth factor activity (Figure 3-11 & 3-12).  
Network pathway analyses for genes ≥5-fold down-regulated in response to rapamycin 
treatment revealed no significantly enriched KEGG annotation terms (p-value <0.05, FDR 
<0.05) by both analyses; however, by GO molecular function in fold-change analyses, various 
receptor binding activities were down-regulated. Findings based on both up-regulated and 
down-regulated transcripts from the rapamycin-treated dataset are divergent from quiescence-
induced changes in transcript profiles, documented by few genes overlapping between 
treatments under both fold-change and log-base (2) analyses, alongside differential pathway 
enrichment.   
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Figure 3-9: Modules Identified in Genes Changing ≥5-Fold in Response to Rapamycin 
Treatment and Quiescence Induction in 2DD Fibroblasts Based on Log-base (2) Analyses. 
Network analyses identified groups of functionally related genes (modules) in (A) ≥5-fold up-
regulated quiescence-induced genes, (B) ≥5-fold down-regulated quiescence-induced genes, 
(C) ≥5-fold up-regulated rapamycin-induced genes, (D) ≥5-fold down regulated rapamycin-
induced genes. Each node (circle) is representative of a gene whilst every colour is 
representative of a module. Solid lines represent genes linked within the same module and 
between modules based on the ReactomeFI database.
  
 
Table 3-2: Network Pathway Annotation Terms Enriched in Quiescence Up-Regulated Genes in 2DD Fibroblasts by Log-Base (2) Analyses. 
Genes ≥5-fold up-regulated in response to quiescence induction were analyzed for enrichment of KEGG terms. The identified enriched pathway 
KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-regulated in 
response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false discovery rates 
(FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the networks. Gene lists 
identified by log-base (2) transforming data. 
 
 
 
Protein 
From 
Network 
P-
Value 
 
FDR 
 
Nodes 
Cadherin 
signaling 
pathway(P) 
12 0 1.60E-04 
PCDHB14,PCDHB13,PCDHB11,PCDHB10, 
PCDHB16,PCDHA7,PCDHB7,PCDHB5,PCDHB6, 
PCDHB3,FZD3,WNT4 
Complement 
and coagulation 
cascades(K) 
10 0 1.60E-04 
SERPING1,TFPI,C3,C2,CFH,CFI,CFD, 
BDKRB2,CFB,PROS1 
Extracellular 
matrix 
organization(R) 
15 0.0001 0.008629 
LTBP4,MADCAM1,ADAMTS5,COL14A1, 
VCAN,FMOD,PCOLCE2,MFAP4,DCN, 
BMP4,BMP2,LAMA2,COL21A1,CTSK,LUM 
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Table 3-3: Network Pathway Annotation Terms Enriched in Quiescence Down-Regulated Genes in 2DD Fibroblasts by Log-Base (2) 
Analyses. Genes ≥5-fold down-regulated in response to quiescence induction were analysed for enrichment of KEGG terms. The identified 
enriched pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to 
be up-regulated in response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and 
false discovery rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the 
networks. Gene lists identified by log-base (2) transforming data.  
 
Protein 
From 
Network 
P-
Value 
FDR Nodes 
Mitotic Prometaphase(R) 22 0 3.54E-14 
AURKB,CDCA8,MAD2L1,ZWINT,NUF2,CDC20,NCAPH,NCAPG,BUB1,ZWILCH, 
BIRC5,CCNB1,CCNB2,SGOL1,SPC24,ERCC6L,PLK1,KIF2C,CDK1,BUB1B, 
CENPM,CENPF 
PLK1 signaling events(N) 14 0 2.12E-13 
AURKA,CDC20,CLSPN,TPX2,BUB1,CCNB1,KIF20A,PRC1,SGOL1,SPC24, 
ERCC6L,PLK1,CDK1,BUB1B 
Mitotic Metaphase and 
Anaphase(R) 
19 0 4.91E-11 
AURKB,PTTG1,CDCA8,MAD2L1,ZWINT,NUF2,CDC20,BUB1,ZWILCH,BIRC5, 
SGOL1,SPC24,ERCC6L,PLK1,KIF2C,UBE2C,BUB1B,CENPM,CENPF 
Aurora B signaling(N) 11 0 6.25E-10 
AURKA,AURKB,CDCA8,NCAPH,NCAPG,BUB1,BIRC5,KIF20A, 
SGOL1,KIF23,KIF2C 
Cell cycle(K) 16 0 6.30E-10 
PTTG1,CCNA2,MAD2L1,CDC20,CDC6,GADD45B,BUB1,CCNB1,CCNB2, 
PKMYT1,ORC1,PLK1,CDC45,CDK1,MCM5,BUB1B 
Cell Cycle 
Checkpoints(R) 
14 0 2.64E-08 
MAD2L1,CDC20,CLSPN,CDC6,CCNB1,CCNB2,PKMYT1,MCM10,ORC1, 
CDC45,CDK1,UBE2C,MCM5,BUB1B 
FOXM1 transcription 
factor network(N) 
9 0 2.09E-07 AURKB,CCNA2,BIRC5,CCNB1,CCNB2,PLK1,CDK1,FOXM1,CENPF 
Oocyte meiosis(K) 12 0 1.43E-06 
AURKA,PTTG1,MAD2L1,CDC20,BUB1,CCNB1,CCNB2,RPS6KA1,PKMYT1, 
SGOL1,PLK1,CDK1 
APC/C-mediated 
degradation of cell cycle 
proteins(R) 
10 0 4.21E-06 AURKA,AURKB,PTTG1,MAD2L1,CDC20,CCNB1,PLK1,CDK1,UBE2C,BUB1B 
  
 
Mitotic G2-G2/M 
phases(R) 
10 0 7.03E-05 AURKA,CCNA2,MYBL2,CCNB1,CCNB2,PKMYT1,PLK1,CDK1,FOXM1,CENPF 
Progesterone-mediated 
oocyte maturation(K) 
9 0 8.54E-05 CCNA2,MAD2L1,BUB1,CCNB1,CCNB2,RPS6KA1,PKMYT1,PLK1,CDK1 
E2F transcription factor 
network(N) 
8 0 9.30E-05 SERPINE1,CCNA2,MYBL2,TK1,CDC6,RRM2,ORC1,CDK1 
Mitotic G1-G1/S 
phases(R) 
10 0 1.64E-04 MYBL2,CDC6,RRM2,CCNB1,PKMYT1,MCM10,ORC1,CDC45,CDK1,MCM5 
ATR signaling 
pathway(N) 
6 0 2.29E-04 CCNA2,CLSPN,CDC6,RAD51,FANCD2,PLK1 
p53 signaling 
pathway(K) 
7 0 7.23E-04 SERPINE1,GTSE1,RRM2,GADD45B,CCNB1,CCNB2,CDK1 
p73 transcription factor 
network(N) 
7 0.0001 0.001074 SERPINE1,CCNA2,RAD51,BUB1,CCNB1,PLK1,CDK1 
Aurora A signaling(N) 5 0.0001 0.001074 AURKA,AURKB,TPX2,BIRC5,TACC3 
Mitotic 
Telophase/Cytokinesis(R) 
3 0.0009 0.014663 KIF20A,PLK1,KIF23 
cdk regulation of dna 
replication(B) 
3 0.0018 0.028243 CDC6,ORC1,MCM5 
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Table 3-4: Network Pathway Annotation Terms Enriched in Rapamycin Up-Regulated Genes in 2DD Fibroblasts by Log-Base (2) 
Analyses. Genes ≥5-fold up-regulated in response to rapamycin treatment were analysed for enrichment of KEGG terms. The identified enriched 
pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-
regulated in response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false 
discovery rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the 
networks. Gene lists identified by log-base (2) transforming data.  
 
Protein 
From 
Network 
P-
Value 
FDR Nodes 
Pathways in cancer(K) 22 0 0.002177 
PTGS2,FGF7,FGF2,SOS2,IL6,PTGER2,CDK6,KRAS,BMP2,CBLB,LAMA3, 
TGFA,HHIP,FZD9,BIRC3,BIRC2,FGF13,WNT4,ITGAV,NKX3-1,ITGA2,PLCB1 
Signaling pathways 
regulating pluripotency of 
stem cells(K) 
12 0 0.003616 FGF2,INHBA,RIF1,IL6ST,LIF,KRAS,BMP2,SMAD9,FZD9,JARID2,WNT4,SKIL 
TGF-beta signaling 
pathway(P) 
8 0.0001 0.018955 
INHBA,ZFYVE16,GDF6,BMP2,SMAD9,BMP6, 
GDNF,SKIL 
Jak-STAT signaling 
pathway(K) 
11 0.0002 0.018955 
IL13RA2,SOS2,IL6,IL11,IL24,SPRY2,CSF2RB, 
IL6ST,LIF,CBLB,IL21R 
TNF signaling pathway(K) 9 0.0002 0.018955 
PTGS2,IL6,IL1B,TNFAIP3,EDN1,LIF,CXCL1, 
BIRC3,BIRC2 
ErbB signaling pathway(K) 8 0.0002 0.018955 EREG,SOS2,HBEGF,KRAS,CBLB,TGFA,SHC2,SHC4 
Signaling by EGFR(R) 11 0.0004 0.026294 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,SPRY2,IL6ST,KRAS,PAG1 
Platelet homeostasis(R) 6 0.0004 0.027269 PDE5A,FGR,PRKG1,ATP2B1,TRPC6,PLA2G4A 
Validated transcriptional 
targets of AP1 family 
members Fra1 and Fra2(N) 
5 0.0006 0.031558 IL6,MGP,THBD,LIF,LAMA3 
Signaling by FGFR(R) 10 0.0006 0.031558 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,SPRY2,IL6ST,KRAS 
NOD-like receptor 
signaling pathway(K) 
6 0.0007 0.031558 IL6,IL1B,TNFAIP3,CXCL1,BIRC3,BIRC2 
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Hypertrophic 
cardiomyopathy (HCM)(K) 
7 0.0009 0.034605 CACNB2,ACTC1,IL6,PRKAA2,ITGAV,ITGA2,ITGA8 
MAPK signaling 
pathway(K) 
13 0.001 0.034605 
CACNB2,TAOK1,FGF7,FGF2,SOS2,RASA2,RPS6KA6,IL1B,NR4A1,KRAS, 
PLA2G4A,FGF13,MAP3K2 
Gastrin-CREB signalling 
pathway via PKC and 
MAPK(R) 
11 0.001 0.034605 GPR68,IL6,DGKI,HBEGF,IL6ST,EDN1,KRAS,TRPC6,AGT,F2RL1,PLCB1 
Signaling by SCF-KIT(R) 9 0.001 0.034764 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,IL6ST,KRAS 
Small cell lung cancer(K) 7 0.0011 0.035635 PTGS2,CDK6,LAMA3,BIRC3,BIRC2,ITGAV,ITGA2 
Glioma(K) 6 0.0013 0.036366 SOS2,CDK6,KRAS,TGFA,SHC2,SHC4 
Cell adhesion molecules 
(CAMs)(K) 
9 0.0014 0.036366 
VCAN,NRCAM,CLDN4,F11R,NLGN1, 
ITGAV,ITGA8,CD274,ICOSLG 
NF-kappa B signaling 
pathway(K) 
7 0.0015 0.036366 PTGS2,IL1B,BCL10,TNFAIP3,DDX58,BIRC3,BIRC2 
Signaling by Type 1 
Insulin-like Growth Factor 
1 Receptor (IGF1R)(R) 
7 0.0015 0.036366 FGF7,FGF2,IL6,IL6ST,KRAS,PRKAA2,SHC2 
FGF signaling pathway(P) 7 0.0016 0.036366 FGF7,FGF2,SOS2,SPRY2,KRAS,FGF13,MAP3K2 
Signalling by NGF(R) 13 0.0016 0.036366 
MEF2A,FGF7,FGF2,EREG,SOS2,IL6,RICTOR,HBEGF,FGD4,NR4A1, 
IL6ST,KRAS,SHC2 
Signaling by ERBB4(R) 9 0.0017 0.036366 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,IL6ST,KRAS 
Integrins in angiogenesis(N) 5 0.0018 0.038509 FGF2,PIK3C2A,EDIL3,F11R,ITGAV 
CD40/CD40L signaling(N) 4 0.0021 0.041874 TNFAIP3,CBLB,BIRC3,BIRC2 
Cell surface interactions at 
the vascular wall(R) 
7 0.0023 0.042963 ANGPT1,SLC7A8,THBD,F11R,KRAS,ITGAV,PROS1 
Signaling by ERBB2(R) 9 0.0024 0.042963 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,IL6ST,KRAS 
Chronic myeloid 
leukemia(K) 
6 0.0024 0.042963 SOS2,CDK6,KRAS,CBLB,SHC2,SHC4 
SHP2 signaling(N) 5 0.0026 0.044254 ANGPT1,IL6,IL6ST,KRAS,PAG1 
ErbB receptor signaling 
network(N) 
3 0.0027 0.046727 EREG,HBEGF,TGFA 
 66 
 
 
Figure 3-10: Modules Identified in Genes Changing Expression ≥5-Fold in Response to 
Rapamycin Treatment and Quiescence Induction Based On Comparative Fold Change 
Analyses in 2DD Fibroblasts. Network analyses identified groups of functionally related 
genes (modules) in (A) ≥5-fold up-regulated quiescence-induced genes, (B) ≥5-fold down-
regulated quiescence-induced genes, (C) ≥5-fold up-regulated rapamycin-induced genes, (D) 
≥5-fold down regulated rapamycin-induced genes. Each node (circle) is representative of a gene 
whilst every colour is representative of a module. Solid lines represent genes linked within the 
same module and between modules based on the ReactomeFI database. 
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Table 3-5: Network Pathway Annotation Terms Enriched in Quiescence Up-Regulated Genes in 2DD Fibroblasts by Fold Change 
Analyses. Genes ≥5-fold up-regulated in response to quiescence induction were analysed for enrichment of KEGG terms. The identified 
enriched pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified 
to be up-regulated in response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) 
and false discovery rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets 
present in the networks. Gene lists identified by comparative fold change analyses. 
 
Protein From 
Network 
P-
Value 
FDR Nodes 
Cadherin 
signaling 
pathway(P) 
18 0 1.33E-08 
PCDHB14,PCDHB12,PCDHB11,PCDHA11,PCDHA12,PCDHA8, 
PCDHA2,PCDHA3,PCDHA4,PCDHA5,PCDHA1,PCDHB7,PCDHB5, 
PCDHB3,PCDHB4,WNT4,PCDHAC2,WNT11 
 
Wnt signaling 
pathway(P) 
23 0 2.12E-05 
PCDHB14,PCDHB12,PCDHB11,GNA14,PCDHA11,PCDHA12,FRZB, 
SFRP2,SFRP4,PCDHA8,PCDHA2,PCDHA3,PCDHA4,PCDHA5, 
PCDHA1,PCDHB7,PCDHB5,PCDHB3,PCDHB4,WNT4, 
PCDHAC2,PLCB1,WNT11 
Complement and 
coagulation 
cascades(K) 
11 0 1.12E-04 SERPING1,TFPI,C3,C2,CFH,CFD,BDKRB2,CFB,PROS1,C1R,C1S 
Extracellular 
matrix 
organization(R) 
18 0 0.002188 
LTBP4,ADAMTS5,COL14A1,VCAN,FMOD,TGFB2,PCOLCE2, 
MFAP4,DCN,VCAM1,MATN1,BMP4,BMP2,LAMA2,COL21A1, 
FBLN1,CTSK,LUM 
Response to 
elevated platelet 
cytosolic Ca2+(R) 
9 0.0001 0.013269 SERPING1,HGF,IGF1,IGF2,TGFB2,CFD,CD36,CLU,PROS1 
Staphylococcus 
aureus 
infection(K) 
7 0.0003 0.026255 C3,C2,CFH,CFD,CFB,C1R,C1S 
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Table 3-6: Network Pathway Annotation Terms Enriched in Quiescence Down-Regulated Genes in 2DD Fibroblasts by Fold Change Analyses. 
Genes ≥5-fold down-regulated in response to quiescence induction were analyzed for enrichment of KEGG terms. The identified enriched pathway 
KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-regulated in 
response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false discovery rates (FDR) 
are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the networks. Gene lists identified 
by comparative fold change analyses.  
 
Protein 
From 
Network 
P-
Value 
FDR Nodes 
Mitotic 
Prometaphase(R) 
16 0 5.92E-11 
AURKB,CDCA8,MAD2L1,ZWINT,CDC20,NCAPH,BUB1,ZWILCH,BIRC5,CCNB1, 
CCNB2,PLK1,KIF2C,CDK1,CENPM,CENPF 
FOXM1 
transcription 
factor network(N) 
10 0 2.55E-08 AURKB,CCNA2,TGFA,BIRC5,CCNB1,CCNB2,PLK1,CDK1,FOXM1,CENPF 
Cell cycle(K) 13 0 7.35E-07 
PTTG1,CCNA2,MAD2L1,CDC20,BUB1,CCNB1,CCNB2,PKMYT1,ORC1, 
PLK1,CDC45,CDK1,MCM5 
Mitotic 
Metaphase and 
Anaphase(R) 
14 0 1.43E-06 
AURKB,PTTG1,CDCA8,MAD2L1,ZWINT,CDC20,BUB1, 
ZWILCH,BIRC5,PLK1,KIF2C,UBE2C,CENPM,CENPF 
Aurora B 
signaling(N) 
8 0 3.38E-06 AURKA,AURKB,CDCA8,NCAPH,BUB1,BIRC5,KIF20A,KIF2C 
PLK1 signaling 
events(N) 
8 0 5.78E-06 AURKA,CDC20,TPX2,BUB1,CCNB1,KIF20A,PLK1,CDK1 
Mitotic G2-G2/M 
phases(R) 
11 0 8.54E-06 AURKA,CCNA2,MYBL2,CCNB1,CCNB2,PKMYT1,PLK4,PLK1,CDK1,FOXM1,CENPF 
Oocyte meiosis(K) 11 0 8.78E-06 AURKA,PTTG1,MAD2L1,CDC20,BUB1,CCNB1,CCNB2,RPS6KA1,PKMYT1,PLK1,CDK1 
Cell Cycle 
Checkpoints(R) 
11 0 1.01E-05 MAD2L1,CDC20,CCNB1,CCNB2,PKMYT1,MCM10,ORC1,CDC45,CDK1,UBE2C,MCM5 
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APC/C-mediated 
degradation of cell 
cycle proteins(R) 
9 0 2.90E-05 AURKA,AURKB,PTTG1,MAD2L1,CDC20,CCNB1,PLK1,CDK1,UBE2C 
Progesterone-
mediated oocyte 
maturation(K) 
9 0 6.31E-05 CCNA2,MAD2L1,BUB1,CCNB1,CCNB2,RPS6KA1,PKMYT1,PLK1,CDK1 
E2F transcription 
factor network(N) 
7 0 7.32E-04 SERPINE1,CCNA2,MYBL2,TK1,RRM2,ORC1,CDK1 
Mitotic G1-G1/S 
phases(R) 
9 0 8.24E-04 MYBL2,RRM2,CCNB1,PKMYT1,MCM10,ORC1,CDC45,CDK1,MCM5 
Gastrin-CREB 
signalling 
pathway via PKC 
and MAPK(R) 
11 0 8.24E-04 EDN1,MCHR1,KISS1,IL6,RPS6KA1,HBEGF,MMP3,P2RY6,ADRA1D,CDK1,OXTR 
Aurora A 
signaling(N) 
5 0 0.00109 AURKA,AURKB,TPX2,BIRC5,TACC3 
p53 signaling 
pathway(K) 
6 0.0002 0.004892 SERPINE1,GTSE1,RRM2,CCNB1,CCNB2,CDK1 
p73 transcription 
factor network(N) 
6 0.0003 0.007304 SERPINE1,CCNA2,BUB1,CCNB1,PLK1,CDK1 
Mitotic 
Prophase(R) 
5 0.0013 0.024442 CCNB1,CCNB2,HIST1H4A,PLK1,CDK1 
Nicotinic 
acetylcholine 
receptor signaling 
pathway(P) 
3 0.0027 0.048744 ACTG2,ACTC1,ACTB 
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Table 3-7: Network Pathway Annotation Terms Enriched in Rapamycin Up-Regulated Genes in 2DD Fibroblasts by Fold Change Analyses. 
Genes ≥5-fold up-regulated in response to rapamycin treatment were analysed for enrichment of KEGG terms. The identified enriched pathway 
KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-regulated in 
response to quiescence and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false discovery rates 
(FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the networks. Gene lists 
identified by comparative fold change analyses. 
 
Protein 
From 
Network 
P-
Value 
FDR Nodes 
Cytokine-cytokine 
receptor interaction(K) 
18 0 0.001921 
HGF,INHBA,CCL20,IL6,TNFSF15,IL11,IL1B,IL24,CSF2RB, 
IL6ST,IFNE,LIF,BMP2,IL20RA,CXCL1,CXCL3,PDGFB,IL21R 
Validated 
transcriptional targets 
of AP1 family members 
Fra1 and Fra2(N) 
7 0 0.001921 IL6,MGP,THBD,NFATC2,LIF,LAMA3,IVL 
Pathways in cancer(K) 20 0.0001 0.016348 
PTGS2,HGF,FGF7,FGF2,IL6,CDK6,LPAR5,BMP2,CBLB,LAMA3,EDNRB,TGFA, 
BIRC3,FGF18,PDGFB,ITGAV,NKX3-1,ITGA2,PLCB1,RASGRP3 
Signaling by EGFR(R) 12 0.0001 0.017694 
SH3GL2,FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1, 
SPRY2,IL6ST,FGF18,PDGFB 
ErbB receptor signaling 
network(N) 
4 0.0002 0.017694 AREG,EREG,HBEGF,TGFA 
Signaling by FGFR(R) 11 0.0002 0.017694 
FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,SPRY2,IL6ST, 
FGF18,PDGFB 
Jak-STAT signaling 
pathway(K) 
11 0.0003 0.017694 
IL6,IL11,IL24,SPRY2,CSF2RB,IL6ST,IFNE,LIF, 
CBLB,IL20RA,IL21R 
Signalling by NGF(R) 15 0.0003 0.017694 
MEF2A,SH3GL2,FGF7,FGF2,EREG,IL6,RICTOR, 
HBEGF,FGD4,NR4A1,IL6ST,NTRK2,FGF18,PDGFB,SHC2 
TNF signaling 
pathway(K) 
9 0.0003 0.017694 PTGS2,CCL20,IL6,IL1B,TNFAIP3,LIF,CXCL1,CXCL3,BIRC3 
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Signaling by SCF-
KIT(R) 
10 0.0004 0.01849 
FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1, 
IL6ST,FGF18,PDGFB 
PIP3 activates AKT 
signaling(R) 
8 0.0005 0.02404 FGF7,FGF2,EREG,RICTOR,HBEGF,NR4A1,FGF18,PDGFB 
Signaling by ERBB4(R) 10 0.0006 0.026028 
FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1, 
IL6ST,FGF18,PDGFB 
Signaling by ERBB2(R) 10 0.0009 0.035945 FGF7,FGF2,EREG,IL6,RICTOR,HBEGF,NR4A1,IL6ST,FGF18,PDGFB 
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Figure 3-11: GO Term Enrichment in Quiescent-Induced and Rapamycin-Treated Gene 
Sets Based on Log-Base (2) Analyses in 2DD Fibroblasts. GO Biological Process terms 
significantly enriched for in quiescence (A) up-regulated and (B) down-regulated genes (≥5-
fold), as well as rapamycin-induced (C) up-regulated and (D) (Figure 3-11 Legend Continued) 
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down-regulated genes (≥5-fold). GO Molecular Process terms significantly enriched for in 
quiescence (E) up-regulated and (F) down-regulated genes (≥5-fold), as well as rapamycin-
induced (G) up-regulated and (H) down-regulated genes (≥5-fold). P-value < 0.05, FDR < 0.05. 
 
 74 
 
Figure 3-12: GO Term Enrichment in Quiescence-Induced and Rapamycin-Treated Gene 
Sets Based on Fold Change Analyses in 2DD Fibroblasts. GO Biological Process terms 
significantly enriched for in quiescence (A) up-regulated and (B) down-regulated genes (≥5-
fold), as well as rapamycin-induced (C) up-regulated and (D) down-regulated genes (≥5-fold). 
GO Molecular Process terms significantly enriched for in quiescence (E) up-regulated and (F) 
down-regulated genes (≥5-fold), as well as rapamycin-induced (G) up-regulated and (H) down-
regulated genes (≥5-fold). P-value < 0.05, FDR < 0.05. 
3.7 Changes Induced by Rapamycin at the Transcript Level Alter Protein Expression 
In order to determine that changes induced by rapamycin treatment of 2DD fibroblasts 
were influential at the protein level, western blots and enzyme linked immuno-sorbent assays 
(ELISA) were performed on the protein equivalents of genes changing significantly in response 
to treatment conditions. The actin, alpha cardiac muscle 1 (ActC1) gene had the highest fold 
increase as a function of rapamycin treatment, as demonstrated by BEDgraphs of the raw 
sequence reads (Figure 3-13A). Western blot analyses confirmed that this increase in transcript 
abundance equated to an increase in the ACTC1 protein (Figure 3-13B). Western blot analysis 
further confirmed an increase in the presence of LIF in response to rapamycin treatment when 
compared to proliferative samples (Figure 3-13B). Cytokine-cytokine receptor interaction was 
one of the most enriched for pathways in genes ≥5 fold up-regulated in response to rapamycin 
treatment, with the genes encoding for the cytokines IL-6, IL-8 and the protein Leukaemia 
Inhibitory Factor (LIF) present within the pathway. ELISA analyses of IL-6 and IL-8 confirmed 
that these cytokines were produced in response to rapamycin treatment and secreted into the 
cell media (Figure 3-13C). Therefore, rapamycin induces changes in gene expression that are 
enriched for in the cytokine-cytokine receptor interaction pathway which are conserved at the 
protein level, with overall rapamycin eliciting a response in fibroblasts that is broadly enriched 
for in cytokines. 
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Figure 3-13: Proteins Levels of LIF, Il-6 and Il-8 Increase in Response to Rapamycin 
Treatment in 2DD Fibroblasts. (A) BEDgraph for ActC1 demonstrating the total number of 
RNAseq reads from the ActC1 gene from proliferative (PRO), quiescent (QUI) and rapamycin 
(RAP) treated fibroblasts. Low numbers of reads were observed in PRO samples with very few 
reads observed in QUI samples. Scale at the top of the panel represents the genomic location 
with the scale on the left of the graphs representing the number of reads. The light grey cap 
represents where the reads mapped exceed the scale. Bottom row demonstrates the coding 
regions with genomic locations, with arrow heads indicating the direction of the gene and the 
blue bars the coding regions. (B) Western blot of whole cell-protein extracts from (PRO) and 
rapamycin-treated (RAP) fibroblasts for ActC1, LIF (~20 kDa) and the load control ActB1 (~37 
kDa). Molecular weights (in kDa) are shown to the right of (Figure Legend 3-13 Continued) 
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the blots. (C) Sandwich ELISA assays confirmed that rapamycin-induced increases in transcript 
profiles from IL-6 and IL-8 genes also caused increased levels of secreted cytokines. Three 
biological replicates of culture media from proliferative (PRO) and 5-day rapamycin-treated 
(RAP) fibroblasts. P-values for one tailed student’s t-tests are shown for IL-6 (*p=0.006) and 
IL-8 (**p=0.038). Error bars = S.E.M.  
3.8 STAT5A/B Binding Sites Are Enriched in Rapamycin-Induced Gene Expression  
 It is possible that rapamycin-induced changes in gene expression are being mediated 
by specific transcription factors. Therefore, transcription factor motif searches using the cis-
element over-representation (CLOVER) algorithm were conducted (Frith et al. 2004). Analyses 
were focused on promoter regions from 1000 bp upstream to 50 bp downstream of the 
transcription start site of genes that exhibited ≥5- fold change in expression. Several binding 
motifs for the Signal Transducer and Activator of Transcription (STAT) family were enriched 
in the promoters of genes up-regulated by rapamycin (Figure 3-14A). Up-regulated genes from 
rapamycin-treated datasets, such as IL-6ST and LIF, are known to be regulated by the 
STAT5A/B transcription factor (Salas et al. 2011). Furthermore, unlike other members of the 
STAT family, STAT5A/B had a significant number of reads in the rapamycin compared too 
proliferative RNA-seq datasets, indicating that it was expressed. Therefore, analysis was 
focused on the STAT5A/B transcription factor in order to determine whether or not STAT5A/B 
is involved in mediated changes in gene expression in response to rapamycin. CLOVER 
analyses revealed that of the 421 identified up-regulated genes by fold change in response to 
rapamycin treatment, 144 (34.2%) contained a STAT5A/B consensus binding element. These 
findings were significant compared to genomic background (p-value <0.05). To confirm 
increased presence of active (phosphorylated) STAT5A/B in the cell nucleus, immuno-
fluorescence microscopy and subsequent line scans demonstrated that cells treated with 
rapamycin have larger, brighter foci of STAT5A/B within the nucleus (Figure 3-14B & 3-14C). 
However, this was only apparent in a sub-population (40%) of labelled cells. Although 
transcript levels of STAT5A/B did not significantly increase by RNAseq, western blot analysis 
of rapamycin-treated 2DD whole protein lysates at 120 h revealed an increase in the amount of 
STAT5A/B, indicating that rapamycin may stabilize STAT5A/B protein levels and drive 
transcription of STAT5A/B-mediated genes (Figure 3-14D).  
In order to confirm the increase of STAT5A/B transcription factor binding in genes up-
regulated by rapamycin treatment at 120 h, chromatin immuno-precipitation (ChIP) assays were 
performed. These assays revealed occupancy of STAT5A/B in the promoters of every 
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rapamycin up-regulated gene tested (15) (Figure3-14E). MMP2, XPO7, and ActinB, which do 
not contain STAT5A/B elements, alongside intergenic region of chromosome 18, did not 
exhibit significant STAT5A/B above input, acting as negative controls. Furthermore, ChIP for 
RNA polymerase II was used as a positive control to validate enrichment of these assays. These 
findings demonstrate that STAT5A/B promoter occupancy increased in rapamycin-treated 
fibroblasts and that STAT5A/B may be a factor key in mediating the reported cytokine 
response.  
 
Figure 3-14: Increased STAT5A/B Promoter Occupancy in Genes Up-Regulated in 
Response to Rapamycin in 2DD Fibroblasts. Using CLOVER, promoters of genes that 
increased expression following rapamycin treatment were identified as enriched in STAT5A/B 
transcription factor binding sites. (A) Position weight matrix/sequence logo of this binding site 
is shown. Scale to the left represents the log-base (2) of the information content of each 
nucleotide and the bottom scale represents the position of those nucleotides within the binding 
site. (B) Immuno-fluorescence for phosphorylated Y694-STAT5A/B (Y694P; red) in 
proliferating (Control) and rapamycin-treated (rapamycin) (Figure 3-14 Legend Continued) 
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fibroblasts. Chromatin is counterstained with H33342 (blue). Scale bar = 10 m. (C) 
Representative line scans (measured in arbitrary intensity units, yellow lines) of 
immunofluorescence for phosphorylated Y694-STAT5A/B (Y694P; red) in proliferating 
(Control) and rapamycin-treated (rapamycin) fibroblasts showing larger brighter foci of 
STAT5A/B (red) in a subpopulation of fibroblasts. Chromatin is counterstained with H33342 
(blue). Intensity values for STAT5A/B (red lines) and chromatin (blue lines) are represented 
graphically. Pixel dimensions = 49.6 nm. (D) Western blot analysis of STAT5A/B (70kDa) of 
proliferative (PRO) and rapamycin treated (RAP) fibroblasts. (E) ChIP assays were used to 
compare promoter occupancy of STAT5A/B in proliferative (Pro/blue) and rapamycin treated 
(Rap/orange) samples. Promoters analysed (X-axis) and the percent enrichment over input 
reported (Y-axis). Error bars = S.E.M. and * = significant enrichment, p-values ≤0.05.  
3.9 CLOVER Analyses Revealed Further Transcription Factor Binding Sites in 
Rapamycin Up-Regulated Genes  
In addition to the examined STAT5A/B consensus sites and binding reported in 
response to rapamycin treatment, CLOVER screens of genes up-regulated ≥5-fold in response 
to rapamycin treatment revealed the presence of binding elements for Nuclear Factor of 
Activated T Cells (NFAT) transcription factor family in 346 of the 422 genes up-regulated by 
rapamycin treatment (82.0%) (Figure 3-15A).  A significant increase in the level of NFATC2 
transcript was also noted as a result of rapamycin treatment. NFAT family members are 
putatively involved in cell proliferation, apoptosis and tumorigenesis, and interestingly have 
been proposed to drive expression of several cytokines (Domhan et al. 2014). It has further 
been reported that NFATC2 may act to repress STAT5A/B function (Kojima et al. 2013). 
30.9% of promoters contained both STAT5A/B and NFAT binding elements, with 90.9% of 
promoters that had STAT5A/B sites also having NFAT sites (Figure 3-15A). ChIP analyses of 
CXCL-1, CXCL-2 and JARID, which had increased STAT5A/B occupancy, exhibited decreased 
NFATC2 binding in rapamycin-treated 2DD fibroblasts; however, JAK2, ATR, IDI-1, IVL and 
LIF showed little or no binding of NFATC2 under both conditions (proliferative and 
rapamycin-treated) (Figure 3-15B). 
A family of proteins, known as Suppressor of Cytokine Synthesis (SOCS), are negative 
regulators of cytokine signalling and are documented to control STAT5 localization; binding 
and sequestering STAT5 molecules in the cytoplasm, controlling transcriptional activation and 
function of STAT5 (Zhao et al. 2010; Lee et al. 2013). RNAseq datasets for rapamycin-treated 
fibroblasts revealed a decrease of 5.05 fold in SOCS1 transcript, qRT-PCR with biological 
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replicates demonstrating a 2.7+/-0.06-fold decrease in SOCS1. In addition to these findings, 
ChIP for STAT5A/B revealed increased promoter occupancy of SOCS1 (Figure 3-15C).  
Figure 3-15: Overlap Between STAT5A/B and NFATC2 Promoters in Genes Up-
Regulated by Rapamycin Treatment, But No Increase in NFACT2 Promoter Occupancy. 
(A) Venn diagram indicating the number of genes up-regulated by rapamycin (red; 421 genes) 
that shared STAT5A/B (green; 143 genes) and NFAT (purple; 345 genes) binding sites. (B) 
ChIP of SOCS1 promoter in proliferative (Pro; blue) and rapamycin (Rap; orange) samples. 
Error bars = S.E.M. and * = p≤0.05. (C) ChIP assays were also performed for NFATC2 
promoter occupancy. Proliferative (Pro/blue) and rapamycin treated (Rap/orange) samples were 
compared. Promoters analysed are given at the bottom and the percent enrichment over input 
reported. 
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3.10 Removal of Rapamycin from Culture Following Treatments Shifts Growth Profiles 
of Fibroblasts Towards Proliferation 
In order to determine if removal of 500 nM rapamycin would result in 2DD fibroblasts 
returning to a normal, proliferative, phenotype, a number of assays were repeated 120 h after 
rapamycin removal. These assays included; population doubling times, flow cytometry, Ki67 
Immunofluorescence and EdU incorporation. Cell counts were recorded following 120 h of 
treatment and then 120 h post-treatment for a total of 240 h. Both population doubling times 
and total population doublings were calculated at both time points (Fig. 3-16A). Following 120 
h of 500 nM rapamycin treatment in 2DD fibroblasts, population doubling times were 
increased, in keeping with previously reported findings (Figure 3-2A & 3-14A). 120 h post-
removal of rapamycin treatment, population doubling times were still higher than that of the 
untreated control, but lower than that following the initial rapamycin treatment (Figure 3-14A). 
In keeping with these findings, total population doublings were lower than the control following 
rapamycin removal; however, were higher than at 120 h of rapamycin treatment. Furthermore, 
after 120 h treatment removal, no significant difference (student’s t-test: p ≥ 0.05) was detected 
between 120 h post-treatment and proliferative 2DD fibroblasts.  Immuno-labelling with the 
proliferative marker Ki67 revealed little difference between post-rapamycin treatment and 
proliferative samples (69.0% and 69.5% respectively) (Fig. 3-16B & 3-16D). Following 
removal of 500 nM rapamycin treatment for 120 h, the percent of cells actively incorporating 
EdU increased in post-rapamycin treated 2DD fibroblasts when compared to proliferative 
fibroblasts (Figure 3-16C & 3-16D).  In order to determine the number of cells in each stage of 
the cell cycle, a cell cycle assay incorporating propidium iodide and utilizing flow cytometry 
was conducted. In samples supplemented with proliferative growth media following 120 h of 
rapamycin treatment, there was an increase in cells in both S-phase (in agreement with data 
from EdU incorporation (Figure 3-15C)) and in cells in G2/M phase when compared to control 
samples, concordant with a decrease in cells in G1/0.  
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Figure 3-16: Removal of Rapamycin After 120 h of Treatment in 2DD Fibroblasts Induces 
Potentially Synchronized and Accelerated Rates of Proliferation. (A) Population doubling 
times (h) (Y-axis) and total population doublings (Y-axis) (Figure 3-16 Legend Continued) 
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for proliferative and 500 nM rapamycin-treated fibroblasts at 120 h of treatment (blue) and 120 
h post-treatment (orange). Error bars = S.E.M.  (B) Representative graph for percent positive 
Ki67 (Y-axis) for proliferative (120 h Pro) and rapamycin-treated fibroblasts at 120 h post-
treatment (120 h Post-Rap). (C) Representative graph for percent positive EdU (Y-axis) in 
proliferative (120 h Pro) and 500 nM rapamycin-treated fibroblasts 120 h post-treatment (120 
h Post-Rap). (D) Representative images of immunofluorescence for proliferative (Left) and 120 
h post-500 nM rapamycin treatment (120 h Post-Rap Treatment, Right) of Ki67 labelling 
(green) and EdU incorporation (red). Chromatin is counterstained with H33342. (E) Propidium 
iodine cell cycle analysis for proliferative and 500 nM rapamycin-treated fibroblasts 120 h post-
treatment (120 h Post-Rap Treatment). Cells counted (Events Counted; Y-axis) and FL2-A (X-
axis).  
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3.11 Discussion  
Primary human foreskin fibroblasts (2DD) were treated in culture with 500 nM 
rapamycin for 120 h. Experiments conducted following this incubation revealed rapamycin-
induced phenotypic changes in 2DD resembling quiescence. Rapamycin treatment and serum-
reduction caused re-localization of chromosomes 18 and 10 within the nuclear volume. RNA 
sequencing analyses demonstrated significantly divergent transcriptional profiles between 
rapamycin-treated and quiescence-induced fibroblasts. In particular, rapamycin up-regulated 
cytokine/chemokine related genes whilst quiescence up-regulated genes from the complement 
and coagulation cascade by fold-change analysis. Although log-base (2) analyses revealed 
enrichment in pathways in cancer in response to rapamycin treatment, many of these genes 
were cytokines, linking this finding back to the cytokine/chemokine enrichment observed in 
fold change analyses. This slight variability reveals the importance of the type of bioinformatics 
analyses and in identified networks being based only on the current state of knowledge – it is 
likely there are as of yet unidentified networks in the transcripts enriched for pathways in cancer 
that will further link this finding back to the cytokine-cytokine receptor pathway. Furthermore, 
these observations confirmed that although rapamycin decreased cell proliferation without 
causing cell death, it did not result in a cellular state similar to quiescence induced by serum 
reduction. In addition, increased occupancy of STAT5A/B in the promoters of rapamycin up-
regulated genes implicating this factor as part of the mechanism mediating rapamycin-induced 
changes in gene expression.  Finally, removal of 500 nM rapamycin treatment for 120 h resulted 
in increased numbers of cells in S-phase, likely the result of cells re-entering the same stage of 
the cell-cycle at the same time after becoming synchronised in the slower, rapamycin-induced 
state.  
Network analyses of both quiescence-induced and rapamycin-treated fibroblasts 
revealed enrichment of several distinct biological pathways. Cellular quiescence is defined as 
a state of reversible growth/proliferation arrest. In transcripts up-regulated by quiescence-
induction, the complement and coagulation cascade was enriched (Table 3-1 & 3-4). This is the 
first report of this finding in normal human fibroblasts. As protein products of these genes are 
linked with serine-type peptidase/endopeptidase activity and are secreted into the extracellular 
space, they may have roles in mediating the extracellular matrix. A condition that may be 
monitored by neighbouring cells in order to determine environmental conditions. Furthermore, 
genes such as SERPING1 and CFHL1 were up-regulated by serum/mitogen removal in normal 
fetal lung fibroblasts (Coller et al. 2006); however, this work did not identify enrichment in GO 
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terms associated with the complement and coagulation pathway. It is possible that common 
genes are involved in regulating quiescence across cell types inducing similar serine-type 
peptidase/endopeptidase activity. In both fold change and log-base (2) RNAseq analyses, down-
regulated genes in response to quiescence were enriched for pathways such as mitotic 
prometaphase, aurora B signalling and cell cycle. Genes such as FOXM1 and CCNB1 were 
present in these enriched pathways as well as the study in fetal lung fibroblasts (Coller et al. 
2006). These observations demonstrate commonalities between these different, although 
similar, cell types in response to quiescence induced by serum reduction. Furthermore, serum 
reduction in culture could be considered a type of dietary restriction, although it has not been 
documented to have the health and lifespan benefits of other DR-based systems. Despite this, 
the divergent findings between rapamycin treatment and quiescence-induction provide initial 
evidence that rapamycin may not directly mimic dietary restriction; however, further work is 
needed in other dietary restriction based conditions that promote health and lifespan. 
Rapamycin treatment induced the up-regulation of genes enriched for in the cytokine-
cytokine receptor pathway, in particular genes related to IL-6 (IL-6, IL-8, IL-11 and LIF). These 
findings confirmed previous computation-based predictions (Zhao et al. 2010; Lee et al. 2013; 
Domhan et al. 2014). Contrary to the enrichment of cytokines in normal human fibroblasts in 
response to rapamycin, findings in human oral keratinocytes revealed inhibition of interleukin-
1 beta (IL-1), TNF and IFN- and enhancement of IL-12p70 expression. Laberge and 
colleagues further indicated that mTOR inhibition via rapamycin, or via the knockdown of 
mTOR components decreases IL-6/cytokine production in senescence fibroblasts (Laberge et 
al. 2015). In human macrophages, rapamycin increased TNF, and IL-6 levels (Su et al. 2015) 
whilst in orbital fibroblasts, rapamycin increased TNFa induced IL-6 and IL-8 secretion by 
inhibiting PDCD4 degradation (Lee et al. 2013). IL-6 production has previously been linked to 
stress-induced premature senescence (SIPS)/replicative senescence and the senescence-
associated secretory phenotype (SASP), with the accumulation of SASP cells associated with 
disease and ageing (Garbers et al. 2013; Kojima et al. 2013); however, it is unlikely that 
fibroblasts have entered SIPS/SASP as cells retained the ability to proliferate, albeit at a slower 
rate. In support of this, no pathway enrichment was identified for these terms and upon removal 
of rapamycin treatment, fibroblasts re-entered the cell cycle. It is possible that rapamycin is 
creating a balance between two states, inducing cytokine production whilst repressing SASP. 
Furthermore, an indirect interaction between STAT5A/B and mTOR has been proposed in T-
cells and in response to cytokine signaling (Saleiro and Platanias 2015); however, the 
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mechanism involved with this is unclear. This finding is important in relation to our data given 
the link between mTOR inhibition and promoting improved health and lifespan, meaning that 
inhibition of mTOR via rapamycin treatment could be promoting improved health and lifespan 
via cytokine induction mediated by STAT5A/B. Our findings, combined with the literature, 
suggest that response to rapamycin is potentially cell-type specific and dose-dependent. Given 
that it has previously been documented that cytokines are enriched in old, senescent fibroblasts, 
this novel finding of cytokine enrichment in young proliferating fibroblasts in response to 
rapamycin, alongside previous work documenting links between cytokines, mTOR and 
STAT5A/B, hints at an important role for cytokines in regulating aging and the balance between 
young and old. 
ELISAs provided further evidence of IL-6 and IL-8 production, displaying an increase 
in the amount of both proteins secreted from fibroblasts treated with rapamycin. Increased 
levels of these cytokines were detected within the culture media after 120 h, but the fold change 
values were not as dramatic as those observed at the transcript level. This finding raises the 
possibility that IL-6 and IL-8 could affect adjacent cells within the environment. Western 
blotting confirmed increased levels of LIF, which is also an IL-6-related secreted protein. 
Future investigations of these proteins should reveal if these signals are part of the program 
caused by disrupted nutrient sensing which promotes increased cellular health and longevity. 
Transcription factor motif screens and subsequent ChIP analysis revealed the novel 
identification of STAT5A/B as one of the factors binding up-regulated gene promoters in 
response to rapamycin in 2DD fibroblasts. One of the genes identified to have a STAT5A/B 
binding site in the promoter encodes the Suppressor of Cytokine Signaling (SOCS) family 
member, SOCS1. The SOCS1 protein, which is a negative regulator of Janus kinases (JAK) and 
STAT proteins, has previously been reported to sequester STAT5A/B in the cytoplasm (Galic 
et al. 2014). In rapamycin-treated fibroblasts, SOCS1 transcript abundance was decreased 5.05 
fold in our RNAseq dataset. The increase in STAT5A/B-mediated transcription of several 
cytokine genes agrees with the model in which SOCS1 forms part of the negative feedback 
loop; decreased expression of the SOCS1 gene possibly leads to decreased protein levels in the 
cytoplasm  (Dimitriou et al. 2008). This loss of SOCS1 protein would, therefore, allow 
STAT5A/B to translocate into the nucleus, where it binds and drives the expression of a large 
number of genes (Peltola et al. 2004) . In addition, several of the cytokines we observed to be 
up-regulated, such as IL-6 and LIF, are reported to up-regulate the expression of SOCS1 (Krebs 
and Hilton 2000). We did not observe an up-regulation of SOCS1 expression; however, this 
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could be due to the ongoing treatment with rapamycin. Future studies will need to examine how 
STAT5A/B and decreased expression of the SOCS1 gene are linked to inhibition of mTOR by 
rapamycin. Although rapamycin has been partially linked with cytokine production in other cell 
types (Zhao et al. 2010; Lee et al. 2013; Domhan et al. 2014), this work further proposes the 
potential mechanisms involved with this stimulation, identifying STAT5A/B and decreased 
levels of SOCS1 transcription as being involved with this rapamycin-mediated response.  Other 
SOCS family members have a range of functions in different cell types, often acting to form a 
negative feedback loop for cytokine signaling (Dimitriou et al. 2008). Immune responses 
implicated in signaling from SOCS family members have been linked to obesity and type II 
diabetes (Galic et al. 2014) . While decreased expression of other SOCS family members was 
observed, these genes did not reach our criteria for significance. However, these observations 
may implicate SOCS family members as potential global regulators controlling rapamycin-
mediated transcription programs in other cell types. In addition to STAT5A/B involvement with 
rapamycin-mediated gene induction, we also identified NFATC2 binding sites to be 
significantly enriched in these promoters. Previous studies have identified a physical interaction 
between STAT5A/B and NFATC2, with NFATC2 acting as a negative regulator (Zheng et al. 
2011). The increased transcription of the NFATC2 gene may be a response to increased activity 
of STAT5A/B; the resulting NFATC2 protein functioning to sequester and inhibit continued 
STAT5A/B-mediated transcription. ChIP analyses demonstrated, at least in a subset of 
promoters analyzed, that NFATC2 is not interfering with STAT5A/B promoter occupancy.  
In conclusion, it has been demonstrated that rapamycin induced a significant change in 
the transcript profiles of normal 2DD human foreskin fibroblasts, distinguishing rapamycin 
treatment from quiescence induction by serum reduction. Furthermore, an increase in 
cytokine/chemokine expression and production, including IL-6, IL-8 and LIF, was observed, 
coinciding with increased STAT5A/B promoter occupancy at many of these genes. This 
STAT5A/B-mediated regulation of gene expression provides novel insight into the mechanisms 
through which rapamycin treatment impacts cell proliferation, gene expression and cytokine 
production. These observations link TOR inhibition with changes in genome function and 
organization independent of quiescence; changes which have the potential to regulate cellular 
health and longevity which, in turn may influence the ageing process at the 
tissue/organ/organismal level. Future work should include an expansion into other foreskin 
fibroblast lines to see if this is maintained regardless of genomic background/individual genome 
types. 
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4.0 The Impact of Metformin on Genome Function and Organization 
4.1 Metformin Reduces Cell Proliferative Rates in NB1 hTERT Fibroblasts 
Metformin has been documented to impact autophagy (both increasing and decreasing 
dependent on the cell line) and reduce cancer cell proliferation across numerous cell lines 
(Anisimov et al. 2011; Ashinuma et al. 2012; Alimova et al. 2014; Brodowska et al. 2014; He 
et al. 2015). Further, metformin has been linked to a decreased incidence of cancer in type II 
diabetic patients (Evans et al. 2005).  In order to confirm these findings and investigate the 
impact of metformin in a novel cell line, the NB1 hTERT cell line was treated with 
concentrations of 0.5-25 mM metformin. Following treatment, cell counts were taken at 72 and 
population doubling times and total population doublings calculated (Fig. 4-1A & 4-1B). 
Metformin treatments in the literature are generally very high and not physiologically relevant. 
Here, concentrations were chosen to be both more physiologically relevant but to also overlap 
with concentrations that have previously resulted in an impact in culture. At 72 h, cell 
population doubling times in response to 5 mM (23.4 h), 10 mM (45.4 h) and 25 mM (106.9 h) 
metformin were longer than the control (20.7 h) (Figure 6A). A decrease in total population 
doublings at 5 mM (3.6 compared to a control of 4.3 after 120 h of treatment), with significant 
decreases observed at 10 mM and 25 mM metformin (2.6 and 1.2 respectively in comparison 
to the proliferative sample at 4.3) was also documented (Fig. 4-1B). No obvious morphological 
changes were noted (Fig. 4-1D). Trypan blue staining revealed no deleterious effects in 
response to metformin treatment, although a slight change between proliferative (97.3% viable) 
and treated with 0.5 mM (92.1% viable), 1 mM Met (93.9% viable), 5 mM (98.3%), 10 mM 
(95.3%), and 25 mM (91.8%) metformin treatment cells (Fig. 4-1C) was noted. 
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Figure 4-1: Metformin Decreased the Rate of NB1 hTERT Proliferation. (A) NB1 hTERT 
cells were grown under normal culture conditions or in the presence of 0.5 mM, 1 mM, 5 mM, 
10 mM or 25mM metformin for 120h (X-axis). Population doubling times were calculated for 
each treatment, including control (Y-axis). (B) The total number of population doublings were 
plotted for control and metformin-treated cultures at 120 h. (C) Trypan blue assays of both 
control and metformin-treated NB1 hTERT are shown with both viable and non-viable values 
given (X-axis) with percent (%) cells on the Y-axis).  Data is representative of single biological 
replicates, with additional replicates (data not shown) demonstrating parallel trends. (D) 
Representative, greyscale, light microscopy images for each metformin treatment (control, 0.5 
mM and 1 mM (top)) and (5 mM, 10 mM, 25 mM (bottom)) at 120 h.  
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4.2 Metformin Reduces Cell Proliferative Rates in Normal Human Fibroblasts 
To establish the impact of metformin on healthy human proliferative cells, fibroblasts 
were treated with 0.5 mM or 1 mM metformin in filtered dH2O for either 72 h or 120 h. Due to 
a lack of literature on metformin in normal human cell lines, these concentrations were chosen 
to determine whether or not lower metformin concentrations would impact cell growth and 
proliferation at a more physiologically relevant level. Population doubling times were measured 
and total population doublings calculated, representative replicates are given (Figure 4-2A and 
4-2B). An increase in population doubling times was observed under both conditions at both 
time points, with the average population doubling time following 72 h in culture increasing 
from 40.1 h in proliferating fibroblasts to 49 h and 54 h in 0.5 mM and 1 mM metformin treated 
cultures respectively. Similarly, following 120 h of treatment, population doubling times 
increased from 46 h in the proliferating culture to 52 h under both 0.5 mM and 1 mM metformin 
treatments. In agreement with the increase in population doubling times, a decrease in total cell 
population doublings was observed, with proliferative samples at 72 h doubling a total of 1.8 
times, and treated samples (0.5 mM metformin and 1 mM metformin) decreasing to 1.5 and 1.3 
total population doublings respectively (Figure 4-2B). At 120 h a similar trend was observed, 
with the proliferative samples having undergone total population doubling of 2.6, and treated 
samples both having a total population doubling of 2.3. There was no evidence of an increase 
in cell death in response to metformin treatments, confirmed via staining with trypan blue 
(Figure 4-2C). It was previously demonstrated that rapamycin, a potential mimetic of caloric 
restriction, caused cells to flatten in a similar manner to quiescent fibroblasts [76]. This feature 
was not induced by treatment with metformin at either 72 h or 120 h (Figure 4-2D). In order to 
further determine the impact of metformin on proliferation, 2DD fibroblasts were fixed and 
labelled for the proliferative marker Ki67. Fibroblasts were treated for 120 h at either 0.5 mM, 
1 mM, 5 mM, 10 mM or 25 mM metformin, with a decrease in the percent positive Ki67 
fibroblasts from the control (67.8%) at 0.5 mM (56.8%), 1 mM (57.7%), 5 mM (56.2%) and 25 
mM (43.4%) (Figure 4-3A & 4-3C). No significant change was observed at 10 mM metformin 
treatment (65.9%) (student t-tests, p>0.05). This data was further confirmed through the use of 
5’-ethynyl-2’deoxyuridine (EdU), a thymidine analogue which is actively incorporated into 
cells replicating DNA. Cells were treated with metformin concentrations ranging from 0.5 mM 
to 25 mM for 120 h. EdU incorporation demonstrated a decrease in S-phase between 
proliferative (16.9%) and 0.5mM metformin treated (12.6%, P<0.05) fibroblasts. Similar, but 
less significant, decreases were observed at 1 mM (14.1%) and 10 mM (15.7%) metformin 
treatment; however, at the high-dose of 25 mM metformin, EdU incorporation was at 6.7%. An 
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increase in EdU incorporation was observed at 5 mM (17.5%) (Figure 4-3A & C). Cell cycle 
analysis using propidium iodide and flow cytometry data further confirms that the number of 
cells in G1/0 in response to metformin is increasing following 120 h of treatment, from 74.0% 
in proliferative samples, to 79.0% in 0.5 mM metformin and 78.8% in 1 mM metformin (Figure 
4-3D). 
Figure 4-2: Metformin Increased the Rate of 2DD Foreskin Fibroblast Population 
Doubling Times, Decreasing the Rate of 2DD Proliferation. (A) 2DD cells were grown under 
normal culture conditions or in the presence of 0.5 mM or 1 mM metformin for 72 h or 120 h 
(X-axis). Population doubling times were calculated for each treatment, including control (Y-
axis). (B) The total number of population doublings were (Figure 4-2 Legend Continued) 
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plotted for control and metformin-treated cultures at 72 h and 120 h. (C) Trypan blue assays of 
both control and metformin-treated 2DD at 120 h are shown with both viable and non-viable 
values given (X-axis) with percent (%) cells on the Y-axis).  Data is representative of single 
biological replicates, with additional replicates (data not shown) demonstrating parallel trends. 
(D) Representative, greyscale, light microscopy images for each metformin treatment (control, 
0.5 mM and 1 mM met at 72 h (top) and 120 h (bottom).  
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Figure 4-3: 0.5 mM and 1 mM Metformin Decreased 2DD Fibroblast Proliferation. (A) 
2DD fibroblasts were grown under either proliferative conditions or treated with 0.5 mM, 1 
mM, 5 mM, 10 mM or 25 mM metformin treatment for 120 h. Percent positive Ki67 (Y-axis) 
Immuno-labelled 2DD following treatment with metformin (X-axis) is shown. (B) Proliferative 
and metformin treated (0.5 mM, 1 mM, 5 mM, 10 mM or 25 mM) (X-axis) 2DD were incubated 
with the thymidine analogue EdU. and percentage positive for EdU reported (Y-axis) at 120 h. 
Error bars for (A) and (B) are the S.E.M., scale bar = 10 µm. (C) Representative merged 
microscopy images of proliferation and metformin treated (0.5 mM, 1 mM, 5 mM, 10 mM and 
25 mM metformin) immuno-labelled for Ki67 (green) or EdU stained (red). Chromatin is 
counterstained with H33342. Scale bar = 10 m (D) Pro, 0.5 mM and 1mM metformin-treated 
fibroblasts were fixed and stained with propidium iodide and DNA content measured by flow 
cytometry. Histograms demonstrate events counted (Y-axis), fluorescence signal (Intensity 
Units, X-axis) measured and the percentage cells in G0/G1, S and G2 phase of the cell cycle 
for each treatment condition. 
4.3 Metformin Increases phosphorylated-AMPK (Thr172) and Decreases LC3 (a marker 
of autophagy) in Normal Human Fibroblasts 
Metformin has previously been proposed to inhibit mTOR through activation of AMPK. 
Activation of AMPK is dependent on phosphorylation of AMPK at Thr172. In order to confirm 
that metformin is acting in a manner physiologically relevant and as indicated by literature, 
western blots using whole cell lysates for phosphorylated AMPK (Thr172) were conducted 
(Figure 4-4), with an increase in phosphorylated AMPK observed. A decrease in the 1 subunit 
of AMPK and no change in were also documented. These findings were in agreement with 
metformin inducing phosphorylation of AMPK potentially resulting in inhibition of mTOR.  
Inhibition of mTOR often results in an increase in autophagy, the process by cellular 
components are recycled. Autophagy is often increased in response to decreases in a cells 
nutrient availability (Blagosklonny 2010). In the normal human 2DD fibroblast, a decrease in 
autophagy concordant with an increase in treatment concentration was noted (Figure 4-4). 
Although the literature frequently lists metformin as inducing an increase in autophagy, this 
decrease is not without precedent, with GO enrichment analyses of the liver and muscle of mice 
fed metformin revealing enrichment for downregulation of autophagy (Martin-Montalvo et al. 
2013). Furthermore, Yang, et al., report no increase in HepG2 cells as a result of metformin 
treatment (10 mM, 24h) whilst Song, et al., report autophagy to increase in the presence of 0.5 
mM metformin. To further validate these findings, higher concentrations of metformin were 
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used to treat both 2DD and NB1 hTERT fibroblasts. Western blot analyses of 2DD and NB1 
hTERTs exposed to 0.5 mM, 5 mM and 10 mM of metformin for 120 h were conducted (Figure 
4-4). This analysis revealed no change in LC3II expression using two different antibodies from 
separate sources, providing further confidence in these findings. These findings were confirmed 
by immunofluorescence, with a decrease from 7.9% LC3 positive fibroblasts in proliferative 
samples to 3.3% in response to 0.5 mM metformin treatment and 4.4% in response to 1 mM 
metformin treatment.  (Figure 4-5). 
Figure 4-4: Western Blot Analyses of AMPK and LC3 in 2DD and NB1 hTERT 
Fibroblasts. Western blot analyses from whole cell lysates of (Figure 4-4 Legend Continued) 
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2DD treated under proliferative, 0.5 mM metformin and 1 mM metformin treatment for 120 h. 
Protein analysed is listed on the left with protein size (kDa) on the right. The bottom two panels 
represent an analyses of 2DD (top) and NB1 hTERT (bottom) cell-lines treated under control 
conditions and with 0.5 mM, 5.0 mM and 10 mM metformin for 120 h. LC3II is detected at 16 
~kDa. For LC3II and -Actin antibodies, 15 g of protein was loaded. For all other antibodies 
40 g was loaded.  
 
Figure 4-5: Detection of LC3I/II Indicates a Decrease in Autophagy as a Result of 0.5 mM 
and 1 mM Metformin Treatment in 2DD Fibroblasts. Representative immunofluorescence 
to detect LC3I/II (green) in proliferative (A), 0.5 mM metformin-treated (B) and 1 mM 
metformin treated (C) fibroblasts. Chromatin is counterstained with H33342 (blue). Scale bar 
= 10 m. (D) Bars for control (pro), 0.5 mM metformin (orange) and 1 mM metformin (grey) 
-treated fibroblasts demonstrating the percent of nuclei identified as positive (Y-axis) for 
LC3I/II.  
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4.4 Metformin Treatment Induces Genome Re-organization in 2DD Fibroblasts 
Based on previous work that chromosome territories rapidly re-position in response to 
serum reduction in culture (Mehta et al. 2010) and that in this work, rapamycin treatment, a 
proposed mimetic of metformin similarly demonstrated re-positioning of chromosomes 10 and 
18 in 2DD fibroblasts, FISH was conducted for chromosomes X, 10 and 18 under proliferative 
conditions, 0.5 mM metformin and 1 mM metformin treatment at 120 h (Figure 4-6). Treatment 
of 2DD fibroblasts with 0.5 mM metformin induced statistically significant (student t-test, 
p≤0.05) re-positioning of chromosomes 10 and 18, 10 towards the nuclear periphery and 18 
towards the nuclear interior when compared to untreated counterparts. At 1 mM metformin 
treatment, repositioning of chromosome 10 was not significant; however, chromosome 18 also 
re-positioned to the nuclear interior. Chromosome X was used as a control with no significant 
change in positioning documented, remaining at the nuclear periphery. These findings are 
similar to that of quiescence-induction and rapamycin treatment.  Furthermore, significant 
difference was reported between 0.5 mM metformin and 1 mM metformin treatments, with 
chromosome 10 at 1 mM metformin occupying a more interior location when compared to 0.5 
mM metformin treatment, and chromosome 18 in response to both 0.5 mM and 1 mM 
metformin located to the nuclear interior, but 1 mM metformin treated samples more so.  In 
addition to these findings, correlation trends reported supported these findings.  
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Figure 4-6: 0.5 mM and 1 mM Metformin Treatments Induce Chromosome Territory 
Repositioning in 2DD Fibroblasts. Chromosomes 10 (top row), 18 (middle row) and the X 
chromosome (bottom row) were identified in control (Pro, first column), 0.5 mM metformin 
treated (0.5 mM Met, second column) and 1 mM metformin treated (1 mM Met, third column) 
2DD fibroblasts by chromosome painting. Red signal represents the identified chromosomes; 
chromatin was counter stained with H33342 (blue). Scale bar = 10 m for all images. Following 
painting, erosion analysis was performed to designate the location of the chromosomes within 
the nuclear volume. Nuclei were broken into five concentric shells of area, shell 1 being most 
exterior and shell 5 being most interior. Graphs for each specific chromosome represents the 
measured ratio of % chromosome signal divided by the % H33342 signal in each shell (Y axis) 
to normalize for DNA content in each shell (X axis). Control positioning is represented by blue 
bars, 0.5 mM metformin-treated by orange and 1 mM metformin-treated in grey. Error bars = 
S.E.M.  Two tailed Student’s test for unequal variance were used to demonstrate significant 
difference in chromosome positioning. * Indicates p-value ≤0.05 between control and treatment 
group. # Indicates significant difference (p-value ≤0.05) between 0.5 mM and 1 mM metformin 
treatment. Correlation calculations were also performed to demonstrate if the trend in 
chromosome positioning was similar or divergent between the samples. Chromosome 10 
proliferative R2 =0.96, 0.5 mM metformin R2=0.96 and 1 mM metformin R2=0.75. 
Chromosome 18 proliferative R2=0.95, 0.5 mM metformin (Figure 4-6 Legend Continued) 
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R2=0.98 and 1 mM metformin R2=0.66. Chromosome X proliferative R2=0.89, 0.5 mM 
metformin R2=0.96 and 1 mM metformin R2=0.95. 
Table 4-1: Correlation Values (R2) for Chromosome Territory Re-Positioning in 2DD 
Fibroblasts in response to 0.5 or 1 mM metformin treatment. Correlation values for 
chromosome territory re-positioning in 2DD fibroblasts threated for 120 h with either 0.5 mM 
or 1 mM metformin treatment at 120 h.  Correlations are given for chromosome 18, 10 and X 
for proliferative (Pro), 0.5 mM metformin (0.5 mM Met) and 1 mM metformin (1 mM Met).  
 
R2 Values 
Chromosome 
10 
Chromosome 
18 
Chromosome 
X 
Pro 0.96 0.95 0.89 
0.5 mM Met 0.96 0.96 0.96 
1 mM Met 0.75 0.75 0.95 
 
To further investigate the impact of cell proliferative state on chromosome territory 
positioning, and to control for cell cycle stage in these analyses, nuclei were also labelled with 
the proliferative marker Ki67 (Figure 4-6). Whilst findings remained consistent in chromosome 
18 regardless of cell proliferative state (re-localizing towards the nuclear interior), chromosome 
10 was analysed to have re-positioned to the nuclear exterior in Ki67 negative fibroblasts, whilst 
towards the interior in Ki67 positive fibroblasts. As with combined samples, there was some 
significant variance between 0.5 mM and 1 mM metformin treatments, indicated a potential 
dose-dependent response.  
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Figure 4-7: Chromosome Territory Positioning in Response to Metformin in Both Ki67 
Positive and Negative 2DD Fibroblasts. Chromosome X (top row), 10 (middle row) and 18 
(bottom row) were identified in Chromosomes 10 (top row), 18 (middle row) and the X 
chromosome (bottom row) were identified in control, 0.5 mM and 1 mM metformin treated 
2DD fibroblasts by chromosome painting.  The first column of graphs is for Ki67 positive (+ve) 
nuclei, the second column for Ki67 negative (-ve) nuclei, the third column is representative 
images of control in X, 10 and 18 for proliferative nuclei.  Red signals represents the identified 
chromosomes; green signal represents Ki67 positive fibroblasts;) chromatin was counter 
stained with H33342 (blue). Scale bar = 5 m for all images. Following painting, nuclei were 
separated based on positive and negative signal for Ki67 and erosion analysis was performed 
to designate the location of the chromosomes within the nuclear volume. Nuclei were broken 
into five concentric shells of area, shell 1 being most exterior and shell 5 being most interior. 
Graphs for each specific chromosome represents the measured ratio of % chromosome signal 
divided by the % H33342 signal in each shell (Y axis) to normalize for DNA content in each 
shell (X axis). Control positioning is represented by blue bars, 0.5 mM metformin by orange 
and 1 mM metformin in grey. Error bars = S.E.M.  Two tailed Student’s test for unequal 
variance were used to demonstrate significant difference in chromosome positioning. * 
Indicates p-value ≤0.05 between control and treatment group. # Indicates significant difference 
(p-value ≤0.05) between 0.5mM and 1mM metformin treatment.  
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4.5 Metformin Treatment induces a Transcript Profile Divergent to rapamycin Treatment 
by reverse transcriptase qPCR 
A number of genes were selected for investigation based on rapamycin treatments of 
2DD fibroblasts and on the metformin literature. As rapamycin and metformin are both 
proposed to be mimetics of caloric restriction, it was expected that genes changing in response 
to rapamycin treatment would also change in response to metformin treatment. Very little work 
has been conducted in understanding the specific genes changing expression in response to 
metformin treatment. Martin-Montalvo et al. (Martin-Montalvo et al. 2013), however, have 
identified a number of genes significantly changing expression in response to long term 
treatment with 0.1% (w/w) and 1% (w/w) metformin in the liver and muscle tissue of male 
C57BL/6 mice. Although the lower treatment extended mean lifespan by 5.83%, 1% (w/w) was 
toxic to mice, shortening lifespan by 14.4%. Microarray profiling of the mice tissues determined 
a global gene expression shift towards caloric restriction. From this, the cytokine-inducible 
SH2-containing protein (CISH) gene was determined as one of the most highly changing genes 
in both metformin-treated (11.6 fold) and caloric restriction (11.58 fold) treated mice.  
To determine if CISH, and other selected genes, were responding to metformin 
treatment in accordance with the literature, 2DD fibroblasts were treated with 0.5 mM and 1 
mM metformin for 120 h, RNA extracted, cDNA libraries made and expression tested by qPCR. 
It was determined that CISH increased expression by 6.8 fold and 5.3 fold respectively. Work 
by Takiyama et al., documented an increase in Hypoxia Inducible Factor (HIF-1a) expression 
in Zucker diabetic fatty rats, whilst DNA-Damage Inducible Transcript 4 (DDIT4) and 
Peroxisome Proliferator-Activated Receptor Alpha (PPARa) have been demonstrated to 
increase expression in cancer models and mice in response to metformin treatment, with both 
further being implicated in alternative pathways for the compound [79]. Despite the literature, 
no significant change in the expression of these genes in normal foreskin fibroblasts following 
metformin treatment was observed at 0.5mM metformin, although 1mM metformin fold change 
was greater than (>)2 for DDIT4, with HIF-1a expression documented at 1.9 and -1.4 
respectively for each treatment, DDIT4 expression changed 1.7 and 2.2 fold respectively, and 
PPARa changed 1.8 and 2.7 fold respective to each treatment (Figure 4-8A).  
It has been proposed that both metformin and rapamycin mimic dietary restriction and 
therefore mimic one another. As such, a number of genes of interest identified as changing 
significantly following 500 nM rapamycin treatment in the same 2DD fibroblast cell line were 
investigated. These included; ACTC1 (266.8 fold up-regulated following rapamycin treatment), 
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IL-8 (24.0 fold up-regulated), IL-11 (37.2 fold up-regulated), LIF (73.0 fold up-regulated) and 
NFATC2 (6.85 fold up-regulated) [76]. Following 120 h of treatment with either 0.5mM 
metformin or 1mM metformin, these genes did show an increase in expression; and although 
changes for IL-8, IL-11, LIF and NFATC2 were greater than two fold in at least one treatment 
concentration, changes were much lower than those observed following rapamycin treatment. 
IL-11 had the greatest response at 0.5mM metformin, with an increase of 5 fold; however, at 1 
mM, this value decreased to 2.3 fold. IL-8 also decreased from a fold change of 2.2 at 0.5 mM 
metformin to 1.9 at 1mM metformin treatment. ACTC1 and NFATC2 demonstrated similar 
trends, whilst LIF increased from 3.0 fold at 0.5 mM metformin to 3.4 fold at 1 mM metformin 
(Figure 3-8B). 
 
 
Figure 4-8: Gene Expression Data for Genes of Interest in Metformin Treated Fibroblasts 
Compared to Rapamycin Treated 2DD Fibroblasts Demonstrated Divergence. To 
determine the impact of metformin on genes previously reported to be altered in response to 
treatment, qPCR was performed on CISH, DDIT4, PPARa, and HIF1a. To provide initial 
indications on whether or not the same genes responding to rapamycin treatment also respond 
to metformin in 2DD fibroblasts, qPCR was performed on ACTC1, IL-8, IL-11, and LIF. 
NFATC2 was tested based on its proposed involvement in the previously noted response to 
rapamycin. Fold change (Y-axis) is noted to the left hand side of the figure, whilst 0.5 mM 
treatment (blue bars), 1 mM treatment (orange bars) and RNAseq-based changed in response 
to 500 nM rapamycin (grey bars) are plotted along the X-axis. Error bars = S.E.M. 
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4.6 Metformin Treatment induces a Transcript Profile Enriched in AP-1 Transcription 
Factor Network (Fold Change Analyses) and Cytokine-Cytokine receptor pathways (Log-
Base (2) Transformed)  
Metformin has previously been proposed to mimic caloric restriction and has 
documented similar effects across numerous model organisms to rapamycin-treatment. 
Although repositioning of chromosome territories was observed in response to metformin 
treatment, changes in chromosome location were not identical to that of rapamycin-treatment 
in the same cell line. To further investigate whether metformin and rapamycin treatments were 
having divergent impacts on genome function, mRNA were isolated from proliferative, 0.5 mM 
and 1 mM 120 h metformin treated fibroblasts. RNAseq with subsequent comparative 
transcriptome analyses were conducted. Raw sequence reads from Illumina-based sequencing 
were mapped to the GRCh38/hg19 reference genome, normalized using RPM and analysed 
using the bioinformatics tool SeqMonk 
(http://www.bioinformatics.bbsrc.ac.uk/projects/seqmonk/).  
Comparisons between RNAseq datasets of 0.5 mM metformin to 1 mM metformin were 
made comparing the log-base (2) number of reads from 0.5 mM metformin-treated fibroblasts 
or 1 mM metformin-treated fibroblasts (Figure 4-9) against the log number of reads from 
proliferative fibroblasts. A subset of genes of interest that changed transcript profiles in either 
0.5 mM or 1 mM metformin treated fibroblasts have been highlighted and genes changing 
expression in both treatment conditions represented in green. In 2DD fibroblasts treated with 
0.5 mM metformin, 443 genes changed expression ≥2-fold (264 up-regulated; 179 down-
regulated), 263 ≥3-fold (154 up-regulated; 109 down-regulated), and 78 ≥5-fold (44 up-
regulated; 34 down-regulated). In 1 mM metformin-treated 2DD fibroblasts, 413 genes changed 
expression ≥2-fold (208 up-regulated; 205 down-regulated), 265 ≥3-fold (132 up-regulated; 
133 down-regulated), and 76 ≥5-fold (34 up-regulated; 42 down-regulated). The majority of 
genes from both 0.5 mM and 1 mM metformin treatments had similar read count values to those 
of proliferating cells (correlations of 0.996 for both), with the scatter plots demonstrating some 
overlap between genes changing expression; however, further analysis revealed that 180 genes 
(106 up-regulated; 74 down-regulated) changing ≥2-fold expression overlapped between 
treatments. Similarly, 109 genes ≥3-fold expression (63 up-regulated; 46 down-regulated) and 
31 genes ≥5-fold expression (20 up-regulated; 11 down-regulated) overlapped between 0.5 mM 
and 1 mM metformin treatments. Therefore, based on log-base (2) analyses the two treatment 
concentrations induce varied transcript expression. The second analysis, based on fold-change 
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in gene expression comparing 0.5mM metformin and 1mM metformin to proliferative 
fibroblast RNAseq datasets revealed similar findings with greater overlap between genes 
changing expression in 0.5 mM and 1 mM metformin treatment (Figure 4-10). RNAseq data 
were validated by RT-qPCR by a selection of sample genes that changed/did not change 
expression in 0.5mM and 1mM metformin-treated fibroblasts (Figure 4-11). 
To determine if there was overlap or divergence in the modules and biological pathways 
enriched for by either 0.5 mM or 1 mM metformin treatment, network analyses using genes 
identified as significantly changing (≥3-fold) were conducted. Cytoscape [248] with 
ReactomeFI [249] was used to classify highly-interacting groups of genes (modules) from the 
RNAseq datasets and to identify the associated pathway annotation terms (Kyoto Encylopedia 
of Genes and Genome; KEGG terms). Two analyses were conducted, one for log-base (2) 
transformed data and one for fold-change based data. In log-base (2) transformed data, 
transcripts up-regulated in response to 0.5 mM metformin treatment, 7 modules were identified 
(Figure 4-12), whilst in transcripts up-regulated in response to 1 mM metformin treatment, 4 
modules were identified (Figure 4-12). In fold-change analysed transcripts, 2 modules were 
identified in 0.5 mM metformin up-regulated transcripts, and 1 module in 1 mM metformin up-
regulated transcripts (p-vale <0.05, FDR <0.05) (Figure 4-12). No modules or networks were 
detected in either analysis of 0.5 mM and 1 mM metformin up-regulated transcripts.  
To further confirm that biological pathways were divergent between 0.5 mM and 1 mM 
metformin treatment, network analyses were conducted. In log-base (2) transformed data for 
both 0.5 mM and 1 mM metformin treatments, the cytokine-cytokine receptor pathway was 
enriched for in genes changing expression ≥3-fold (p-vale <0.05, FDR <0.05) (Table 4-2 & 4-
3). These transcripts further revealed enrichment for influenza and interferon alpha/beta 
signalling. In fold change based analysis, the AP-1 transcription factor pathway was most 
enriched for both 0.5 mM and 1 mM metformin treated fibroblasts (p-vale <0.05, FDR <0.05) 
(Table 4-4 & 4-5). GO terms for biological processes and molecular function continued these 
findings, with similar enrichment in terms between 0.5 mM and 1 mM metformin treatments 
for each analysis. Specifically, log-transformed transcripts in response to 0.5 mM and 1 mM 
metformin were enriched for GO biological processes in ageing, and GO molecular function in 
double-stranded DNA binding and sequence specific binding (p-vale <0.05, FDR <0.05) 
(Figure 4-13).  Similarly, in fold-change based data, transcripts changing in response to 0.5 mM 
and 1 mM metformin treatment were enriched for in GO biological processes such as cytokine-
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mediated signalling pathways, whilst cytokine and chemokine activity was enriched for in GO 
molecular function (p-vale <0.05, FDR <0.05) (Figure 4-13).  
 
 
Figure 4-9: Scatter Plots and Venn Diagrams Demonstrate Different Transcript Profiles 
Following 0.5 mM and 1 mM Metformin Treatment in 2DD Fibroblasts. (A) Scatter plots 
comparing changes in gene expression between proliferative 2DD fibroblasts and 2DD treated 
with 0.5 mM metformin (left panel) and between proliferative 2DD fibroblasts and 2DD treated 
with 1 mM metformin (right panel) for transcript abundance changes of 2-fold. (B) Scatter plots 
comparing changes in gene expression between proliferative 2DD fibroblasts and 2DD treated 
with 0.5 mM metformin (left panel) and between proliferative (Figure 4-9 Legend Continued) 
2DD fibroblasts and 2DD treated with 1 mM metformin (right panel) for transcript abundance 
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changes of 3 fold. (C) Scatter plots comparing changes between proliferative 2DD fibroblasts 
and 2DD treated with 0.5 mM metformin (left panel) and between proliferative 2DD fibroblasts 
and 2DD treated with 1 mM metformin (right panel) for transcript abundance changes of 5-
fold. For all plots, the number of counts for each transcript identified by RNAseq for 
proliferative (X-axes) and metformin treated (Y-axes) fibroblasts was log-base (2) transformed. 
Each square represents an individual transcript. Transcripts exhibiting a significant fold change 
in response to 0.5 mM metformin when compared to proliferative samples are coloured blue, 
in response to 1 mM metformin coloured red, and overlapping between the two treatment 
conditions coloured green. Grey squares represent transcripts that did not change abundance at 
the listed cut-off values. (D) Venn diagrams demonstrating the number of genes up-regulated 
or down-regulated between 0.5 mM (blue) and 1 mM metformin (red) treated fibroblasts in 
comparison to proliferative fibroblasts. Numbers in the overlapped areas indicate the number 
of genes changing expression in both treatment groups.  
 
 
 
Figure 4-10: Venn Diagrams for Transcripts Changing ≥2-Fold, ≥3-Fold and ≥5-Fold in 
0.5 mM and 1 mM Metformin-Treated Fibroblasts Based on Fold Change Analysis in 
2DD Fibroblasts. Venn diagrams demonstrating the number of genes up-regulated or down-
regulated in 0.5 mM (red) and 1 mM (blue) metformin-treated fibroblasts compared to 
proliferative fibroblasts. Numbers in the overlapping regions indicate the number of transcripts 
changing expression in response to both 0.5 mM and 1 mM metformin treatment.  
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Figure 4-11: RNA-Sequencing Validation of Gene Fold Changes by RT-qPCR in 
Response to 0.5 mM and 1 mM Metformin Treatment in 2DD Fibroblasts. RT-qPCR was 
conducted on a subset of genes identified to have changed transcript profiles by RNAseq. This 
was conducted for 0.5 mM and 1 mM metformin-treated fibroblasts. The relative fold change 
(using five individual normalizing genes) in these transcript profiles from proliferative cells is 
shown (blue bars) as well as the fold change predicted by RNAseq (orange bars. Values on the 
right of the dashed line represent control genes with RNAseq values and RT-qPCR 
comparisons; to the left of the dashed line are selected genes that were ≥2-fold by RNAseq in 
0.5 mM metformin-treated fibroblasts with the corresponding RT-qPCR fold changes.  
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Figure 4-12: Modules Identified in Genes Up-Regulated ≥3-fold in Response to 0.5 mM 
and 1mM Metformin Treatment in 2DD Fibroblasts. Network analyses identified groups of 
functionally related genes (modules in ≥3-fold up-regulated (A) 0.5 mM and (B) 1 mM 
metformin-induced genes based on log-base (2) transformed data. Modules are also presented 
for (C) 0.5 mM and (D) 1 mM metformin-induced genes based on fold-change data. Each node 
(circle) is representative of a gene whilst every colour is representative of a module. Solid lines 
represent genes linked within the same module and between modules based on the ReactomeFI 
database.
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Table 4-2: Network Pathway Annotation Terms Enriched in 0.5mM Metformin Up-Regulated Genes in 2DD Fibroblasts by Log-Base (2) Analyses. 
Genes ≥5-fold up-regulated in response to 0.5 mM metformin treatment were analyzed for enrichment of KEGG terms. The identified enriched pathway 
KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-regulated in response 
to 0.05 mM metformin and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false discovery rates (FDR) are 
presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the networks. Gene lists identified by log-
base (2) transforming data.  
 
Protein 
From 
Network 
p-
Value 
FDR Nodes 
Influenza A(K) 10 0 1.30E-05 IL1B,MX1,IL1A,OAS1,OAS2,TNFSF10,HLA-DMB,TNF,RSAD2,CXCL8 
Interferon alpha/beta signaling(R) 7 0 1.47E-05 MX1,MX2,BST2,OAS1,OAS2,OASL,RSAD2 
Cytokine-cytokine receptor 
interaction(K) 
10 0 1.79E-04 IL1B,IL1A,IL21,CCL8,TNFSF10,TNF,CXCL3,CXCL2,CXCL8,TNFRSF18 
Leishmaniasis(K) 6 0 2.53E-04 IL1B,IL1A,HLA-DMB,FOS,TNF,FCGR2A 
Salmonella infection(K) 6 0 4.68E-04 IL1B,IL1A,FOS,CXCL3,CXCL2,CXCL8 
Measles(K) 7 0 4.68E-04 
IL1B,MX1,IL1A,OAS1,OAS2,TNFSF10, 
CCND2 
Rheumatoid arthritis(K) 6 0 4.68E-04 IL1B,IL1A,HLA-DMB,FOS,TNF,CXCL8 
Legionellosis(K) 5 0 5.44E-04 IL1B,TNF,CXCL3,CXCL2,CXCL8 
TNF signaling pathway(K) 6 0 0.00102 IL1B,FOS,TNF,CXCL3,CXCL2,VCAM1 
Inflammatory bowel disease 
(IBD)(K) 
5 0 0.00102 IL1B,IL1A,IL21,HLA-DMB,TNF 
signal transduction through il1r(B) 4 0 0.001226 IL1B,IL1A,FOS,TNF 
Pertussis(K) 5 0.0001 0.001552 IL1B,IL1A,FOS,TNF,CXCL8 
Osteoclast differentiation(K) 6 0.0001 0.001829 IL1B,IL1A,FOS,FOSB,TNF,FCGR2A 
HTLV-I infection(K) 8 0.0001 0.001829 
WNT2,ATF3,HLA-DMB,FOS, 
CCND2,TNF,VCAM1,WNT7B 
Graft-versus-host disease(K) 4 0.0001 0.001829 IL1B,IL1A,HLA-DMB,TNF 
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Type I diabetes mellitus(K) 4 0.0001 0.002076 IL1B,IL1A,HLA-DMB,TNF 
Calcineurin-regulated NFAT-
dependent transcription in 
lymphocytes(N) 
4 0.0001 0.00253 FOS,EGR3,TNF,CXCL8 
NF-kappa B signaling pathway(K) 5 0.0002 0.002551 IL1B,TNF,CXCL2,CXCL8,VCAM1 
Malaria(K) 4 0.0002 0.002551 IL1B,TNF,CXCL8,VCAM1 
Cellular roles of Anthrax toxin(N) 3 0.0002 0.002551 IL1B,TNF,VCAM1 
Interleukin signaling pathway(P) 4 0.0003 0.003571 IL1A,IL21,FOS,CXCL8 
NOD-like receptor signaling 
pathway(K) 
4 0.0003 0.003794 IL1B,TNF,CXCL2,CXCL8 
nfkb activation by nontypeable 
hemophilus influenzae(B) 
3 0.0003 0.00437 IL1B,TNF,CXCL8 
IL27-mediated signaling events(N) 3 0.0004 0.005089 IL1B,EBI3,TNF 
Herpes simplex infection(K) 6 0.0006 0.006606 IL1B,OAS1,OAS2,HLA-DMB,FOS,TNF 
Chemokine signaling pathway(K) 6 0.0006 0.00677 GNG4,FGR,CCL8,CXCL3,CXCL2,CXCL8 
AP-1 transcription factor 
network(N) 
4 0.0006 0.006926 ATF3,FOS,FOSB,CXCL8 
Interferon gamma signaling(R) 4 0.0007 0.00699 OAS1,OAS2,OASL,VCAM1 
African trypanosomiasis(K) 3 0.0009 0.009192 IL1B,TNF,VCAM1 
Apoptosis(K) 4 0.0013 0.01344 IL1B,IL1A,TNFSF10,TNF 
Death Receptor Signalling(R) 2 0.0021 0.018673 TNFSF10,TNF 
il-10 anti-inflammatory signaling 
pathway(B) 
2 0.0021 0.018673 IL1A,TNF 
Chagas disease (American 
trypanosomiasis)(K) 
4 0.0027 0.022433 IL1B,FOS,TNF,CXCL8 
Senescence-Associated Secretory 
Phenotype (SASP)(R) 
3 0.0027 0.022433 IL1A,FOS,CXCL8 
stress induction of hsp 
regulation(B) 
2 0.0028 0.022433 IL1A,TNF 
Toll-like receptor signaling 
pathway(K) 
4 0.0029 0.022879 IL1B,FOS,TNF,CXCL8 
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Tuberculosis(K) 5 0.003 0.024349 IL1B,IL1A,HLA-DMB,TNF,FCGR2A 
cadmium induces dna synthesis 
and proliferation in 
macrophages(B) 
2 0.0032 0.025662 FOS,TNF 
ATF-2 transcription factor 
network(N) 
3 0.0042 0.029098 ATF3,FOS,CXCL8 
Downstream signaling in naïve 
CD8+ T cells(N) 
3 0.0052 0.036575 FOS,TNF,TNFRSF18 
Fertilization(R) 2 0.0062 0.043088 ADAM20,ZP1 
nf-kb signaling pathway(B) 2 0.0062 0.043088 IL1A,TNF 
Hepatitis C(K) 4 0.0064 0.044476 OAS1,OAS2,TNF,CXCL8 
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Table 4-3: Network Pathway Annotation Terms Enriched in 1mM Metformin Up-Regulated Genes in 2DD Fibroblasts by Log-Base (2) 
Analyses. Genes ≥5-fold up-regulated in response to 1 mM metformin treatment were analyzed for enrichment of KEGG terms. The identified enriched 
pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to be up-regulated 
in response to 1 mM metformin and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) and false discovery 
rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present in the networks. Gene lists 
identified by log-base (2) transforming data.  
 
Proteins 
From 
Network 
p-
Value 
FDR Nodes 
Interferon alpha/beta signaling(R) 7 0 8.46E-06 MX1,MX2,BST2,OAS1,OAS2,OASL,RSAD2 
Influenza A(K) 9 0 1.83E-05 CXCL10,IL1B,MX1,IL1A,OAS1,OAS2,HLA-DMB,RSAD2,CXCL8 
Cytokine-cytokine receptor 
interaction(K) 
8 0 0.002562 CXCL10,IL1B,IL1A,IL21,CCL8,CXCL3,CXCL2,CXCL8 
Measles(K) 6 0.0001 0.002562 IL1B,MX1,IL1A,OAS1,OAS2,CCND2 
Salmonella infection(K) 5 0.0001 0.002659 IL1B,IL1A,CXCL3,CXCL2,CXCL8 
GPCR ligand binding(R) 9 0.0001 0.00333 
CXCL10,WNT2,PTH1R,MCHR1, 
TAS1R1,CXCL3,CXCL2,CXCL8, 
HTR2A 
Legionellosis(K) 4 0.0002 0.004676 IL1B,CXCL3,CXCL2,CXCL8 
TNF signaling pathway(K) 5 0.0002 0.00521 CXCL10,IL1B,CXCL3,CXCL2,VCAM1 
Inflammatory bowel disease 
(IBD)(K) 
4 0.0003 0.00707 IL1B,IL1A,IL21,HLA-DMB 
Interferon gamma signaling(R) 4 0.0004 0.008443 OAS1,OAS2,OASL,VCAM1 
Leishmaniasis(K) 4 0.0005 0.008443 IL1B,IL1A,HLA-DMB,FCGR2A 
Prion diseases(K) 3 0.0008 0.013048 IL1B,IL1A,C8G 
Rheumatoid arthritis(K) 4 0.001 0.014865 IL1B,IL1A,HLA-DMB,CXCL8 
NF-kappa B signaling pathway(K) 4 0.0011 0.014865 IL1B,CXCL2,CXCL8,VCAM1 
Graft-versus-host disease(K) 3 0.0012 0.015521 IL1B,IL1A,HLA-DMB 
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1
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Type I diabetes mellitus(K) 3 0.0014 0.01636 IL1B,IL1A,HLA-DMB 
Malaria(K) 3 0.0019 0.02221 IL1B,CXCL8,VCAM1 
Chemokine signaling pathway(K) 5 0.0023 0.025641 
CXCL10,CCL8,CXCL3, 
CXCL2,CXCL8 
Interleukin signaling pathway(P) 3 0.0026 0.025641 IL1A,IL21,CXCL8 
NOD-like receptor signaling 
pathway(K) 
3 0.0028 0.028346 IL1B,CXCL2,CXCL8 
Osteoclast differentiation(K) 4 0.004 0.035567 IL1B,IL1A,FOSB,FCGR2A 
Cellular roles of Anthrax toxin(N) 2 0.004 0.036279 IL1B,VCAM1 
AP-1 transcription factor 
network(N) 
3 0.005 0.040171 ATF3,FOSB,CXCL8 
Pertussis(K) 3 0.0061 0.048571 IL1B,IL1A,CXCL8 
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Table 4-4: Network Pathway Annotation Terms Enriched in 0.5mM Metformin Up-Regulated Genes in 2DD Fibroblasts by Fold Change 
Analyses. Genes ≥5-fold up-regulated in response to 0.5 mM metformin treatment were analyzed for enrichment of KEGG terms. The identified 
enriched pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified 
to be down-regulated in response to 1 mM metformin and belonging to a specific pathway was identified. P-value (with 0 values equating to 
<0.0001) and false discovery rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets 
present in the networks. Gene lists identified by log-base (2) transforming data.  
 
Proteins From 
Network 
p-Value FDR Nodes 
AP-1 transcription factor network(N) 3 0 0.004281 FOS,ATF3,FOSB 
HTLV-I infection(K) 4 0.0001 0.004281 VCAM1,FOS,ATF3,CCND2 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes(N) 
2 0.0008 0.040847 FOS,EGR3 
ATF-2 transcription factor network(N) 2 0.0012 0.045389 FOS,ATF3 
Amphetamine addiction(K) 2 0.0017 0.045389 FOS,FOSB 
Prolactin signaling pathway(K) 2 0.0019 0.045389 FOS,CCND2 
Glucocorticoid receptor regulatory 
network(N) 
2 0.0022 0.045389 FOS,NR4A1 
Circadian entrainment(K) 2 0.0034 0.04696 FOS,KCNJ3 
Estrogen signaling pathway(K) 2 0.0036 0.04696 FOS,KCNJ3 
TNF signaling pathway(K) 2 0.0043 0.04696 VCAM1,FOS 
Cholinergic synapse(K) 2 0.0046 0.04696 FOS,KCNJ3 
Dopaminergic synapse(K) 2 0.0061 0.04696 FOS,KCNJ3 
Osteoclast differentiation(K) 2 0.0061 0.04696 FOS,FOSB 
Hepatitis B(K) 2 0.0075 0.04696 FOS,EGR3 
Generic Transcription Pathway(R) 2 0.0076 0.04696 NR4A2,NR4A1 
Oxytocin signaling pathway(K) 2 0.0089 0.04696 FOS,KCNJ3 
Viral carcinogenesis(K) 2 0.0145 0.04696 EGR3,CCND2 
MAPK signaling pathway(K) 2 0.0221 0.04696 FOS,NR4A1 
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Fc epsilon receptor (FCERI) signaling(R) 2 0.0334 0.04696 FOS,NR4A1 
PI3K-Akt signaling pathway(K) 2 0.0386 0.04696 CCND2,NR4A1 
 
 
Table 4-5: Network Pathway Annotation Terms Enriched in 1mM Metformin Up-Regulated Genes in 2DD Fibroblasts by Fold Change 
Analyses. Genes ≥5-fold up-regulated in response to 0.5 mM metformin treatment were analyzed for enrichment of KEGG terms. The identified 
enriched pathway KEGG annotation terms (GeneSet) from network analyses are listed. The total number of genes from the network identified to 
be down-regulated in response to 1 mM metformin and belonging to a specific pathway was identified. P-value (with 0 values equating to <0.0001) 
and false discovery rates (FDR) are presented. All P-Value and FDR are <0.05. Nodes identify specific genes/proteins from our datasets present 
in the networks. Gene lists identified by log-base (2) transforming data. 
 Proteins 
From 
Network 
p-
Value 
FDR Nodes 
HTLV-I infection(K) 4 0 5.16E-04 VCAM1,FOS,ATF3,CCND2 
AP-1 transcription factor network(N) 3 0 5.16E-04 FOS,ATF3,FOSB 
ATF-2 transcription factor network(N) 2 0.0005 0.021043 FOS,ATF3 
Amphetamine addiction(K) 2 0.0007 0.021043 FOS,FOSB 
Prolactin signaling pathway(K) 2 0.0008 0.021043 FOS,CCND2 
Glucocorticoid receptor regulatory network(N) 2 0.0009 0.021043 FOS,NR4A1 
TNF signaling pathway(K) 2 0.0019 0.033352 VCAM1,FOS 
Osteoclast differentiation(K) 2 0.0026 0.033352 FOS,FOSB 
MAPK signaling pathway(K) 2 0.0097 0.033352 FOS,NR4A1 
Fc epsilon receptor (FCERI) signaling(R) 2 0.0149 0.033352 FOS,NR4A1 
PI3K-Akt signaling pathway(K) 2 0.0172 0.033352 CCND2,NR4A1 
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Figure 4-13: GO Term Enrichment in 0.5 mM and 1 mM Metformin Up-Regulated Gene 
Sets Based on Fold Change Analyses and Log-Base (2) Transformed 2DD Fibroblast Data. 
GO Biological Process terms significantly enriched for in genes ≥3-fold up-regulated in 
response to 0.5 mM metformin for both (A) log-base (2) transformed data and (B) fold change 
based data. Pie chart demonstrating GO term enrichment for Biological Process in genes ≥3-
fold up-regulated in response to 1 mM metformin for both (C) log base (2) transformed data 
and (D) fold change based data. GO Molecular function terms significantly enriched for in 
genes ≥3-fold up-regulated in response to 0.5 mM metformin for both (E) log base (2) 
transformed data and (F) fold change based data. Pie chart demonstrating GO term enrichment 
for Molecular Process in genes ≥3-fold up-regulated in response to 1 mM metformin for both 
(G) log base (2) transformed data and (H) fold-change based data. 
Removing Metformin Treatment for 120 h Results in Return to Untreated Phenotype and 
Transcript Profiles 
In order to determine whether or not removal of 0.5 mM metformin or 1 mM metformin 
treatments would result in 2DD fibroblasts returning to a normal, proliferative, phenotype, a 
number of assays were repeated, including; population doubling times, flow cytometry, Ki67 
Immunofluorescence and EdU incorporation. Cell counts were recorded following 120 h of 
treatment and then 120 h post-treatment for a total of 240 h. Both population doubling times 
and total population doublings were calculated at both time points (Figure 4-14A). At 120 h of 
either 0.5 mM or 1 mM metformin treatment, population doubling times and total population 
doublings were consistent with previous findings (Figure 4-2). 120 h following removal of 
treatment, population doubling times and total population doublings shifted towards a 
proliferative profile, with no significant difference (p≥0.05) detected between proliferative and 
0.5 mM or 1 mM metformin treated samples (Figure 4-12A). Immuno-labelling with the 
proliferative marker Ki67 was conducted and revealed that in 2DD post- 0.5 mM and 1 mM 
metformin treatments, levels of the marker were much higher (81.0% and 73.1% respectively) 
than in proliferative 2DD (69.5%) (Figure 4-14B & 4-14D). EdU incorporation in 0.5 mM and 
1 mM 120 h post-metformin treatment 2DD fibroblasts revealed a slight increase in cells in S-
phase from 12.2% in proliferative samples to 17.0 and 15.8 in 0.5 mM and 1 mM post-treatment 
fibroblasts respectively (Figure 4-14C & Figure 4-14D) In order to determine the number of 
cells in each stage of the cell cycle, a cell cycle assay incorporating propidium iodide and 
utilizing flow cytometry was conducted. In samples supplemented with proliferative growth 
media following 120 h of metformin treatment, both 0.5 mM and 1 mM metformin treatment 
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revealed a slight increase in fibroblasts in G2/M and a slight decrease in S-phase (conversely 
to the slight increase in S-phase by EdU); however, these samples show no significant however, 
these samples show no significant difference to proliferative samples with the numbers of cells 
in G1/0 at 81.4% and 80.3% respectively compared to proliferative of 80.8% (Figure 4-14B). 
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Figure 4-14: Removal of 0.5 mM and 1 mM Metformin after 120 h of Treatment Induces 
a Shift Towards Proliferative Characteristics in Normal 2DD Fibroblasts. (A) Population 
doubling times (h) (Y-axis) and total population doublings (Y-axis) for proliferative (120 h Pro; 
240 h Pro), 120 h 0.5 mM (0.5 mM Met) and 1 mM metformin (1 mM Met)-treated and 120 h 
0.5 mM (Post-0.5 mM Met) and 1 mM (Post-1 mM Met) metformin post-treatment fibroblasts 
(X-axis) at 120 h of treatment (blue) and 120 h post-treatment (orange). Error bars = S.E.M. 
(B) Representative graph for percent positive Ki67 (Y-axis) in proliferative and metformin-
treated fibroblasts 120 h post-treatment.  (C) Representative graph for percent positive EdU (Y-
axis) for proliferative and metformin-treated fibroblasts at 120h post-treatment. (D) 
Representative images of immunofluorescence for proliferative (Pro, Left), 0.5 mM metformin 
(0.5mM Met, Centre) and 1 mM metformin (1mM Met, Right) -treated fibroblasts. Ki67 
labelling (green) and EdU incorporation (red). Chromatin is counterstained with H33342. Scale 
bar = 10 m. (E) Propidium iodine cell cycle analysis for proliferative, 0.5 mM metformin and 
1 mM metformin-treated fibroblasts 120 h post-treatment. Cell counts (Y-axis) and FL2-A (X-
axis). 
4.7 Rapamycin Treatment and Metformin Treatment Induce Different Biological Impacts 
at 120 h of Treatment 
For the first time it is possible to determine whether or not metformin and rapamycin 
are mimicking one another at the transcriptomic level in the same normal cell line, as proposed 
by the literature. In log transformed analyses, genes changing ≥3-fold up-regulated between 0.5 
mM metformin and 500 nM rapamycin-treated fibroblasts revealed just three genes (FGR, 
FOSB, IL1B) overlapping between treatments (0.4%), whilst no overlap was noted in down-
regulated data. In fold change analyses, 3 genes (NR4A2, NR4A1, FOSB) overlapped (30% of 
0.5 mM metformin up-regulated genes, but 0.23% of total genes). Again, there was no overlap 
between 0.5 mM metformin and 500 nM rapamycin down-regulated genes. These findings were 
similar in genes ≥3-fold up-regulated in response to 1 mM metformin when compared to 500 
nM rapamycin treatment for both log-base (2) transformed data and fold change analyses with 
2 (FOSB, IL1B) of 813 (0.25%) genes overlapping in log-base (2) up-regulated samples and 1 
of 281 genes changing expression in down-regulated genes. In fold change analyses, 2 of 1319 
(0.15%) genes were common between 1 mM metformin and rapamycin in up-regulated data 
and no genes overlapped in down-regulated data (Figure 4-15).  
In log-base (2) transformed analyses comparing 0.5 mM metformin treatment and 
quiescence-induction, 9 of 719 (1.25%) genes (FGF9, CYP21A2, GDF10, AP001610.5, 
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SIPA1L2 AC106786.1, CCND2, H19, GAP43) overlapped in ≥3-fold up-regulated groups, 
whilst there was no overlap in down-regulated groups. In fold change analyses, 4 of 1283 
(0.31%) up-regulated genes (NR4A2, KCNJ3, VCAM1, CCND2) were common between 0.5 
mM metformin and quiescence. Conversely to log-base (2) transformed data, 3 of 798 (0.38%) 
genes (overlapped between 0.5 mM metformin and quiescence-induced down-regulated groups. 
Finally, when comparing genes changing ≥3-fold between 1 mM metformin-treatment and 
quiescence-induction, 8 (AATK, FGF9, AP001610.5, SIPA1L2, TMEM229B, CCND2, H19, 
GAP43) of 689 (1.15%) genes were common in log-base (2) up-regulated genes, whilst there 
was no overlap in down-regulated groups. In fold change analyses findings were similar, with 
3 (H19, VCA1, CCND2) of 1284 (2.34%) genes overlapping in up-regulated groups and 3 
(LRRC38, PRPRB, ANKRD1) of 798 (0.38%) genes overlapping in groups down regulated by 
1 mM metformin treatment or quiescence-induction (Figure 4-15).  
 
Figure 4-15: Venn diagrams for both log-base (2) transformed and fold change based data 
demonstrating divergence between 0.5 mM and 1 mM metformin treatments with 500 nM 
rapamycin treatment and quiescence-induction in 2DD Fibroblasts. Log-base (2) Venn 
diagrams (left) for (A) 0. 5 mM metformin (Met) vs 500 nM rapamycin (Rap), (B) 1 mM Met 
vs 500 nM Rap, (C) 0.5 mM Met vs quiescence induction and (Figure 4-15 Legend Continued) 
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(D) 1 mM Met vs quiescence induction in 2DD fibroblasts. Overlapping regions represent 
overlap in transcripts between treatments. Fold change based (right) Venn diagrams for (A) 0.5 
mM Met vs 500 nM Rap, (B) 1 mM Met vs 500 nM Rap, (C) 0.5 mM Met vs quiescence 
induction and (D) 1 mM Met vs quiescence induction in 2DD fibroblasts. Overlapping regions 
represent overlap in transcripts between treatments. In all diagrams, metformin treatment (either 
0.5 mM or 1 mM) is in red and rapamycin-treatment or quiescence induction in blue.  
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4.8 Discussion  
We observed that 0.5 mM and 1 mM metformin treatment decreased cell proliferative 
rates, including levels of Ki67 and EdU positive fibroblasts, and induced the re-localization of 
chromosomes 18 and 10 within the nuclear volume. These re-localizations were similar, but not 
identical to that of rapamycin-treatment and quiescence induction. A decrease in autophagy was 
detected with an increase in phosphorylated AMPK (Thr172). Furthermore, whilst transcript 
profiles between 0.5 mM and 1 mM metformin somewhat divergent, pathway analysis and GO 
term analysis revealed very similar enrichment. When considering type of analysis, it is clear 
that log transforming the data generated slightly divergent datasets to analyses based on fold 
change, and although the resultant pathway enrichment for both 0.5 mM and 1 mM metformin 
treatments were divergent between analyses, there were still strong similarities and links 
between the datasets that support both analyses as important in determining the impact of 
metformin treatment in primary normal human fibroblasts.  
Although similar findings were reported in both 0.5 mM metformin and 1 mM 
metformin in terms of both growth assays (Ki67), detection of AMPK phosphorylation and 
autophagy (western blots), pathway enrichment and GO biological and molecular processes, 
with the majority of genes changing expression at all fold-cut offs overlapping substantially, 
there were still a number of genes that were not shared between the two treatments. Pathway 
analysis of the overlapping genes in both ≥3-fold up and down-regulated genes in log-base (2) 
transformed data revealed enrichment for cytokine-cytokine receptor interaction and AP-1 
transcription factor network enrichment. Pathway analyses of overlapping genes in the fold 
change analyses for metformin treatments revealed similar findings, with the AP-1 transcription 
factor network as most enriched. Analysis of non-shared transcripts for 0.5 mM metformin log 
based analyses showed little pathway enrichment but included processes such as death receptor 
signalling, fertilization, WNT signalling pathway and IL-27 mediated signalling events whilst 
genes responding to 1 mM metformin but not overlapping demonstrated no pathway 
enrichment. These findings indicate that whilst 0.5 mM metformin induces more genes to 
change expression, the impact of metformin in fibroblasts is dose dependent and perhaps a 
higher concentration here has resulted in a more specific cellular response, with transcripts not 
common between treatments being non-specific responses. It is important to note; however, 
that interactions between these genes may not yet have been identified and that databases such 
as Cytoscape with ReactomeFI are only as useful as the information available to-date. In fold 
change analyses, genes not overlapping between the treatments demonstrated no networks. 
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Despite the difference in analyses, the AP-1 transcription factor was among the most enriched 
pathways in response to fold-change, and still ranked significantly in pathway enrichment for 
log-base (2) transformed data. Furthermore, the AP-1 transcription factor network was enriched 
for both 0.5 mM and 1 mM metformin treatments. 
The transcription factor activator protein-1 (AP-1) represents hetero- and homo-dimers 
of the FOS and JUN proteins. c-FOS and c-JUN are mostly expressed in mammalian cells in 
response to growth factors, cytokines, oxidative stress and pharmacological stimuli. This can 
lead to regulation of cell proliferation, differentiation and inflammation (Chiu et al. 1988; 
Curran and Franza 1988). Furthermore, the AP-1 transcription factor network is extensively 
involved in both NF-B and TNF- signalling (Fujioka et al. 2004), pathways which were also 
enriched in these analyses.   
The enrichment of AP-1 transcription factor network has been linked to ageing – 
increasing in rat kidneys with age. Metformin is a proposed mimetic of caloric restriction; 
however, in the case of caloric restriction AP-1 transcription factors were decreased in rat 
kidney (Kim et al. 2002), whereas in human fibroblasts in response to metformin AP-1 
transcription factor network was enriched in up-regulated genes. Therefore, it is possible that 
caloric restriction and metformin induce divergent effects in order to increase health and 
lifespan. Although this increase in AP-1 transcription factor activity was observed in rats, it has 
previously been reported that DNA binding activity of the AP-1 transcription factor decreases 
with age in human lung fibroblast (MRC-5) culture (Sheerin et al. 2001) and that AP-1 
transcription factor activity is required for initiation of DNA synthesis and is lost during cellular 
ageing (Riabowol et al. 1992), therefore the enrichment of the AP-1 transcription factor 
network pathway in genes up-regulated in response to metformin is promising in using 
metformin as a drug to improve health and lifespan.  
AP-1 transcription factor has extensively been linked to the modulation of reactive 
oxygen species (ROS), specifically ROS induction via NF-B and AP-1 transcription factors 
(Zhou et al. 2001). AP-1 and NF-kB pathways may be interacting with one another, modulating 
the activity of each other.  NF-kB regulates elk-1, which is activated by ERK to induce 
expression of c-FOS and FOS-b in response to certain stimuli in human pancreatic tumor cell 
line (Fujioka et al. 2004).  Blocking NF-kB activation inhibits AP-1 activity and NF-kB activity 
is involved in ROS and serum induced AP-1 activation (Fujioka et al. 2004). Metformin has 
previously been documented to decrease ROS levels in both cancer and healthy cell cultures 
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(Algire et al. 2012; Queiroz et al. 2014). It could be that metformin is inducing expression of 
genes associated with the AP-1 transcription network pathway, priming cells for ROS assault. 
Alternatively, it could be that metformin is reducing ROS via the AP-1 transcription factor 
pathway.  
Cytokine-Cytokine receptor interactions were enriched in the log transformed analysis 
of 0.5 mM and 1 mM metformin treated fibroblasts. AP-1 transcription factor network was also 
enriched in this analysis, although less so than in the fold change analyses. Furthermore, 
relationships between AMPK, AP-1 and IL-6 expression have been identified. Specifically, it 
is thought that IL-6 inhibition of adrenal androgen release is mediated via the activation of 
AMPK, specifically that IL-6 activates AMPK (Ruderman et al. 2006), increasing expression 
of AP-1 family members (Xiao et al. 2004). Given this link it could be possible that this 
pathway is involved in numerous other cell regulatory processes, including growth and repair.  
A key assumption has been made within the literature, that metformin is a mimetic of 
dietary restriction. Based on these findings, this is unlikely completely the case, and may 
depend on the definition of “mimetic”. DR has been clearly documented to decrease energy and 
induce changes in the cellular ratio of AMP:ATP and NAD:NADH. The key players involved 
in the mediation of this process, and the ultimate extension of health and lifespan associated 
with DR are AMPK and SIRT1(Bordone and Guarente 2005; Greer et al. 2007; Onken and 
Driscoll 2010; Mercken et al. 2014; Gillespie et al. 2016), often affecting common down-stream 
targets such as NF-B. SIRT1 has been documented to suppress AP-1 transcriptional activity, 
directly interacting with c-FOS and c-JUN (Zhang et al. 2009), although there is some 
controversy, with some groups suggesting that SIRT1 interacts with c-Jun and JunD but not c-
FOS. This could be a cell and organism dependent factor in which members of the AP-1 
transcription network pathway SIRT1 interacts with. These findings provide a link between the 
enrichment of the AP-1 transcription factor network and the AMPK/SIRT1 interaction that has 
been extensively linked to DR and other DR mimetics, possible benefiting health and lifespan. 
Therefore, although there is extensive divergence in the literature over transcriptome profiles 
and genes changing expression in response to both metformin and DR, these changes may be 
mediated by the same key modulators.  
As a mimetic of DR, metformin has often also been proposed as mimicking rapamycin 
(another DR mimetic). Comparative analyses of genes changing expression ≥3-fold between 
500 nM rapamycin-treated, serum-reduction induced quiescence and 0.5 mM or 1 mM 
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metformin-treated 2DD fibroblasts demonstrated little overlap between genes changing 
expression in response to metformin and rapamycin treatments, and between genes changing 
expression in response to both rapamycin and metformin treatments and quiescence-induction. 
Although there is clear divergence between treatments, it is important to consider that there are 
far lower numbers of genes are changing expression in metformin treatments and therefore a 
higher percentage of these genes are shared. Despite this, combined with pathway analysis, it 
is evident that metformin-treatment and rapamycin-treatment induce divergent transcript 
profiles in 2DD fibroblasts. 
In summary, it has been demonstrated for the first time in normal human fibroblasts that 
the impact of metformin on foreskin cells in culture extends to changes in genome organization, 
repositioning chromosomes within the nuclear volume. Furthermore, it has been demonstrated 
that two different methods of bioinformatics analyses (log-base (2) transformed and fold 
change) may reveal different outcomes, highlighting a need to determine which method may be 
more appropriate for differential gene expression analyses. This work has also strengthened the 
argument for metformin inducing dose and cell/tissue/organism-dependent responses. Finally, 
novel enrichment of the AP-1 transcription factor network has been documented as enriched in 
response to both 0.5 mM and 1 mM metformin, proposing a potential downstream effector 
pathway for metformin treatment mediated by the well-established SIRT1/AMPK interaction.  
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5.0 Conclusions 
It was observed that both rapamycin and metformin treatment of normal human foreskin 
fibroblasts (2DD) for 120 h impacted genome function (gene expression) and genome 
organization (positioning of chromosomes within the nucleus). Specifically, in response to 500 
nM rapamycin, 2DD exhibited decreased cell proliferation with no evidence of cell death. In 
addition, cellular morphology appeared more flattened, reminiscent of quiescence-induction. In 
order to determine whether or not rapamycin was inducing a quiescent-like state, chromosome 
territory positioning was monitored, with chromosome 10 moving to the periphery and 18 to 
the interior under both rapamycin-treatment and quiescence-induction. However, analysis of 
transcript profiles by RNAseq and subsequent pathway analyses revealed that rapamycin-
treated and quiescence-induction induced divergent responses. Specifically, in response to 
quiescence-induction in 2DD fibroblasts, genes up-regulated ≥5-fold were demonstrated 
enrichment in the complement and coagulation. Divergent from quiescence-induction, genes 
up-regulated ≥5-fold in response to rapamycin-treatment demonstrated enrichment of the 
cytokine-cytokine receptor pathway. Changes at the transcript level were confirmed as 
biologically having an impact through western blot assays to measure protein expression and 
ELISA assays to monitor cytokine secretion. Analysis of the promoter regions of genes 
changing ≥5-fold in response to rapamycin was conducted using cis-element over-
representation analysis (CLOVER). These analyses identified transcription factor binding sites 
that were enriched in genes significantly changing expression in response to rapamycin. 
CLOVER, combined with biological analysis via chromatin immuno-precipitation (ChIP) 
assays, identified and confirmed signal transduction and activator of transcription 5A/B 
(STAT5A/B) as a potential mediator of genes changing expression in response to rapamycin 
treatment. This STAT5A/B-mediation of gene expression provides novel insight into how 
rapamycin functions to impact cell proliferation, chromosome territory positioning, gene 
expression and cytokine production. These findings further linked TOR inhibition with changes 
in genome function and organization independent of quiescence.  
Treatment with either 0.5 mM or 1 mM metformin, as with rapamycin treatment, 
resulted in decreased cell proliferation in healthy human fibroblasts with no evidence of cell 
death; however, decreases in cell proliferation and increases in population doubling times were 
less drastic than those observed in rapamycin treatment. Chromosome territory positioning of 
chromosomes 10 and 18 at 120 h of treatment were assayed, with chromosome 10 moving 
towards the periphery and 18 to the interior under 0.5 mM metformin treatment whilst at 1 mM 
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only chromosome 10 exhibited significant re-positioning to the nuclear periphery. RNA 
sequencing and subsequent pathway analyses revealed that despite the differences in 
chromosome territory positioning, both 0.5 mM and 1 mM metformin up-regulated genes 
demonstrated enrichment for the AP-1 transcription factor pathway whilst no pathways were 
enriched for in the significantly down-regulated transcripts. Future aims could examine a 
potential link between the AP-1 transcription factor pathway and its potential mediation by the 
SIRT1/AMPK interaction previously highlighted as key in modulating health and lifespan.  
Finally, although it has frequently been suggested that rapamycin and metformin are 
mimetics of dietary restriction, and therefore of one another, these observations indicate a   clear 
divergence in transcript profiles in both log-base (2) transformed or fold-change based analyses; 
however, it is possible that although inducing divergent transcript profiles, rapamycin and 
metformin induce changes in gene expression that eventually result in the same downstream 
effects resulting in previously reported health and lifespan extension. 
 These findings highlight that the proposed mimetics of dietary restriction, rapamycin 
and metformin, induced divergent transcript profiles. Therefore, it is important to be cognisant 
of rapamycin and metformin functioning differentially to mimic dietary restriction and the 
potential of various targets in improving health and lifespan as part of the human aging process.    
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6.0 Future Directions 
These observations and conclusions raise many more questions and avenues of 
investigation. It has been established that normal human foreskin fibroblasts induced into 
quiescence, or treated with either rapamycin or metformin, exhibit numerous changes in both 
genome organization and genome function. In order to further understand these changes in 
genome organization, and to establish whether or not re-organization of the genome is involved 
in the mechanism mediating changes in gene expression, various analysis could be conducted. 
Firstly, a sliding-window algorithm could be used to identify potential regions of the genome 
that contain clusters of genes that are like regulated in response to rapamycin and metformin. 
Further analyses of genome folding within these regions using chromosome conformation 
capture (3C) could be used to determine if these particular regions containing 
activated/repressed gene clusters change in response to these conditions. 3C is only able to 
examine a single genomic interaction either between two genes or a gene-enhancer. Therefore, 
since changes in chromosome territory positioning is indicative of changes in organization 
genome wide, Hi-C, a derivative of 3C, could be employed to examine changes in folding across 
the entire genome, enabling the identification of other regions that are linked to the differential 
expression of rapamycin and metformin responsive genes.  
 In order to identify the mechanism mediating the identified changes in genome function 
in response to metformin treatment, the cis-element overrepresentation (CLOVER) algorithm 
could be employed to identify over- and under-represented transcription factor binding sites in 
genes significantly changing expression. As with the rapamycin-base findings, chromatin 
immuno-precipitation (ChIP) assays could then be used to confirm if the identified transcription 
factors are physically binding to the promoter region of the genes of interest. ChIP-sequencing 
(ChIP-seq) could then be conducted on both rapamycin and metformin-treated samples to 
identify genome-wide protein-DNA interactions (transcription factors binding to the promoter 
regions of genes across the genome). Within the literature a diverse range of cell-types have 
been treated with either rapamycin or metformin; therefore, it is likely that these findings may 
be cell-type dependent. In order to establish whether or not a common mechanism is mediating 
response to either rapamycin or metformin, experiments should be repeated across cell-types. 
If the data sets are available, it may also be possible to conduct meta-analyses to determine if 
any common pathways exist. Finally, to identify the significance of the proposed mechanisms 
mediating the response to treatments, knock-down and knock-out studies should be conducted 
in cell culture to determine if these mechanisms are responsible for the changes in genome 
organization and function in cells. If successful, these studies should be repeated in model 
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organisms. Findings from these experiments could further provide evidence as to the 
importance of these mechanisms in extending both health and lifespan.  
 Metformin and rapamycin have both been proposed as mimetics of dietary restriction, 
inducing similar health and lifespan extending benefits across species; however, little work has 
been conducted in the same cell line treated under conditions of dietary restriction, metformin 
or rapamycin treatment. In order to provide new insight into the impact of these conditions on 
genome function and organization, conducting further cell growth assays, chromosome territory 
positioning, RNAseq and ChIP in foreskin fibroblasts treated under conditions of dietary 
restriction will provide novel insight into the extent to which metformin and rapamycin mimic 
caloric restriction, further providing new perspectives on the impact of these treatment 
conditions on improving health and lifespan.  
 Finally, in order to understand the importance of genome organization and function in 
disease, experiments could be conducted in fibroblast cells suffering from Hutchinson-Gilford 
Progeria Syndrome (HGPS). These patients exhibit an accelerated ageing phenotype, 
succumbing to cardiovascular disease or stroke at approximately 15 years of age. In HGPS 
fibroblasts, chromosome mis-localization and genome-wide changes in gene expression have 
been reported. Having established the impact of metformin, rapamycin and dietary restriction 
in normal human fibroblasts, with extensive literature documenting the health and lifespan 
extending-benefits of these compounds, expanding these treatment conditions to HGPS cells 
could result in re-positioning of mis-localized chromosomes to that or normal human 
fibroblasts. Genome function (changes in gene expression) could be examined by RNAseq to 
determine if function is also restored to that of normal human fibroblasts. Further analyses, such 
as ChIPseq and knock out analyses on transcription factors identified as potentially mediating 
changes in gene expression induced by rapamycin or metformin, could further elucidate 
mechanisms involved in HGPS and those promoting a shift towards increasing health and 
lifespan, particularly as rapamycin and metformin have previously been documented to alter 
health and lifespan across numerous model organisms.  
 In summary, the future directions of this work are numerous and could range from 
understanding the fundamental impact of rapamycin and metformin on genome function and 
organization. These findings could further improve understanding of the fundamental biology 
of ageing. This work could then be extended to investigations in disease phenotypes, 
specifically those involving premature or accelerated ageing such as HGPS.   
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